日本臨牀　63/増刊号3　臨床分子内分泌学2

出版社： 日本臨牀社
発行日： 2005-03-28
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 臨床分子内分泌学2―心血管内分泌代謝系（下）
電子書籍版： 2005-03-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

14,410 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,410 円(税込)

購入する

目次

  • 日本臨牀　63/増刊号3　臨床分子内分泌学2

    ―目次―

    特集　臨床分子内分泌学2―心血管内分泌代謝系（下）

    7． レニン-アンジオテンシン系 　 　
    　1． 概　論 　 　
    　2． 基礎研究の進展 　 　
    　3． 薬理作用と生理作用 　 　
    　4． 病態と疾患からみたレニン-アンジオテンシン系 　 　
    　5． 特　論 　 　

    8． アルドステロン 　 　
    　1． 概　論 　 　
    　2． 基礎研究の進展 　 　
    　3． 薬理作用と生理作用 　 　
    　4． 病態と疾患からみたアルドステロン 　 　
    　5． 特論 　 　

    9． カリクレイン-キニン系 　 　
    　1． 概論 　 　
    　2． 基礎研究の進展 　 　
    　3． 薬理作用と生理作用 　 　
    　4． 病態と疾患からみたカリクレイン-キニン系 　 　
    　5． 特論 　 　

    10． バソプレシン 　 　
    　1． 概論 　 　
    　2． 基礎研究の進展 　 　
    　3． 薬理作用と生理作用 　 　
    　4． 病態と疾患からみたバソプレシン 　 　
    　5． 特論 　 　

    11． 特論―カテコールアミン― 　 　
    　1． カテコールアミンの発見と意義
    　2． 病態と疾患からみたカテコールアミン 　 　
    　3． 交感神経抑制薬の展望

    12． 特論―エストロゲン― 　 　
    　1． エストロゲンの循環調節因子としての意義
    　2． 病態と疾患からみたエストロゲン 　 　
    　3． ホルモン補充療法(HRT)と心血管病予防
    　4． 選択的エストロゲン受容体モジュレーター(SERM)
    　5． アンジオテンシン受容体サブタイプとエストロゲンの
    　　　　クロストーク

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

VII レニン - アンジオテンシン系

P.11 掲載の参考文献
1) ニコラス・ボステル-ビネイほか : 高血圧の世紀 (1896-1996), 先端医学社, 1997.
 
2) 日和田邦男 : レニン・アンジオテンシン系研究の歴史 : レニン・アンジオテンシン系の主要年代一覧. レニン・アンジオテンシン系と高血圧 (日和田邦男ほか編), p20-23, 先端医学社, 1998.
 
3) 荒川規矩男 : レニン・アンジオテンシン系研究の歴史 : 歴史的総括. レニン・アンジオテンシン系と高血圧 (日和田邦男ほか編), p24-28, 先端医学社, 1998.
 
4) Ogihara T, et al : Angiotensin blockade. Lancet i : 219, 1974.
PubMed
5) Brunner HR, et al : Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet ii : 1045-1048, 1973.
 
6) Yang HY, et al : A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 214 : 374-376, 1970.
PubMed
7) Ondetti MA, et al : Design of specific inhibitors of angiotensin-converting enzyme : new class of orally active antihypertensive agents. Science 196 : 441-444, 1977.
PubMed
8) Jacob HJ, et al : Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell 67 : 213-224, 1991.
PubMed
9) Urata H, et al : Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 91 : 1269-1281, 1993.
 
10) Okunishi H, et al : Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 2 : 277-284, 1984.
 
11) Nakamaru M, et al : Beta-adrenoceptor-mediated release of angiotensin II from mesenteric arteries. Am J Physiol 250 : H144-148, 1986.
PubMed
12) Dzau VJ : Significance of the vascular renin-angiotensin pathway. Hypertension 8 : 553-559, 1986.
PubMed
13) Dzau V, Braunwald E : Resolved and unresolved issues in the prevention and treatment of coronary artery disease : a workshop consensus statement. Am Heart J 121 : 1244-1263, 1991.
PubMed
P.15 掲載の参考文献
1) Tigerstedt R, Bergman PG : Scand Arch Physiol 8 : 223-270, 1898.
 
2) Santos RA, et al : Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 (14) : 8258-8263, 2003.
 
3) Jeunemaitre X, et al : Molecular basis of human hypertension : role of angiotensinogen. Cell 71 (1) : 169-180, 1992.
PubMed
4) Graves SW, et al : Genes, phenotypes and hypertensive pregnancies. Nat Genet 4 (1) : 7-8, 1993.
PubMed
5) Ward K, et al : A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet 4 (1) : 59-61, 1993.
 
6) Arngrimsson R, et al : Angiotensinogen : a candidate gene involved in preeclampsia? Nat Genet 4 (2) : 114-115, 1993.
PubMed
7) Ohkubo H, et al : Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci USA 87 (13) : 5153-5157, 1990.
PubMed
8) Mullins JJ, et al : Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344 (6266) : 541-544, 1990.
PubMed
9) Alderman MH, et al : Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324 (16) : 1098-1104, 1991.
PubMed
10) Caulfield M, et al : Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 330 (23) : 1629-1633, 1994.
PubMed
11) Nibu Y, et al : Identification of cell type-dependent enhancer core element located in the 3'-downstream region of the human angiotensinogen gene. J Biol Chem 269 (46) : 28598-28605, 1994.
 
12) Yanai K, et al : Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcription initiation site affects its transcriptional activity. J Biol Chem 272 (48) : 30558-30562, 1997.
PubMed
13) Sato N, et al : Association of variants in critical core promoter element of angiotensinogen gene with increased risk of essential hypertension in Japanese. Hyperetnsion 30 (3 Pt 1) : 321-325, 1997.
 
14) Ishigami T, et al : Essential hypertension and 5' upstream core promoter region of human angiotensinogen gene. Hyperetnsion 30 (6) : 1325-1330, 1997.
 
15) Cambien F, et al : Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359 (6396) : 641-644, 1992.
PubMed
16) Bonnardeaux A, et al : Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24 (1) : 63-69, 1994.
PubMed
17) Benetos A, et al : Influence of angiotensin II type 1 receptor polymorphism on aortic stiffness in never-treated hypertensive patients. Hypertension 26 (1) : 44-47, 1995.
PubMed
18) Nguyen G, et al : Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109 (11) : 1417-1427, 2002.
PubMed
19) Suzuki F, et al : Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 278 (25) : 22217-22222, 2003.
PubMed
20) Ichihara A, et al : Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 114 (8) : 1128-1135, 2004.
 
P.21 掲載の参考文献
1) Kimura S, et al : Effects of thyroid hormone on angiotensinogen and renin messenger RNA levels in rats. Jpn J Pharmacol 52 : 281-285, 1990.
PubMed
2) Nakamura A, et al : Regulation of liver angiotensinogen and kidney renin mRNA levels by angiotensin II. Am J Physiol 258 : E1-6, 1990.
PubMed
3) Yanai K, et al : A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. J Biol Chem 271 : 15981-15986, 1996.
 
4) Celerier J, et al : Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 39 : 224-228, 2002.
PubMed
5) Dzau VJ : Theodore Cooper Lecture : Tissue angiotensin and pathobiology of vascular disease : a unifying hypothesis. Hypertension 37 : 1047-1052, 2001.
 
6) Tamura K, et al : Tissue-specific regulation of angiotensinogen gene expression in spontaneously hypertensive rats. Hypertension 27 : 1216-1223, 1996.
PubMed
7) Massiera F, et al : Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 15 : 2727-2729, 2001.
PubMed
8) Jones BH, et al : Angiotensinogen gene expression in adipose tissue : analysis of obese models and hormonal and nutritional control. Am J Physiol 273 : R236-242, 1997.
PubMed
9) Schorr U, et al : Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 16 : 1475-1480, 1998.
 
10) Kamide K, et al : Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 32 : 482-487, 1998.
PubMed
11) Kamide K, et al : Insuhn-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth. J Hypertens 22 : 121-127, 2004.
PubMed
12) Jeunemaitre X, et al : Molecular basis of human hypertension : role of angiotensinogen. Cell 71 : 169-180, 1992.
PubMed
13) Sethi AA, et al : Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease : a meta-analysis. Arterioscler Thromb Vasc Biol 23 : 1269-1275, 2003.
PubMed
14) Inoue I, et al : A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99 : 1786-1797, 1997.
PubMed
P.26 掲載の参考文献
1) Baudin B : New aspects on angiotensin-converting enzymes : from gene to disease. Clin Chem Lab Med 40 : 256-265, 2002.
PubMed
2) Sturrock ED : Structure of angiotensin I-converting enzyme. Cell Mol Life Sci 61 : 2677-2686, 2004.
PubMed
3) Franke FE, et al : Angiotensin I-converting enzyme and potential substrates in human testis and testicular tumors. APMIS 111 : 234-244, 2003.
PubMed
4) Santhamma KR, et al : Role of tyrosine phosphorylation in the regulation of cleavage secretion of angiotensin converting enzyme. J Biol Chem 279 : 40227-40236, 2004.
PubMed
5) Natesh R, et al : Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 421 : 551-554, 2003.
 
6) Georgiadis D, et al : Role of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin. Circ Res 93 : 148-154, 2003.
 
7) Coates D : The angiotensin converting enzyme (ACE). Int J Biochem Cell Biol 35 : 769-773, 2003.
PubMed
8) Fuchs S, et al : Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. Curr Hypertens Rep 6 : 124-128, 2004.
PubMed
9) Fuchs S, et al : Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 279 : 15946-15953, 2004.
 
10) Danilczyk U, et al : A story of two ACEs. J Mol Med 81 : 227-234, 2003.
 
11) Turner AJ, Hooper NM : The angiotensin-converting enzyme gene family : genomics and pharmacology. Trends Pharmacol Sci 23 : 177-183, 2002.
PubMed
12) Oudit GY, et al : The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13 : 93-101, 2003.
PubMed
13) Turner AJ, et al : ACEH/ACE2 is a novel mammalian metallocarboxypeptida se and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can J Physiol Pharmacol 80 : 346-353, 2002.
 
14) Chappell MC, et al : Novel aspects of the renal renin-angiotensin system : angiotensin- (1-7), ACE2 and blood pressure regulation. Contrib Nephrol 143 : 77-89, 2004.
PubMed
15) Crackower MA, et al : Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 : 822-828, 2002.
PubMed
P.34 掲載の参考文献
1) de Gasparo M, et al : International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 : 415-472, 2000.
PubMed
2) Horiuchi M, et al : Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33 : 613-621, 1999.
PubMed
3) Santos RA, et al : Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 : 8258-8263, 2003.
 
4) Albiston AL, et al : Evidence that the angiotensin IV (AT (4) ) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276 : 48623-48626, 2001.
PubMed
5) Dzau VJ : Theodore Cooper Lecture : Tissue angiotensin and pathobiology of vascular disease : a unifying hypothesis. Hypertension 37 : 1047-1052, 2001.
 
6) Wu L, et al : Roles of AT2 receptor stimulation associated with selective AT1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104 : 2716-2721, 2001.
 
7) Suzuki J, et al : Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 106 : 847-8532002.
PubMed
8) WU L, et al : Regulation of IκB and MCP-1 by angiotensin II type 2 receptor-activated SHP-1 in fetal vascular smooth muscle cells. Mol Endocrinol 18 : 666-678, 2004.
 
9) Akishita M, et al : Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102 : 1684-1689, 2000.
PubMed
10) Wu L, et al : Effect of AT1 receptor blockade on cardiac remodeling in AT2 receptor null mice. Arterioscler Thromb Vasc Biol 22 : 49-54, 2002.
PubMed
11) Senbonmatsu T, et al : Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest 106 : R25-R29, 2000.
PubMed
12) Sugino H, et al : A poptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension 37 : 1394-1398, 2001.
 
13) Masaki H, et al : Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101 : 527-535, 1998.
PubMed
14) Yang Z, et al : Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 106 : 106-111, 2002.
PubMed
15) Ichihara S, et al : Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 106 : 2244-2249, 2002.
PubMed
16) Oishi Y, et al : Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 41 : 814-818, 2003.
PubMed
17) Adachi Y, et al : Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 107 : 2406-2408, 2003.
PubMed
18) Xu J, et al : Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 40 : 244-250, 2002.
PubMed
19) Iwai M, et al : Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 : 843-848, 2004.
PubMed
20) Miura S, Kamik SS : Ligand-independent signals from angiotensin Inype 2 receptor induce apoptosis. EMBO J 19 : 4026-4035, 2000.
 
21) Zou Y, et al : Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6 : 499-506, 2004.
PubMed
22) Wang C, et al : Identification of a domain in the angiotensin II type 1 receptor determining Gq coupling by the use of receptor chimeras. J Biol Chem 270 : 16677-16682, 1995.
PubMed
23) Hayashida W, et al : Intracellular third loop domain of angiotensin II type 2 receptor : Role in the cellular signal transduction and functional expression. J Biol Chem 271 : 21985-21992, 1996.
 
24) Lehtonen JY, et al : Analysis of functional domains of angiotensin II type 2 receptor involved in apoptosis. Mol Endocrinol 13 : 1051-1060, 1999.
PubMed
25) Daviet L, et al : Cloning and charactehzation of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem 274 : 17058-17062, 1999.
PubMed
26) Cui T, et al : ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receltor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun 279 : 938-941, 2000.
PubMed
27) Senbonmatsu T, et al : A novel angiotensin II type 2 receptor signaling pathway : possible role in cardiac hypertrophy. EMBO J 22 : 6471-6482, 2003.
 
28) Nouet S, et al : Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 279 : 28989 -28997, 2004.
 
29) AbdAlla S, et al : AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 : 94-98, 2000.
PubMed
30) AbdAlla S, et al : The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276 : 39721-39726, 2001.
PubMed
P.41 掲載の参考文献
1) de Gasparo M, et al : International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 : 415-472, 2000.
PubMed
2) Davisson RL, et al : Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 106 : 103-106, 2000.
 
3) Sadoshima J, et al : Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 : 977-984, 1993.
PubMed
4) Funakoshi Y, et al : Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 34 : 118-125, 1999.
PubMed
5) Takeda K, et al : Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 21 : 868-873, 2001.
PubMed
6) Takekoshi K, et al : Angiotensin II type 2 receptor counter-regulates type 1 receptor in catecholamine synthesis in cultured porcine adrenal medullary chromaffin cells. Hypertension 39 : 142-148, 2002.
PubMed
7) Ichiki T, et al : Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377 : 748-750, 1995.
PubMed
8) Ohkubo N, et al : Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96 : 3954-3962, 1997.
PubMed
9) Kakuchi J, et al : Developmental expression of renal angiotensin II receptor genes in the mouse. Kidney Int 47 : 140-147, 1995.
PubMed
10) Stoll M, et al : The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95 : 651-657, 1995.
PubMed
11) Nickenig G, et al : Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100 : 2131-2134, 1999.
PubMed
12) Takeda K, et al : Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102 : 1834-1839, 2000.
PubMed
13) Ichiki T, et al : Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells. Circ Res 77 : 1070-1076, 1995.
PubMed
14) Horiuchi M, et al : Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. J Biol Chem 272 : 11952-11958, 1997.
PubMed
P.47 掲載の参考文献
1) Santos RA, et al : Angiotensin- (1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100 (14) : 8258-8263, 2003.
 
2) Donoghue M, et al : A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (5) : E1-E9, 2000.
 
3) Ohkubo H, et al : Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci USA 87 (13) : 5153-5157, 1990.
PubMed
4) Mullins JJ, et al : Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344 (6266) : 541-544, 1990.
PubMed
5) Fukamizu A, et al : Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268 (16) : 11617-11621, 1993.
 
6) Takimoto E, et al : Hypertension induced in pregnant mice by placental renin and matemal angiotensinogen. Science 274 (5289) : 995-998, 1996.
 
7) Gura T : Mouse model for pregnancy problem? Science 274 (5289) : 922, 1996.
PubMed
8) Saito T, et al : An essential role for angiotensin II type 1 a receptor in pregnancy-associated hypertension with intrauterine growth retardation. FASEB J 18 (2) : 388-390, 2004.
PubMed
9) Tanimoto K, et al : Angiotensinogen-deficient mice with hypotension. J Biol Chem 269 (50) : 31334-31337, 1994.
PubMed
10) Kim HS, et al : Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92 (7) : 2735-2739, 1995.
PubMed
11) Krege JH, et al : Male-female dfierences in fenility and blood pressure in ACE-deficient mice. Nature 375 (6527) : 146-148, 1995.
PubMed
12) Esther CR Jr, et al : Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74 (5) : 953-965, 1996.
PubMed
13) Niimura F, et al : Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 96 (6) : 2947-2954, 1995.
PubMed
14) Yanai K, et al : Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J Biol Chem 275 (1) : 5-8, 2000.
PubMed
15) Crackower MA, et al : Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (6891) : 822-828, 2002.
PubMed
16) Walther T, et al : Sustained long term potentiation and anxiety in mice lackmg the Mas protooncogene. J Biol Chem 273 (19) : 11867-11873, 1998.
 
17) Kakinuma Y, et al : Anti-apoptotic action of angiotensin fragments to neuronal cells from angiotensinogen knock-out mice. Neurosci Lett 232 (3) : 167-170, 1997.
PubMed
18) Kakinuma Y, et al : Impaired blood-brain barrier function in angiotensinogen-deficient mice. Nat Med 4 (9) : 1078-1080, 1998.
PubMed
19) Li W, et al : Angiotensin-convening enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (6965) : 450-454, 2003.
 
P.52 掲載の参考文献
1) Masaki H, et al : Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101 : 527-535, 1998.
PubMed
2) Tsutsumi Y, et al : Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104 : 925-935, 1999.
PubMed
3) Ito M, et al : Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92 : 3521-3525, 1995.
PubMed
4) Chen X, et al : Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J physiol 272 (3 Pt 2) : F299-304, 1997.
 
5) Tsuchida S, et al : Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 101 : 755-760, 1998.
PubMed
6) Hein L, et al : Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 377 : 744-747, 1995.
PubMed
7) Ichiki T, et al : Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 377 : 748-750, 1995.
PubMed
8) Oliverio MI, et al : Angiotensin II responses in AT1A receptor-deficient mice : a role for AT1B receptors in blood pressure regulation. Am J Physiol 272 (4 Pt 2) : F515-520, 1997.
 
9) Harada K, et al : Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100 : 2093-2099, 1999.
PubMed
10) Chen R, et al : Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension 42 : 542-547, 2003.
PubMed
11) Davisson RL, et al : Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 106 : 103-106, 2000.
 
12) Akishita M, et al : Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102 : 1684-1689, 2000.
PubMed
13) Wu L, et al : Effect of AT1 receptor blockade on cardiac remodeling in AT2 receptor null mice. Arterioscler Thromb Vasc Biol 22 : 49-54, 2002.
PubMed
14) Wu L, et al : Roles of AT2 receptor stimulation associated with selective ATl receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104 : 2716-2721, 2001.
 
15) Li Z, et al : Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 284 : H116-121, 2003.
PubMed
16) Iwai M, et al : Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 : 843-848, 2004.
PubMed
P.59 掲載の参考文献
1) Higaki J, et al : A new sensitive direct radioimmunoassay for human plasma rennin and its clinical application. J Lab Clin Med 104 : 947, 1984.
 
P.64 掲載の参考文献
1) Ihara M, et al : High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology 94 : 247-253, 2000.
PubMed
2) Ihara M, et al : Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 33 : 1399-1405, 1999.
PubMed
3) Uehara Y, et al : Increased chymase activity in internal thoracic artery of patients with hypercholesterolemia. Hypertension 35 : 55-60, 2000.
PubMed
4) Toth T, et al : Mast cells in rapidly progressive glomerulonephritis. J Am Soc Nephrol 10 : 1498-1505, 1999.
PubMed
5) Takai S, et al : Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 69 : 1725-1732, 2001.
PubMed
6) Takai S, et al : An orally active chymase inhibitor, BCEAB, suppresses heart chymase activity in the hamster. Jpn J Pharmacol 86 : 124-126, 2001.
PubMed
7) Jin D, et al : Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci 71 : 437-446, 2002.
PubMed
8) Uehara Y, et al : Chymase inhibition suppresses high -cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 55 : 870-876, 2002.
PubMed
9) Inoue Y, et al : Antihypertensive and antihypertrophic effects of chymase inhibitor in human chymase transgenic mice. Circ J 66 : 802, 2002.
 
10) Hoshino F, et al : Chymase inhibition improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 41 : S11-S18, 2003.
PubMed
11) Naruse M, et al : Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40 : 28-33, 2002.
PubMed
P.69 掲載の参考文献
1) Levy D, et al : Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 322 : 1561-1566, 1990.
PubMed
2) Villarreal FJ, et al : Myocardial remodeling in hypertensive Ren-2 transgenic rats. Hypertension 25 : 98-104, 1995.
PubMed
3) Bohm M, et al : Reduction of cardiac hypertrophy in TGR (mREN2) 27 by angiotensin II receptor blockade. Mol Cell Biochem 163-164 : 217-221, 1996.
 
4) Paradis P, et al : Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci USA 97 : 931-936, 2000.
PubMed
5) Liu YH, et al : Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 27 : 7-13 1996.
PubMed
6) Harada K, et al : Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation 97 : 1369-1380, 1999.
 
7) Yamagishi H, et al : Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardia1-infarcted rats. J Mol Cell Cardiol 25 : 1369-1380, 1993.
PubMed
8) Harada K, et al : Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100 : 2093-2099, 1999.
PubMed
9) Komuro I, Yamazaki Y : Control of cardiac gene expression by mechanical stress. Annu Rev Physiol 55 : 55-75, 1993.
 
10) Sadoshima J, et al : Autocrine secretion of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 : 977-984, 1993.
PubMed
11) Zou Y, et al : Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6 : 499-506, 2004.
PubMed
12) Seta K, et al : AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway Without nuclear translocation of ERKs. J Biol Chem 277 : 9268-9277, 2002.
PubMed
13) Van Biesen T, et al : Mitogenic signaling via G protein-coupled receptors. Endocr Rev 17 : 698-714, 1996.
 
14) Masaki H, et al : Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest 101 : 527-535, 1998.
PubMed
15) Tsutsumi Y, et al : Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104 : 925-935, 1999.
PubMed
P.75 掲載の参考文献
1) Kim S, Iwao H : Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (1) : 11-34, 2000.
PubMed
2) Izumi Y, et al : Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res 88 (11) : 1120-1126, 2001.
 
3) Yasumoto H, et al : Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats. Gene Ther 8 (22) : 1682-1689, 2001.
PubMed
4) Izumi Y, et al : Activation of apoptosis signal-regulating kinase 1 in injured artery and its critical role in neointimal hyperplasia. Circulation 108 (22) : 2812-2818, 2003.
PubMed
5) Izumiya Y, et al : A poptosis signal-regulating kinase 1 plays a pivota1 role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res 93 (9) : 874-883, 2003.
 
6) Kim S, et al : Beneficial effects of combined blockade of ACE and AT1 receptor on intimal hyperplasia in balloon-injured rat artery. Arterioscler Thromb Vasc Biol 22 (8) : 1299-1304, 2002.
PubMed
P.83 掲載の参考文献
1) Navar LG, et al : Regulation of intrarenal angiotensin II in hypertension. Hypertension 39 : 316-322, 2002.
PubMed
2) Harris PJ, Young JA : Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflugers Arch 367 : 295-297, 1977.
PubMed
3) Schuster VL, et al : Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest 73 : 507-515, 1984.
PubMed
4) Liu FY, Cogan MG : Angiotensin II stimulation of hydrogen ion secretion in the rat early proximal tubule ; Modes of action, mechanisms, and kinetics. J Clin Invest 82 : 601-607, 1988.
PubMed
5) Geibel J, et al : Angiotensin II stimulates both Na+ - H+ exchange and Na+/HCO3- cotransport in rabbit proximal tubule. Proc Natl Acad Sci USA 87 : 7917-7920, 1990.
 
6) Douglas JG, Hopfer U : Novel aspect of angiotensin receptors and signal transduction in the kidney. Annu Rev Physiol 56 : 649-669, 1994.
PubMed
7) Liu FY, Cogan MG : Angiotensin II stimulates early proximal bicarbonate absorption in the rat by decreasing cyclic adenosine monophosphate. J Clin Invest 84 : 83-91, 1989.
PubMed
8) Madhun ZT, et al : An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J Clin Invest 88 : 456-461, 1991.
PubMed
9) Jacob LS, Douglas JG : Angiotensin II type 2 receptor subtype mediates phospholipase A2-dependent signaling in rabbit proximal tubular epithelial cells. Hypertension 28 : 663-668, 1996.
 
10) Amlal H, et al : Angiotensin II controls Na+ - K+ (NH4+) -2Cl- cotransport via 20-HETE and PKC in medullary thick ascending limb. Am J Physiol 274 : C1047-C1056, 1998.
 
11) Lu M, et al : Effect of angiotensin II on the apical K+ channel in the thick ascending limb of the rat kidney. J Gen Physiol 108 : 537-547, 1996.
 
12) Lerolle N, et al : Angiotensin II inhibits NaCl absorption in the rat medullary thick ascending limb. Am J Physiol 287 : F404-F410, 2004.
 
13) Good DW, et al : Angiotensin II inhibits HCO3- absorption via a cytochrome P-450-dependent pathway in MTAL. Am J Physiol 276 : F726-F736, 1999.
 
14) Wang T, et al : Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am J Physiol 271 : F143-F149, 1996.
PubMed
15) Harrison-Bernard LM, et al : Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 273 : F170-F177, 1997.
PubMed
16) Bell PD, et al : Angiotensin II stimulates macula densa basolateral sodium/hydrogen exchange via type 1 angiotensin II receptors. J Am Soc Nephrol 10 : 225-229, 1999.
 
17) Kovacs G, et al : Angiotensin II directly stimulates macula densa Na-2Cl-K cotransport via apical AT (1) receptors. Am J Physiol 282 : 301-306, 2002.
 
18) Traynor T, et al : Tubuloglomerular feedback in ACE-deficient mice. Am J Physiol 276 : F751-F757, 1999.
PubMed
19) Carroll MA, et al : Cytochrome P-450-dependent HETEs : profile of biological activity and stimulation by vasoactive peptides. Am J Physiol 271 : R863-R869, 1996.
PubMed
20) Kohagura K, et al : Involvement of cytochrome P450 metabolites in the vascular action of angiotensin II on the afferent arterioles. Hypertens Res 24 : 551-557, 2001.
PubMed
21) Sun CW, Roman RJ : 20-HETE contributes the inhibition of K+ channel activity and the vasoconstrictor effect of angiotensin II in rat renal arterioles. Hypertension 34 : 338, 1999.
 
22) Kohagura K, et al : Endogenous nitric oxide and epoxyeicosatrienoic acid modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol Scand 168 : 107-112, 2000.
PubMed
23) Arima S, et al : Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 100 : 2816-2823, 1997.
PubMed
24) Cupples WA, et al : Angiotensin II and prostaglandins in control of vasa recta blood flow. Am J Physiol 254 : F417-F424, 1988.
PubMed
25) Roman RJ, Smits C : Laser-Doppler determination of papillary blood flow in young and adult rats. Am J Physiol 251 : F115-F124, 1986.
 
26) Pallone TL : Vasoconstriction of outer medullary vasa recta by angiotensin II is modulated by prostaglandin E2. Am J Physiol 266 : F850-F857, 1994.
PubMed
P.88 掲載の参考文献
1) Kerr JF, et al : A poptosis : a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 : 239-257, 1972.
 
2) Griendling KK, et al : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 : 1141-1148, 1994.
PubMed
3) Horiuchi M, et al : Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33 : 613-621, 1999.
PubMed
4) Horiuchi M, et al : Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res 84 : 876-882, 1999.
PubMed
5) Dimmeler S, Zeiher AM : Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. Regul Pept 90 : 19-25, 2000.
 
6) Ohashi H, et al : Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ Res 94 : 785-793, 2004.
PubMed
7) Yamada T, et al : Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 93 : 156-160, 1996.
PubMed
8) Yamada T, et al : Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action : an in vitro gene transfer study. Life Sci 63 : PL289-295, 1998.
 
9) Suzuki J, et al : Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 106 : 847-853, 2002.
PubMed
10) Cigola E, et al : Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res 231 : 363 -371, 1997.
 
11) Diep QN, et al : Effect of AT (1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 282 : H1635-1641, 2002.
PubMed
12) Goldenberg I, et al : Angiotensin II-induced apoptosis in rat cardiomyocyte culture : a possible role of AT1 and AT2 receptors. J Hypertens 19 : 1681-1689, 2001.
 
13) Sugino H, et al : Apoptosis is not increased in myocardium overexpressing type 2 angiotensin II receptor in transgenic mice. Hypertension 37 : 1394-1398, 2001.
 
P.94 掲載の参考文献
1) Folli F, et al : Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100 : 2158-2169, 1997.
 
2) Higashiura K, et al : The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats. Am J Hypertens 13 : 290-297, 2000.
 
3) Togashi N, et al : The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 18 : 1605-1610, 2000.
PubMed
4) Sharma AM, et al : Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40 : 609-611, 2002.
PubMed
5) Kobayashi R, et al : Role of angiotensin II in high fructose-induced left ventricular hypertrophy in rats. Hypertension 21 : 1051-1055, 1993.
PubMed
6) Iyer SN, et al : AT1 receptor density changes during development of hypertension in hyperinsulinemic rats. Clin Exp Hypertens 18 : 793-810, 1996.
PubMed
7) Kamide K, et al : Insulin and insulin-like growth factor-I promotes angiotensinogen production and growth in vascular smooth muscle cells. J Hypertens 18 : 1051-1056, 2000.
 
8) Kuboki K, et al : Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. Circulation 101 : 676-681, 2000.
PubMed
9) Kamide K, et al : The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens 15 : 66-71, 2002.
PubMed
10) Kamide K, et al : Insulin-mediated growth in aortic smooth muscle and the vascular renin-angiotensin system. Hypertension 32 : 482-487, 1998.
PubMed
11) Nagai M, et al : Role of endothelin-1 induced by insulin in the regulation of vascular cell growth. Am J Hypertens 16 : 223 -228, 2003.
 
12) Ogihara T, et al : Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats. Diabetes 50 : 573-583, 2001.
PubMed
13) Benson SC, et al : Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43 : 993-1002, 2004.
PubMed
14) Schupp M, et al : Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 : 2054-2057, 2004.
PubMed
15) Fujimoto M, et al : An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576 : 492-497, 2004.
PubMed
16) Furuhashi M, et al : Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42 : 76-81, 2003.
PubMed
17) Takeda K, et al : Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102 : 1834-1839, 2000.
PubMed
18) Sugawara A, et al : Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142 : 3125-3134, 2001.
PubMed
19) Julius S, et al : Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomised trial. Lancet 363 : 2022-2031, 2004.
 
20) Opie LH, Schall R : Old antihypertensives and new diabetes. J Hypertens 22 : 1453-1458, 2004.
PubMed
21) Verdecchia P, et al : Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 43 : 963-969, 2004.
PubMed
22) Eberly LE, et al : Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality : the multiple risk factor intervention trial experience. Diabetes Care 26 : 848-854, 2003.
PubMed
23) Tikellis C, et al : Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53 : 989-997, 2004.
PubMed
24) Lindholm LH, et al : Metabolic outcome during 1 year in newly detected hypertensives : results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21 : 1563-1574, 2003.
 
P.99 掲載の参考文献
1) Griendling KK, et al : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 : 1141-1148, 1994.
PubMed
2) Landmesser U, et al : Role of p47 (phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40 : 511-515, 2002.
PubMed
3) Wang HD, et al : Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 88 : 947-953, 2001.
PubMed
4) Gregg D, et al : Rac regulates cardiovascular superoxide through diverse molecular interactions : more than a binary GTP switch. Am J Physiol Cell Physiol 285 : C723-734, 2003.
PubMed
5) Sussman MA, et al : Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac 1. J Clin Invest 105 : 875-886, 2000.
 
6) Ushio-Fukai M, et al : Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21 : 489-495, 2001.
PubMed
7) Seshiah PN, et al : Angiotensin II stimulation of NAD (P) Hoxidase activity : upstream mediators. Circ Res 91 : 406-413, 2002.
 
8) Bendall JK, et al : Pivotal role of a gp91 (phox) -containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105 : 293-296, 2002.
PubMed
9) Shimosawa T, et al : Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation 105 : 106-111, 2002.
PubMed
10) Matsui H, et al : Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 109 : 2246-2251, 2004.
PubMed
11) Kawai J, et al : Endogenous adrenomedullin protects against vascular response to injury in mice. Circulation 109 : 1147-1153, 2004.
PubMed
12) Higashi Y, et al : Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 346 : 1954-1962, 2002.
PubMed
13) Guzik TJ, et al : Functional effect of the C242T polymorphism in the NAD (P) Hoxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 102 : 1744-1747, 2000,
 
14) Schachinger V, et al : NADH/NADPH oxidase p22 phox gene polymorphism is associated with improved coronary endothelial vasodilator function. Eur Heart J 22 : 96-101, 2001.
PubMed
15) Gardemann A, et al : The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis 145 : 315-323, 1999.
 
16) Pizzi C, et al : Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme a reductase in cardiac Syndrome X : role of superoxide dismutase activity. Circulation 109 : 53-58, 2004.
PubMed
17) Zimmerman MC, et al : Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res 95 : 210-216, 2004.
PubMed
18) Bertelsen M, et al : Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia 44 : 605-613, 2001.
PubMed
19) Najib S, Sanchez-Margalet V : Homocysteine thiolactone inhibits insulin signaling, and glutathione has a protective effect. J Mol Endocrinol 27 : 85-91, 2001.
 
20) Rudich A, et al : Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes 47 : 1562-1569, 1998.
PubMed
21) Rudich A, et al : Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol 272 : E935-940, 1997.
PubMed
22) Xing G, et al : Angiotensin II-induced insulin resistance is enhanced in adrenomedullin-deficient mice. Endocrinology 145 : 3647-3651, 2004.
PubMed
23) Germano G, et al : Enhanced platelet release of superoxide anion in systemic hypertension : role of AT1 receptors. J Hypertens 22 : 1151-1156, 2004.
PubMed
24) Beswick RA, et al : NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 38 : 1107-1111, 2001.
PubMed
25) Rey FE, et al : Novel competitive inhibitor of NAD (P) Hoxidase assembly attenuates vascular O2- and systolic blood pressure in mice. Circ Res 89 : 408-414, 2001.
 
26) Cayatte AJ, et al : S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 21 : 1577-1584, 2001.
PubMed
27) Berry C, et al : Investigation into the sources of superoxide in human blood vessels : angiotensin II increases superoxide production in human internal mammary arteries. Circulation 101 : 2206-2212, 2000.
PubMed
28) Nagaya N, et al : Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats. Am J Physiol Heart Circ Physiol 285 : H2125-2131, 2003.
PubMed
P.106 掲載の参考文献
1) Asahara T, et al : Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 : 964-967, 1997.
PubMed
2) Sasaki K, et al : Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest 109 : 603-611, 2002.
PubMed
3) Egami K, et al : Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112 : 67-75, 2003.
PubMed
4) Silvestre JS, et al : Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ Res 90 : 1072-1079, 2002.
PubMed
5) Walther T, et al : Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 17 : 2061-2067, 2003.
PubMed
6) Ichiki T : Role of rennin angiotensin system in angiogenesis : It is still elusive. Arterioscler Thromb Vasc Biol 24 : 622-624, 2004.
 
7) Volpert OV, et al : Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98 : 671-679, 1996.
PubMed
8) Lever AF, et al : Do inhibitors of angiotensin-1-converting enzyme protect against risk of cancer? Lancet 352 : 179-184, 1998.
PubMed
9) Fabre JE, et al : Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 99 : 3043-3049, 1999.
PubMed
10) Murohara T, et al : Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101 : 2567-2578, 1998.
PubMed
11) Fujiyama S, et al : Angiotensin AT1 and AT2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF) -mediated EGF receptor transactivation. Circ Res 88 : 22-29, 2001.
PubMed
12) Toko H : Angiotensin II type 1 a receptor is involved in cell infiltration, cytokine production, and neovascularization in infarcted myocardium. Arterioscler Thromb Vasc Biol 24 : 664-670, 2004.
PubMed
13) Nahmod KA, et al : Control of dendritic cell differentiation by angiotensin II. FASEB J 17 : 491-493, 2003.
PubMed
14) Nishida M, et al : Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110 : 1859-1868, 2002.
PubMed
P.110 掲載の参考文献
1) Unger T, et al : Angiotensin receptors. J Hypertens 14 : S95-103, 1996.
 
2) Davisson RL, et al : Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 106 : 103-106, 2000.
 
3) Tsuchida S, et al : Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 101 : 755-760, 1998.
PubMed
4) Nagatomo T, et al : 4 : Transient outward current in adult rat supraoptic neurones with slice patch-clamp technique : inhibition by angiotensin II. J Physiol 485 : 87-96, 1995.
PubMed
5) Ozaki Y, et al : Potentiation by angiotensin II of spontaneous excitatory postsynaptic currents in rat supraoptic magnocellular neurones. J Neuroendocrinol. (in press)
 
6) Chu CP, et al : Enhanced effects of central angiotensin II on cardiovascular and drinking responses in inbred polydipsic (STR/N) mice. Brain Res 962 : 129-134, 2003.
PubMed
7) Merrill DC, et al : Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest 97 (4) : 1047-1055, 1996.
 
8) Morimoto S, et al : Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter. Circ Res 89 (4) : 365-372, 2001.
PubMed
9) Ferrario CM, et al : The renin-angiotensin system : physiological actions in the central nervous system. In : Pathophysiology of Hypertension : Handbook of Hypertension, Vol 8 (ed by Zanchetti A, Tarazi RC), p 431-454, Amsterdam, The Netherland : Elsevier, 1986.
 
10) Wright JW, et al : Angiotensin II (3-8) (ANG IV) hippocampal binding : potential role in the facilitation of memory. Brain Res Bull 32 : 497-502, 1993.
PubMed
11) Fontes MA, et al : Evidence that angiotensin- (1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specfic receptors. Brain Res 665 : 175-180, 1994.
 
12) Ferrario CM, et al : Angiotensin- (1-7) : a new hormone of the angiotensin system. Hypertension 18 : III126-133, 1991.
PubMed
P.118 掲載の参考文献
1) Brown MJ : The causes of essential hypertension. Br J Clin Pharmacol 42 : 21-27, 1996.
PubMed
2) Jeunemaitre X, et al : Molecular basis of human hypertension : role of angiotensinogen. Cell 71 : 169-180, 1992.
PubMed
3) Ishikawa K, et al : T+31C polymorphism of angiotensinogen gene and essential hypertension. Hypertension 37 : 281-285, 2001.
PubMed
4) Nakajima T, et al : Nucleotide diversity and haplotype structure of the human angiotensinogen gene in two populations. Am J Hum Genet 70 : 108-123, 2002.
PubMed
5) Katsuya T, et al : Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res 26 : 521-525, 2003.
PubMed
6) Hunt SC, et al : Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension : trials of hypertension prevention, phase II. Hypertension 32 : 393-401, 1998.
PubMed
7) Cambien F, et al : Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359 : 641-644, 1992.
PubMed
8) Ohishi M, et al : Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 331 : 1097-1098, 1994.
PubMed
9) Higaki J, et al : Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men : the Suita Study. Circulation 101 : 2060-2065, 2000.
PubMed
10) Takahashi N, et al : Minireview : computer sirnulations of blood pressure regulation by the renin-angiotensin system. Endocrinology 144 : 2184-2190, 2003.
PubMed
11) Takami S, et al : Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 13 : 121-127, 2000.
PubMed
12) Komlosi P, et al : Current mechanisms of macula densa cell signalling. Acta Physiol Scand 181 : 463-469, 2004.
PubMed
13) Williams JS, et al : Influence of dietary sodium on the renin-angiotensin-aldosterone system and prevalence of left ventricular hypertrophy by EKG criteria. J Hum Hypertens, 2004. (in press)
 
14) Dzau VJ, et al : Pathophysiologic and therapeutic importance of tissue ACE : aconsensus report. Cardiovasc Drugs Ther 16 : 149-160, 2002.
 
15) Dzau VJ : Markers of malign across the cardiovascular continuum : interpretation and application. Circulation 109 : IV1-2, 2004.
PubMed
16) 楽木宏実, 荻原俊男 : ARBの将来. The Renin-Angiotensin System, 第1版 (堀内正嗣ほか編), p361 -368, メディカルレビュー社, 2003.
 
P.124 掲載の参考文献
1) Kellerman PS : Cellular and metabolic consequences of chronic ischemia on kidney function. Semin Nephrol 16 (1) : 33-42, 1996.
PubMed
2) Hackenthal E, et al : Morphology, physiology, and molecular biology of renin secretion. Physiol Rev 70 (4) : 1067-1116, 1990.
PubMed
3) Ichihara A, et al : Transmural pressure inhibits prorenin processing in juxtaglomerular cell. Am J Physiol 277 (1 Pt 2) : R220-228, 1999.
 
4) Nafz B, et al : Flow versus pressure in the control of renin release in conscious dogs. Am J physiol 273 (2 Pt 2) : F200-205, 1997.
 
5) Suzuki H, et al : Alterations in plasma and cerebrospinal fluid norepinephrine and angiotensin II during the development of renal hypertension in conscious dogs. Hypertension 5 (2 Pt 2) : 1139-148, 1983.
 
6) Ferrario CM, et al : An externally adjustable renal artery clamp. J Appl Physiol 31 (4) : 635-637, 1971.
 
7) Masaki Z, et al : Effects of SQ 20,881 on the intact kidney of dogs with two-kidney, one clip hypertension. Hypertension 2 (5) : 649-656, 1980.
PubMed
8) Suzuki H, et al : Characterization of neurohormonal changes following the production of the benign and malignant phases of two-kidney, two-clip Goldblatt hypertension. Jpn Heart J 28 (3) : 413-426, 1987.
PubMed
9) Kumagai H, et al : Baroreflex control of renal sympathetic nerve activity is potentiated at early phase of two-kidney, one-clip Goldblatt hypertension in conscious rabbits. Circ Res 67 (6) : 1309-1322, 1990.
PubMed
10) Nakamoto H, et al : Role of nitric oxide in the evolution of renal ischemia in two-kidney, one-clip renovascular hypertension. Hypertens Res 21 (4) : 267-277, 1998.
PubMed
11) Zoccali C, et al : Atherosclerotic renal artery stenosis : epidemiology, cardiovascular outcomes, and clinical prediction rules. J Am Soc Nephrol 13 (Suppl 3) : S179-183, 2002.
 
12) Conlon PJ, et al : Survival in renal vascular disease. J Am Soc Nephrol 9 (2) : 252-256, 1998.
PubMed
13) Vashist A, et al : Renal artery stenosis : a cardiovascular perspective. Am Heart J 143 (4) : 559-564, 2002.
PubMed
14) Pickering TG, et al : Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis : treatment by angioplasty or surgical revascularisation. Lancet ii (8610) : 551-552, 1988.
PubMed
15) Textor SC : Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol 17 (1) : 67-76, 1997.
PubMed
16) Rushton AR : The genetics of fibromuscular dysplasia. Arch Intern Med 140 (2) : 233-236, 1980.
PubMed
17) Gill KS, Fowler RC : Atherosclerotic renal arterial stenosis : clinical outcomes of stent placement for hypertension and renal failure. Radiology 226 (3) : 821-826, 2003.
PubMed
P.130 掲載の参考文献
1) Fujita T, et al : Factors influencing blood pressure in salt-sensitive patients with hypertension. Am J Med 69 : 334-344, 1980.
PubMed
2) Fujita T, et al : Systemic and regional hemodynamics in patients with salt-sensitive hypertension. Hypertension 16 : 235-244, 1990.
PubMed
3) Laragh JH : Hypertension-Mechanism, Diagnosis, and Manegement- (ed by David JO, et al), p69-79, Hospital Practice Pub Co., New York, 1977.
 
4) Laragh JH : Frontiers in Hypertension Research (ed by Laragh JH, et al), P 183-199, Springer-Verlag, New York, 1981.
 
5) Sealey JE, Laragh JH : Hypertension-Pathophysiology, Diagnosis, and Manegement- (ed by Laragh JO, et al), p 1089-1103, Raven Press, New York, 1990.
 
6) Williams GH, et al : Parallel adrenal and renal abnormalities in young patients with essential hypertension. Am J Med 72 : 907-914, 1982.
PubMed
7) Shoback DM, et al : Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 72 : 2115-2124, 1983.
PubMed
8) Hollenberg NK, et al : Abnormal renal sodium handling in essential hypertension. Reladon to failure of renal and adrenal modulation of responses to angiotensin II. Am J Med 81 : 412-418, 1986.
PubMed
9) Fujita T, Sato Y : Changes in renal and central noradrenergic activity with potassium in DOCA-salt rats. Am J Physiol 246 : F670-F675, 1984.
PubMed
10) Ono A, et al : High calcium diet prevents baroreflex impairment in salt-loaded spontaneously hypertensive rats. Hypertension 24 : 83-90, 1994.
PubMed
11) Huang BS, Leenen FH : Both brain angiotensin II and 'ouabain' contribute to sympathoexcitation and hypertension in Dahl S rats on high salt diet. Hypertension 32 : 1028-1033, 1998.
 
12) Inoue I, et al : A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99 : 1786-1797, 1997.
PubMed
13) Nara Y, et al : Blood pressure cosegregates with a microsatellite of angiotensin I converting enzyme (ACE) in F2 generation from a cross between original normotensive Wistar-Kyoto rat (WKY) and stroke-prone spontaneously hypertensive rat (SHRSP). Biochem Biophys Res Commun 181 : 941-946, 1991.
PubMed
P.135 掲載の参考文献
1) Kurtz A, Wagner C : Regulation of renin secretion by angiotensin II-AT1 receptors. J Am Soc Nephrol 10 : S162-S168, 1999.
PubMed
2) Tanabe A, et al : Angiotensin II type 1 receptor expression in two cases of juxtaglomerular cell tumor : correlation to negative feedback of renin secretion by angiotensin II. Horm Metab Res 31 : 429-434, 1999.
PubMed
3) 木原達 : Juxtaglomerular cell tumor (Robertson-Kihara症候群). 日本臨牀 36 (増刊 : 注目の疾患・問題の領域) : 1184-1185, 1978.
 
4) Corvol P, et al : Renin-secreting tumor. Endocrinol Metab Clin North Am 23 (2) : 255-270, 1994.
PubMed
5) Tanabe A, et al : A very small juxtaglomerular cell tumor preoperatively identified by magnetic resonance imaging. Intern Med 35 : 295-300, 1996.
PubMed
6) Koriyama N, et al : A case of renal juxtaglomerular cell tumor : usefulness of segmental sampling to prove autonomic secretion of the tumor. Am J Med Sci 318 (3) : 194-197, 1999.
PubMed
7) 小見亘ほか : 腎動脈造影下CTが診断に有用であったレニン産生腫瘍の一例. 日内会誌 87 : 1136-1137, 1998.
 
8) Tanaka T, et al : Juxtaglomerular cell tumor. Arch Pathol Lab Med 117 : 1161-1164, 1993.
PubMed
9) Kodet R, et al : Juxtaglomerular cell tumor. An immunohistochemical, electron-microscopic, and in situ hybridization study. Am J Surg Pathol 18 (8) : 837-842, 1994.
PubMed
10) Lopez G-Asenjo JA, et al : Juxtaglomerular cell tumor of the kidney. Morphological, immunohistochemical and ultrastructural studies of a new case. Pathol Res Pract 187 : 354-359, 1991.
PubMed
11) Bruneval P, et al : Detection and localization of renin messenger RNA in human pathological tissues using in situ hybridization. Am J Pathol 131 : 320-330, 1988.
PubMed
12) 宇野雅博ほか : レニン産生腎腫瘍の1例. 日泌尿会誌 84 (6) : 1130-1133, 1993.
 
13) Corvol P, et al : Seven lessons from renin-secreting tumors. Kidney Int 35 (Suppl 25) : S38-S44, 1988.
 
P.141 掲載の参考文献
1) Blumenfeld JD, Laragh JH : Management of hypertensive crises : the scientific basis for treatment decisions. Am J Hypertens 14 : 1154-1167, 2001.
PubMed
2) Lip GY, et al : The failure of malignant hypertension to decline : a survey of 24 years' experience in a multiracial population in England. J Hypertens 12 : 1297-1305, 1994.
 
3) Fleming S : Malignant hypertension-the role of the paracrine renin-angiotensin system. J pathol 192 : 135-139, 2000.
PubMed
4) Tamura K, et al : LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression. Proc Natl Acad Sci USA 97 : 8513-8518, 2000.
PubMed
5) Fukamizu K, et al : Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 268 : 11617-11621, 1993.
 
6) Shimokama T, et al : The Tsukuba hypertensive mouse (transgenic mouse carrying human genes for both renin and angiotensinogen) as a model of human malignant hypertension : development of lesions and morphometric analysis. Virchows Arch 432 : 169-175, 1998.
 
7) Horiuchi M, et al : Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33 : 613-621, 1999.
PubMed
8) Horiuchi M, et al : Interferon-gamma induces AT (2) receptor expression in fibroblasts by Jak/STAT pathway and interferon regulatory factor-1. Circ Res 86 : 233-240, 2000.
PubMed
9) Akishita M, et al : Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2 : 13-20, 2000.
PubMed
10) Daviet L, et al : Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem 274 : 17058-17062, 1999.
PubMed
11) Cui T, et al : ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun 279 : 938-941, 2000.
PubMed
12) Lopez-Ilasaca M, et al : The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell 14 : 5038-5050, 2003.
 
P.148 掲載の参考文献
1) 宮崎瑞夫 : レニン・アンジオテンシン系. 日本臨牀 62 : 21-27, 2004.
Medical*Online
2) Dzau VJ : Theodore Cooper Lecture : Tissue angiotensin and pathobiology of vascular disease : a unifying hypothesis. Hypertension 37 : 1047-1052, 2001.
 
3) 甲斐久史, 今泉勉 : 左室リモデリングと心不全. 心不全フロンティア (小室一成編), p75-84, メディカルレビュー社, 2003.
 
4) Zou Y, et al : Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6 : 499-506, 2004.
PubMed
5) Kuwahara F, et al : TGF-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106 : 130-135, 2002.
 
6) Kuwahara F, et al : Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 41 : 819-823, 2003.
PubMed
7) Kuwahara F, et al : Hypertensive myocardial fibrosis and diastolic dysfunction-Another model of inflammation-. Hypertension 43 : 739-745, 2004.
 
8) Tokuda K, et al : Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 43 : 499-503, 2004.
PubMed
9) Yoshida J, et al : AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure. Hypertension 43 : 686-691, 2004.
PubMed
10) The SOLVD Investigators : The effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 : 293-302, 1991.
PubMed
11) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
12) Pitt B, et al ; Eplerenone Posrt-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
 
13) Granger CB, et al : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors : the CHARM-Alternative trial. Lancet 362 : 772-776, 2003.
PubMed
14) Pfeffer MA, et al ; Valsaltan in Acute Myocardial Infarction Trial Investigators : Valsaltan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
 
15) Yasuf S, et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function : the CHARM-Preserved trial. Lancet 362 : 777-781, 2003.
 
P.153 掲載の参考文献
1) Brenner BM : The history and future of renoprotection. Kidney Int 64 : 1163-1168, 2003.
PubMed
2) Arendshorst WJ, Navar LG : Renin circulation and glomerular hemodynamics. In : Disease of the Kidney, 4th ed (ed by Schrier RW, Gottschalk CW), p 65-117, Little Brown, Boston, 1998.
 
3) 木村玄次郎 : 腎内血行動態. Annual Review 腎臓 1990 (越川省三編), p35-43, 中外医学社, 1990.
 
4) 木村玄次郎 : 腎と高血圧-分かってきた血圧との密接な関係. 毎日ライフ 9 : 41-44, 1994.
 
5) Kimura G, Brenner BM : The renal basis for salt sensitivity in hypertension. In : Hypertension : Pathophysiology, Diagnosis and Management, 2nd ed (ed by Laragh JH, Brenner BM), p 1569-1588, Raven Press, New York, 1995.
 
6) Kimura G, Brenner BM : A method for distinguishing salt-sensitive from non-salt-sensitive forms of human and experimental hypertension. Curr Opin Nephrol Hypertens 2 : 341-349, 1993.
PubMed
7) Kimura G, et al : Renal mechanisms of salt sensitivity in hypertension. Curr Opin Nephrol Hypertens 3 : 1-12, 1994.
PubMed
8) Kimura G, et al : Internal hemodinamics in patients with essential hypertension. Circ Res 69 : 421-428, 1991.
 
9) Brenner BM, et al : Dietary protein intake and the progressive nature of kidney disease : the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307 : 652-659, 1982.
PubMed
10) Weir MR, Dworkin LD : Antihypertensive drugs, dietary salt, and renal protection : how low should you go and with which therapy? Am J Kidney Dis 32 : 1-22, 1998.
 
11) Ruggenenti P, et al : Effect of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 9 : 2096-2101, 1998.
PubMed
12) 岡田雅弘ほか : 腎疾患. The Renin-Angiotensin System (堀内正嗣ほか編), p309-314, メディカルレビュー社, 2003.
 
P.160 掲載の参考文献
1) Duntas L, et al : Serum angiotensin-converting enzyme activity and active renin plasma concentrations in insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 16 : 203-208, 1992.
PubMed
2) Nishiyama A, et al : Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39 : 129-134, 2002.
 
3) Carey RM, Siragy HM : The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 14 : 274-281, 2003.
PubMed
4) Anderson S, et al : Renal renin-angiotensin system in diabetes : functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265 : F477-486, 1993.
PubMed
5) Zimpelmann J, et al : Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 58 : 2320-2330, 2000.
PubMed
6) Pagtalunan ME, et al : Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99 : 342 -348, 1997.
 
7) Mifsud SA, et al : Podocyte foot process broadening in experimental diabetic nephropathy : amelioration with renin-angiotensin blockade. Diabetologia 44 : 878-882, 2001.
PubMed
8) Gilbert RE, et al : The renin-angiotensin system and the long-term complications of diabetes : pathophysiological and therapeutic considerations. Diabet Med 20 : 607-621, 2003.
 
9) Sugimoto H, et al : Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli : glomerular hyperfiltration is a potential mechanism of ICAM-1upregulation. Diabetes 46 : 2075-2081, 1997.
 
10) Okada S, et al : Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52 : 2586-2593, 2003.
PubMed
11) Yamamoto T, et al : Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90 : 1814-1818, 1993.
PubMed
12) Staessen JA, et al : The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 15 : 1579-1592, 1997.
 
13) Lewis EJ, et al : The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 : 1456-1462, 1993.
 
14) Katayama S, et al : Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus : a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 55 : 113-121, 2002.
 
15) Parving HH, et al : The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 : 870-878, 2001.
PubMed
16) Viberti G, et al : Microalbuminuria reduction with valsaltan in patients with type 2 diabetes mellitus. Circulation 106 : 672-678, 2002.
PubMed
17) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 : 861-869, 2001.
PubMed
18) Rodby RA, et al : The Irbesartan type II diabetic nephropathy trial : study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 15 : 487-497, 2000.
 
19) Mogensen CE, et al : Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes : the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321 : 1440-1444, 2000.
PubMed
20) Rossing K, et al : Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy : a randomized double-blind crossover trial. Diabetes Care 26 : 2268-2274, 2003.
PubMed
21) Mogensen CE, Cooper ME : Diabetic renal disease : from recent studies to improved clinical practice. Diabet Med 21 : 4-17, 2004.
PubMed
22) 大賀佐起子ほか : 糖尿病性腎症. EBMジャーナル 5 : 38-43, 2004.
 
P.166 掲載の参考文献
1) Alderman MH, et al : Association of the rennin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324 : 1098-1104, 1991.
 
2) Daugherty A, et al : Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105 : 1605 -1612, 2001.
 
3) Griendling KK, et al : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 : 1141-1148, 1994.
PubMed
4) Yusuf S, et al : Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients : The HOPE study investigators. N Engl J Med 342 : 145-153, 2000.
 
5) Pfeffer MA, et al : Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction : Results of the Survival and Ventricular Enlargement trial. N Engl J Med 327 : 669-677, 1992.
 
6) No authors listed : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure : The SOLVD Investigators. N Engl J Med 325 : 293-302, 1991.
 
7) Hayek T, et al : The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 44 : 579-587, 1999.
PubMed
8) Hayek T, et al : Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 161 : 65-74, 2002.
PubMed
9) Candido R, et al : Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 : 246-253, 2002.
PubMed
10) Dahlof B, et al : Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertention study (LIFE) : a randomized trial against atenolol. Lancet 359 : 995-1003, 2002.
 
11) Julius S, et al : Outcome in hypertensive patients at high cardiovascular risk treated with regimens based valsartan or amlodipine : the VALUE randomized trial. Lancet 363 : 2022-2031, 2004.
 
12) Candido R, et al : Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109 : 1536-1542, 2004.
 
13) Wang CH, et al : C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 : 1783-1790, 2003.
PubMed
14) Wassmann S, et al : Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94 : 534-541, 2004.
PubMed
15) Keidar S, et al : Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development. A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109 : 2213-2220, 2004.
PubMed
P.170 掲載の参考文献
1) Halperin ML, Goldstein MB (ed) : Hypokalemia. In : Fluid, Electrolyte, and Acid-Base Physiology, p401-446, WB Saunders, Philadelphia, 1999.
 
2) Marples D, et al : Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest 97 : 1960-1968, 1996.
PubMed
3) Jaeger P, et al : Ammonium transport in rat cortical tubule : relationship to potassium metabolism. Am J Physiol 245 : F593-600, 1983.
PubMed
4) Schwartz WB, Relman AS : Effects of electrolyte disorders on renal structure and function. N Engl J Med 276 : 383-389 contd, 1967.
PubMed
5) Riemenschneider T, Bohle A : Morphologic aspects of low-potassium and low-sodium nephropathy. Clin Nephrol 19 : 271-279, 1983.
 
6) France R, et al : Intracellular granules of the renal medulla in a case of potassium depletion due to renal potassium wasting. Electron microscopic comparison with renal medullary granules in the potassium-depleted rat. Am J Pathol 91 : 299-312, 1978.
 
7) Torres VE, et al : Association of hypokalemia, aldosteronism, and renal cysts. N Engl J Med 322 : 345-351, 1990.
PubMed
8) Ogasawara M, et al : Clinical implications of renal cyst in primary aldosteronism. Endocr J 43 : 261-268, 1996.
PubMed
9) Linas SL : Mechanism of hyperreninemia in the potassium-depleted rat. J Clin Invest 68 : 347-355, 1981.
 
10) Suga S, et al : Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. Am J Physiol Renal Physiol 281 : F620-629, 2001.
PubMed
11) Tolins Jp, et al : Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. J Clin Invest 79 : 1447-1458, 1987.
PubMed
12) O'Reilly DS : Increased ammoniagenesis and the renal tubular effects of potassium depletion. J Clin Pathol 37 : 1358-1362, 1984.
PubMed
13) Tsao T, et al : Expression of insulin-like growth factor-1 and transforming growth factor-beta in hypokalemic nephropathy in the rat [In Process Citation]. Kidney Int 59 : 96-105, 2001.
 
14) Suga S, et al : Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency. Kidney Int 61 : 951-958, 2002.
PubMed
15) Suga S, et al : Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms. J Am Soc Nephrol 14 : 397-406, 2003.
PubMed
P.178 掲載の参考文献
1) Bartter FC, et al : Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med 33 : 811-828, 1962.
PubMed
2) Gitelman HJ, et al : A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79 : 221-235, 1966.
PubMed
3) Bettinelli A, et al : Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis : Bartter and Gitelman syndromes. J Pediatr 120 (1) : 38-43, 1992.
PubMed
4) Bettinelli A, et al : Genetic heterogeneity in tubular hypomagnesemia-hypokalemia with hypocalcuria (Gitelman's syndrome). Kidney Int 47 (2) : 547-551, 1995.
PubMed
5) Bianchetti MG, et al : The biochemical diagnosis of Gitelman disease and the definition of "hypocalciuria". Pediatr Nephrol 18 (5) : 409-411, 2003.
PubMed
6) Simon DB, et al : Gitelman'svariant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 12 (1) : 24-30, 1996.
 
7) Simon DB, et al : Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 13 (2) : 183-188, 1996.
 
8) Simon DB, et al : Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 14 (2) : 152-156, 1996.
 
9) Simon DB, et al : Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet 17 (2) : 171-178, 1997.
PubMed
10) Estevez R, et al : Barttin is a Cl-channel beta-subunit crucial for renal Cl-reabsorption and inner ear K+secretion. Nature 414 (6863) : 558-561, 2001.
PubMed
11) Birkenhager R, et al : Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29 (3) : 310-314, 2001.
PubMed
12) Waldegger S, et al : Barttin increases surface expression and changes current properties of ClC-K channels. Pflugers Arch 444 (3) : 411-418, 2002.
PubMed
13) Hebert SC : Bartter syndrome. Curr Opin Nephrol Hypertens 12 (5) : 527-532, 2003.
PubMed
14) Vargas-Poussou R, et al : Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol 13 (9) : 2259-2266, 2002.
PubMed
15) Watanabe S, et al : Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360 (9334) : 692-694, 2002.
PubMed
16) Goodman AD, et al : Pathogenesis of Bartter's syndrome. N Engl J Med 129 : 1435-1439, 1969.
 
17) Fujita T, et al : The pathogenesis of Bartter's syndrome. Am J Med 63 : 464-474, 1977.
 
18) White MG : Bartter's syndrome. Arch Intern Med 129 : 41-47, 1972.
PubMed
19) Fichman MP, et al : Role of prostaglandins in the pathogenesis of Bartter's syndrome. Am J Med 60 : 785-797, 1976.
PubMed
20) Fujita T, et al : Independent roles of prostaglandin and the renin-angiotensin system in abnormal vascular reactivity in Bartter's syndrome. Am J Med 73 : 71-76, 1982.
PubMed
21) Gill JR, Bartter FC : Evidence for a prostaglandin-independent defect in chloride reabsorption in the loop of Henle as a proximal cause of Bartter's syndrome. Am J Med 65 : 766-772, 1978.
PubMed
22) Calo LA., et al : Increased expression of regulator of G protein signaling-2 (RGS-2) in Bartter's/Gitelman's syndrome. A role in the control of vascular tone and implication for hypertension. J Clin Endocrinol Metab 89 : 4153-4157, 2004.
PubMed
23) Yoshida H, et al : Angiotensin II type 1 receptor gene abnormality in a patient with Bartter's syndrome. Kidney Int 46 (6) : 1505-1509, 1994.
 
P.187 掲載の参考文献
1) 伊藤裕 : 高血圧を合併した糖尿病の臨床-RAS系. 日本臨牀 61 : 1145-1153, 2003.
 
2) 伊藤裕 : メタボリックドミノとは-生活習慣病の新しいとらえ方-. 日本臨牀 61 : 1842-1843, 2003.
 
3) 伊藤裕 : 降圧剤の多彩な作用を考えた治療への新しいアプローチ : メタボリックドミノを考えて. 日内会誌 93 : 79-86, 20004.
 
4) 伊藤裕 : 生活習慣病の新しいとらえ方-メタボリックドミノ-. 日本薬剤師会雑誌 56 : 417-423, 2004.
 
P.193 掲載の参考文献
1) Kim S, Iwao H : Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (1) : 11-34, 2000.
PubMed
2) Lithell H, et al : The Study on Cognition and Prognosis in the Elderly (SCOPE) : principal results of a randomized double-blind intervention trial. J Hypertens 21 (5) : 875-886, 2003.
 
3) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359 (9311) : 995-1003, 2002.
PubMed
4) Cohn JN, Tognoni G : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (23) : 1667-1675, 2001.
PubMed
5) Pfeffer MA, et al : Effects of candesartan on mortality and morbidity in patients with chronic heart failure : the CHARM-Overall programme. Lancet 362 (9386) : 759-766, 2003.
PubMed
6) Heffer MA, et al : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (20) : 1893-1906, 2003.
 
7) Brenner BM, et al : Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (12) : 861-869, 2001.
PubMed
8) Lewis EJ, et al : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (12) : 851-860, 2001.
PubMed
9) Julius S, et al : Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomised trial. Lmcet 363 (9426) : 2022-2031, 2004.
 
10) Weber MA, et al : Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363 (9426) : 2049-2051, 2004.
PubMed
P.199 掲載の参考文献
1) 金勝慶 : ACE阻害薬とARBの併用効果. 循環器科 53 : 493-501, 2003.
 
2) Azizi M, et al : Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 18 : 1139-1147, 2000.
PubMed
3) Mogensen CE, et al : Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes : the Candesartan And Lisinopril Microalbuminuria (CALM) study. BMJ 321 : 1440-1444, 2000.
PubMed
4) Ruilope LM, et al : Safety of the combination of valsartan and benazepril in patients with chronic renal disease : European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18 : 89-95, 2000.
 
5) Waeber B, et al : Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens 19 : 2097-2104, 2001.
 
6) Azizi M, Menard J : Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109 : 2492-2499, 2004.
PubMed
7) Kim S, et al : Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 103 : 148-154 2001.
PubMed
8) Kim S, et al : Beneficial effects of combined blockade of ACE and AT1 receptor on intimal hyperplasia in balloon-injured rat artery. Arterioscler Thromb Vasc Biol 22 : 1299-1304, 2002.
PubMed
9) Cohn JN, Tognoni G : Arandomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 : 1667-1675, 2001.
 
10) McMurray JJ, et al : Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet 362 : 767-771, 2003.
PubMed
11) Pfeffer MA, et al ; Valsartan in Acute Myocardial Infarction Trial Investigators : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 : 1893-1906, 2003.
 
12) 中尾尚之ほか : ACE阻害薬とARBの併用の臨床-COOPERATE研究を中心に-. Mebio 20 : 23-29, 2003.
 
13) Russo D, et al : Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38 : 18-25, 2001.
PubMed
14) Nakao N, et al : Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) : a randomised controlled trial. Lancet 361 : 117-124, 2003.
PubMed
P.205 掲載の参考文献
1) Lakkis J, et al : RAAS escape : a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 5 : 408-417, 2003.
PubMed
2) Pitt B : Effect of aldosterone blockade in patients with systolic left ventricular dysfunction : implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217 : 53-58, 2004.
PubMed
3) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999.
 
4) Tanabe A, et al : Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. J Hypertens 22 : 1017-1023, 2004.
PubMed
5) Stier CT Jr, et al : Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10 : 97-107, 2002.
PubMed
6) Staessen J, et al : Rise of plasma aldosterone during long-term captopril treatment. N Engl J Med 304 : 1110, 1981.
PubMed
7) August JT, et al : Response of normal subjects to large amounts of aldosterone. J Clin Invest 37 : 1549-1555, 1958.
PubMed
8) Naruse M, et al : Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40 : 28-33, 2002.
PubMed
9) McKelvie RS, et al : Comparison of candesartan, enalapril, and their combination in congestive heart failure : randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100 : 1056-1064, 1999.
PubMed
10) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
11) Sato A, et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 : 64-68, 2003.
PubMed
12) Epstein M : Aldosterone receptor blockade and the role of eplerenone : evolving perspectives. Nephrol Dial Transplant 18 : 1984-1992, 2003.
PubMed
13) Juurlink DN, et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 : 543-551, 2004.
PubMed

VIII アルドステロン

P.212 掲載の参考文献
1) Simpson SA, et al : Isolierung eines neuen kristallisierten Hormones aus Nebennieren mit besonders hoher Wirksamkeit auf den Mineral-stoftwechsel. Experientia 9 : 333-335, 1953.
PubMed
2) Houssay BA, Sammartino R : Modifications histologiques de la surrenale chez les chiens hypophysoprives ou a tuber lese. CR Sce Biol 114 : 717-723, 1933.
 
3) Deane HW, Greep RO : A morphological and histochemical study of the rat's adrenal cortex after hypophysectomy, with comments on the liver. Am J Anat 79 : 117-146, 1946.
 
4) Deane HW, et al : The effect of altered sodium or potassium intake on the width and cytochemistry of the zona glomerulosa of the rat's adrenal cortex. Endocrinology 43 : 133-153, 1948.
PubMed
5) Simpson SA, et al : Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet i : 226-227, 1952.
PubMed
6) Mattox VR, et al : Properties of a sodium-retaining principle from beef adrenal extract. J Am Chem Soc 75 : 4869-4870, 1953.
 
7) Conn JW : Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 : 3-17, 1955.
PubMed
8) Evans BM, Milne MD : Potassium-losing nephritis presenting as a case of periodic paralysis. Br Med J 2 : 1067 -1071, 1954.
 
9) Luetscher JA Jr, et al : Observations of the sodium-retaining corticoid (aldosterone) in the urine of children and adults in relation to sodium balance and edema. J Clin Invest 3 : 1441-1446, 1954.
 
10) Davis JO, et al : Increased aldosterone secretion in dogs with right-sided congestive heart failure and in dogs with thoracic inferior vena cava consUiction. J Clin Invest 36 : 689-694, 1957.
PubMed
11) Bartter FC : Cardiac failure and hormonal control of fluid and electrolyte balance. Surg Gynecol Obstet 118 : 767-777, 1964.
PubMed
12) Kagawa CM, et al : Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126 : 1015-1016, 1957.
PubMed
13) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
14) Delcayre C, et al : Cardiac aldosterone production and ventricular remodeling. Kidney Int 57 : 1346-1351, 2000.
PubMed
15) Weinberger MH, et al : Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15 : 709-716, 2002.
PubMed
P.219 掲載の参考文献
1) Payne AH, Hales DB : Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25 : 2003-2030, 2004.
 
2) White PC, et al : Disorders of steroid ll beta-hydroxylase isozymes. Endocr Rev 15 : 421-438, 1994.
 
3) Bassett MH, et al : The regulation of aldosterone synthase expression. Mol Cell Endocrinol 217 : 67-74, 2004.
PubMed
4) Mitani K, et al : Effects of long term stimulation of ACTH-and angiotensin II secretions on the rat adrenal cortex. Endocr Res 22 : 421-431, 1996.
 
5) Begeot M, et al : Variations in guanine-binding proteins (Gs, Gi) in cultured bovine adrenal cells. Consequences on the effects of phorbol ester and angiotensin II on adrenocorticotropin-induced and cholera-toxin-induced cAMP production. Eur J Biochem 174 : 317-321, 1988.
PubMed
6) Shen T, et al : Localization and differential expression of adenylyl cyclase messenger ribonucleic acids in rat adrenal gland determined by in situ hybridization. Endocrinology 138 : 4591-4598, 1997.
PubMed
7) Breault L, et al : Angiotensin II receptors in the human adrenal gland. Endocr Res 22 : 355-361, 1996.
PubMed
8) Condon JC, et al : Calmodulin-dependent kinase I regulates adrenal cell expression of aldosterone synthase. Endocrinology 143 : 3651-3657, 2002.
PubMed
9) Sirianni R, et al : A role for src tyrosine kinase in regulating adrenal aldosterone production. J Mol Endocrinol 26 : 207-215, 2001.
PubMed
10) Gu J, et al : 12-lipoxygenase pathway increases aldosterone production, 3', 5'-cyclic adenosine monophosphate response element-binding protein phosphorylation, and p38 mitogen-activated protein kinase activation in H295R human adrenocortical cells. Endocrinology 144 : 534-543, 2003.
PubMed
11) Chen XM, et al : Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 272 : F299-F304, 1997.
 
12) Yagci A, et al : Induction of steroidogenic enzymes by potassium in cultured rat zona glomerulosa cells depends on calcium influx and intact protein synthesis. Endocrinology 137 : 4331-4338, 1996.
PubMed
13) Bassett MH, et al : Differential regulation of aldosterone synthase and l l beta-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol 28 : 125-135, 2002.
 
14) Kobayashi S, et al : Ubc9 interacts with chicken ovalbumin upstream promoter-transcription factor I and represses receptor-dependent transcription. J Mol Endocrinol 32 (1) : 69-86, 2004.
PubMed
15) Rehman KR, et al : Profiling the steroidogenic pathway in human feta1 and adult adrenals. J Soc Gynecol Investig 10 : 372-380, 2003.
 
P.224 掲載の参考文献
1) Liakos P, et al : Transforming growth factor beta 1 inhibits aldosterone and cortisol production in the human adrenoconical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression. J Endocrinol 176 : 69-82, 2003.
PubMed
2) Hanke CJ, Campbell WB : Endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells : modulation by oxygen. Am J Physiol Endocrinol Metab 279 : E846-E854, 2000.
PubMed
3) Rebuffat P, et al : Stimulation of endogenous nitric oxide production is involved in the inhibitory effect of adrenomedullin on aldosterone secretion in the rat. Peptides 22 : 923-926, 2001.
PubMed
4) Clyne CD, et al : Calcium regulates human CYP11B2 transcription. Endocr Res 22 : 485-492, 1996.
PubMed
5) Cherradi N, et al : Regulation of mineralocorticoid biosynthesis by calcium and the StAR protein. Endocr Res 24 : 355-362, 1998.
PubMed
6) Rossier MF, et al : Duality of the voltage-dependent calcium influx in adrenal glomerulosa cells. Endocr Res 24 : 443-447, 1998.
PubMed
7) Lalevee H, et al : Intracellular transport of calcium from plasma membrane to mitochondria in adrenal H295R cells : implication for steroidogenesis. Endocrinology 144 : 4575-4585, 2003.
 
8) Clark BJ, Combs R : Angiotensin II and cyclic adenosine 3', 5'-monophosphate induce human steroidogenic acute regulatory protein transcription through a common steroidogenic factor-1 element. Endocrinology 140 : 4390-4398, 1999.
PubMed
9) Osman H, et al : Repression of DAX-1 and induction of SF-1 expression. Two mechanisms contributing to the activation of aldosterone biosynthesis in adrenal glomerulosa cells. J Biol Chem 277 : 41259-41267, 2002.
 
10) Clyne CD, et al : Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Mol Endocrinol 11 : 638-649, 1997.
PubMed
11) Cherradi N, et al : Angiotensin II activates cholesterol ester hydrolase in bovine adrenal glomenllosa cells through phosphorylation mediated by p42/p44 mitogen-activated protein kinase. Endocrinology 144 : 4905-4915, 2003.
PubMed
12) Kigoshi T, et al : Involvement of tyrosine kinase in citrate-stimulated aldosterone production in bovine glomerulosa cells. Am J Physiol Endocrinol Metab 279 : E140-E145, 2000.
PubMed
13) Betancourt-Calle S, et al : Elevated K (+) induces myristoylated alanine-rich C-kinase substrate phosphorylation and phospholipase D activation in glomerulosa cells. Mol Cell Endocrinol 184 : 65-76, 2001.
PubMed
14) Cherradi N, et al : Atrial natriuretic peptide inhibits calcium-induced steroidogenic acute regulatory protein gene transcription in adrenal glomerulosa cells. Mol Endocrinol 12 : 962-972, 1998.
PubMed
15) Hanke CJ, et al : Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect. Endocrinology 139 : 4053-4060, 1998.
PubMed
P.230 掲載の参考文献
1) Chen SY, et al : Epithehal sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA 96 : 2514-2519, 1999.
 
2) Naray-Fejes-Toth A, et al : sgk is an aldosterone-induced kinase in the renal collecting duct : effects on epithelial Na+ channels. J Biol Chem 274 : 16973-16978, 1999.
PubMed
3) Bhargava A, Pearce D : Mechanisms of mineralocorticoid action : determinants of receptor specificity and actions of regulated gene products. Trends Endocrinol Metab 15 : 147-153, 2004.
PubMed
4) Wulff P, et al : Impaired renal Na+ retention in the SGK1-knockout mouse. J Clin Invest 110 : 1263-1268, 2002.
PubMed
5) Stockand JD : New ideas about aldosterone signaling in epithelia. Am J physiol 282 : F559-F576, 2002.
 
6) Shi H, et al : Membrane topology and immunolocarization of CHIF in kidney and intestine. Am J Physiol 280 : F505-F512, 2001.
 
7) Snyder PM, et al : Serum and glucocorticoid-regulated kinase modulates Nedd4-2-mediated inhibition of the epithelial Na ; channel. J Biol Chem 277 : 5-8, 2002.
 
8) Rocha R, et al : Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 : 4828-4836, 2002.
PubMed
9) Rocha R, et al : Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 : 451-458, 1998.
PubMed
10) Takeda Y, et al : Cardiac aldosterone production in genetically hypertensive rats. Hypertension 36 : 495-500, 2000.
PubMed
11) Takeda Y, et al : Calcineurin inhibitoin attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 105 : 677-679, 2002.
 
12) Klein K, Henk W : Klinisch-experimentelle Untersuchungen ttber den Einfluss von Aldosteron auf Haemodynamic und Gerinnung. Z Kreislaufforsch 52 : 40-53, 1963.
 
13) Spach C, Streeten DH : Retardation of sodium exchange in dogs erythrocytes by physiological concentrations of aldosterone, in vitro. J Clin Invest 43 : 217-227, 1964.
PubMed
14) Losel RM, et al : Nongenomic effects of aldosterone : cellular aspects and clinical implications. Steroids 67 : 493-498, 2002.
PubMed
15) Alzamora R, et al : Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35 : 1099-1104, 2000.
 
P.237 掲載の参考文献
1) Shepard KE, et al : Equivalent affinity of aldosterone and corticosterone for type I receptors in kidney and hippocampus : Direct binding studies. J Steroid Biochem Mol Biol 28 : 737-742, 1987.
 
2) Edwards CR, et al : Localization of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet ii : 986-989, 1988.
 
3) Krozowski ZS, Funder JW : Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 80 : 6056-6060, 1983.
PubMed
4) Stewart PM, et al : Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 347 : 88-91, 1996.
PubMed
5) Berger S, et al : Mineralocorticoid receptor knockout mice : Pathophysiology of Na metabolism. Proc Natl Acad Sci USA 95 : 9424-9429, 1998.
PubMed
6) Hirasawa G, et al : Colocalization of 11 beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab 82 : 3859-3863, 1997.
PubMed
7) Hirasawa G, et al : 11Beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in human feta1 development. J Clin Endocrinol Metab 84 : 1453-1458, 1999.
PubMed
8) Hirasawa G, et al : 11Beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human placenta. J Clin Endocrinol Metab 85 : 1306-1309, 2000.
PubMed
P.243 掲載の参考文献
1) Rogerson FM, et al : Mineralocorticoid receptor binding, structure and function. Mol Cell Endocrinol 217 : 203-212, 2004.
PubMed
2) Bhargava A, Pearce D : Mechanisms of mineralocorticoid action : determinants of receptor specificity and actions of regulated gene products. Trends Endocrinol Metab 15 : 147-153, 2004.
PubMed
3) Berger S, et al : Mineralocorticoid receptor knockout mice : Pathophysiology of Na+metabolism. Proc Natl Acad Sci USA 95 : 9424-9429, 1998.
PubMed
4) Hubert C, et al : Effects of mineraloconicoid receptor gene disruption on the components of the renin-angiotensin system in 8-day-old mice. Mol Endocrinol 13 : 297-306, 1999.
PubMed
5) Schulz-Baldes A, et al : Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice. Pflugers Arch 443 : 297-305, 2001.
PubMed
6) Berger S, et al : Mineralocorticoid receptor knockout mice : lessons on Na+ metabolism. Kidney Int 57 : 1295-1298, 2000.
PubMed
7) Gass P, et al : Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep 1 : 447-451, 2000.
PubMed
8) Beggah AT, et al : Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proc Natl Acad Sci USA 99 : 7160-7165, 2002.
PubMed
9) Menuet DL, et al : Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 276 : 38911-38920, 2001.
 
10) Menuet DL, et al : Expression and function of the human mineralocorticoid receptor : lessons from transgenic mouse models. Mol Cell Endocrinol 217 : 127-136, 2004.
 
11) Wulff P, et al : Impaired renal Na+retention in the sgk1-knockout mouse. J Clin lnvest 110 : 1263-1268, 2002.
 
12) Rubera I, et al : Collecting duct-specific gene inactivation of αENaC in the mouse kidney does not impair sodium and potassium balance. J Clin Invest 112 : 554-565, 2003.
 
13) Wang Q, et al : Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol 286 : F1178-F1184, 2004.
 
14) Kotelevtsev Y, et al : Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J Clin Invest 103 : 683-689, 1999.
 
15) Qin W, et al : Transgenic model of aldosteorne-driven cardiac hypertrophy and heart failure. Circ Res 93 : 69-76, 2003.
PubMed
P.248 掲載の参考文献
1) 小島滋恒 : 正常新生児および小児における血漿アルドステロン濃度, 血漿レニン活性の年齢的差異, および血漿・血球内電解質, 経口ナトリウム摂取量との関連. 日内会誌 55 : 1019-1037, 1979.
 
2) Tsunoda K, et al : Effect of age on the renin-angiotensin-aldosterone system in normal subjects : simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. J Clin Endocrinol Metab 62 : 384 -389, 1986.
 
3) Weinberger MH, et al : The diagnosis of primary aldosteronism and separation of two major sub-types. Arch Intern Med 153 : 2125-2129, 1993.
 
4) Olivieri O, et al : Aldosterone to Renin ratio in a primary care setting : the Bussolengo study. J Clin Endocrinol Metab 89 : 4221-4226, 2004.
 
5) Koshida H, et al : Falsely elevated plasma aldosterone concentration by direct radioimmunoassay in chronic renal failure. J Lab Clin Med 114 : 294-300, 1989.
PubMed
6) Hamblmg C, et al : Re-eva luation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol 36 : 499-503, 1992.
 
7) Rossi GP, et al : Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings : results in 104 consecutive cases. J Clin Endocrinol Metab 86 : 1083-1090, 2001.
 
8) Iwaoka T, et al : Localization of aldosterone-producing adenoma : venous sampling in primary aldosteronism. Endocrinol Jpn 37 : 151-157, 1990.
PubMed
P.255 掲載の参考文献
1) Booth RE, et al : Aldosterone. Adv Physiol Educ 26 : 8-20, 2002.
PubMed
2) Stokes JB, Sigmund RD : Regulation of rENaC mRNA by dietary NaCl and steroids : organ, tissue, and steroid heterogeneity. Am J Physiol Cell Physiol 274 (6) : C1699-1707, 1998.
 
3) Volk KA, et al : ENaC is the predominant Na+ channel in the apical membrane of the rat renal inner medullary collecting duct. J Clin Invest 96 : 2748-2757, 1995.
 
4) Zhou ZH, Bubien JK : Nongenomic regulation of ENaC by aldosterone. Am J physiol Cell Physiol 281 (4) : C1118-1130, 2001.
PubMed
5) Lingrel JB, et al : Molecular genetics of Na, K-ATPase. Prog Nucleic Acid Res Mol Biol 38 : 37-89, 1990 (Review).
PubMed
6) Beesley AH, et al : Regulation of distal nephron K+ channels (ROMK) mRNA expression by aldosterone in rat kidney. J Physiol 509 (Pt 3) : 629-634, 1998.
 
7) Gekle M, et al : The mineralocorticoid aldosterone activates a proton conductance in cultured kidney cells. Am J Physiol Cell Physiol 42 : C1673-1678, 1997.
 
8) Gekle M, et al : Rapid actions of aldosterone on cells from renal epithelium : the possible role of EGF-receptor signaling. Steroids 67 (6) : 499-504, 2002.
PubMed
9) Kim GH, et al : The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci USA 95 (24) : 14552-14557, 1998.
PubMed
10) Webster M, et al : Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 13 (4) : 2031-2040, 1993.
PubMed
11) Park J, et al : Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 18 (11) : 3024-3033, 1999.
PubMed
12) Chen SY, et al : Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA 96 (5) : 2514-2519, 1999.
PubMed
13) Loffing J, et al : Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system : possible role of SGK. Am J Physiol Renal Physiol 280 (4) : F675-682, 2001.
PubMed
14) Record RD, et al : Phosphatidylinositol 3-kinase activation is required for insulin-stimulated sodium transport in A6 cells. Am J Physiol 274 (4) : E611-617, 1998.
PubMed
15) Setiawan I, et al : Stimulation of Xenopus oocyte Na (+), K (+) ATPase by the serum and glucocorticoid-dependent kinase sgk1. Pflugers Arch 444 (3) : 426-431, 2002.
PubMed
16) Spindler B, et al : Characterization of early aldosterone-induced RNAs identified in A6 kidney epithelia. Pflugers Arch 434 (3) : 323-331, 1997.
PubMed
17) Stockand JD, et al : Regulation of Na (+) reabsorption by the aldosterone-induced small G protein K-Ras2A. J Biol Chem 274 (50) : 35449-35454, 1999.
PubMed
18) Adachi M, et al : Activation of epithelial sodium channels by prostasin in Xenopus oocytes. J Am Soc Nephrol 12 (6) : 1114-1121, 2001.
PubMed
19) Narikiyo T, et al : Regulation of prostasin by aldosterone in the kidney. J Clin Invest 109 (3) : 401-408, 2002.
PubMed
P.262 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
2) Pitt B, et al ; Eplerenone Post-Acute Myocardial lnfarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (14) : 1309-1321, 2003.
 
3) Harada E, et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 : 137-139, 2001.
PubMed
4) Silvestre JS, et al : Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273 : 4883-4891, 1998.
PubMed
5) Mizuno Y, et al : Aldosterone production is activated in the failing ventricles in humans. Circulation 103 (1) : 72-77, 2001.
PubMed
6) Yoshimura M, et al : Expression of aldosterone synthase gene in the failing human heart, quantitative analysis using modified real-time PCR. J Clin Endocrinol Metab 87 (8) : 3936-3940, 2002.
PubMed
7) Yamamoto N, et al : Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 39 (5) : 958-962, 2002.
PubMed
8) Takeda Y, et al : Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 19 (3 Pt 2) : 635-639, 2001.
 
9) Ito T, et al : Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 107 : 807-810, 2003.
PubMed
P.267 掲載の参考文献
1) Funder JW : Aldosterone, mineralocorticoid receptors and vascular inflammation. Mol Cell Endocrinol 217 : 263-269, 2004.
PubMed
2) Brilla CG, Weber KT : Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120 : 893-901, 1992.
PubMed
3) Rocha R, et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 (5) : H1802-1810, 2002.
PubMed
4) Ikeda U, et al : Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin 1 beta. Eur J Pharmacol 290 : 69-73, 1995.
PubMed
5) Arima S, et al : Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43 : 352-357, 2004.
PubMed
6) Uhrenholt TR, et al : Rapid nongenomic effects of aldosterone on rodent vascular function. Acta Physiol Scand 181 : 415-419, 2004.
PubMed
7) Alzamora R, et al : Nongenomic effects of aldosterone on Na+, K+ -adenosine triphosphatase in arterial vessels. Endocrinology 144 : 1266-1272, 2003.
 
8) Rocha R, et al : Aldosterone : A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141 : 3871-3878, 2000.
PubMed
9) Harada E, et al : Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 (2) : 137-139, 2001.
PubMed
10) Klar J, et al : Aldosterone enhances renin gene expression in juxtaglomerular cells. Am J physiol Renal Physiol 286 (2) : F349-355, 2003.
PubMed
11) Zenanaro M-C, et al : Characterization of human mineralocorticoid receptor gene 5'regulatory region : evidence for differential hormonal regulation of two alternative promoters via non classical mechanism. Mol Endocrinol 12 (12) : 1549-1560, 1996.
 
12) Bonvalet JP, et al : Aldosterone : intracellular receptors in human heart. Eur Heart J 16 (Suppl) : 92-97, 1995.
 
13) Yoshida M, et al : Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail, 2004. (in press)
 
14) Nishizaka MK, et al : Impiared endothelium-dependent flow-mediated vasodilatation in hypertensive subjects with hyperaldosteronism. Circulation 109 : 2857-2861, 2004.
PubMed
15) Abiose AK, et al : Effects of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am J Cardiol 93 : 1564-1566, 2004.
PubMed
16) Funder JW : Is aldosterone bad for the heart? Trends Endocrinol Metab 15 : 139-142, 2004.
PubMed
P.273 掲載の参考文献
1) Shibata H, et al : Signhicance of steroidogenic enzymes in the pathogenesis of adrenal tumour. Acta Endocrinol (Copenh) 128 (3) : 235-242, 1993.
PubMed
2) Suzuki H : Pathophysiology and diagnosis of primary aldosteronism. Biomed Pharmacother 54 (Suppl 1) : 118s-123s, 2000.
 
3) Dawson A, et al : The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. Expert Rev Cardiovasc Ther 2 (1) : 29-36, 2004.
PubMed
4) Uhrenholt TR, et al : Rapid non-genomic effects of aldosterone on rodent vascular function. Acta Physiol Scand 181 (4) : 415-419, 2004.
PubMed
5) Funder JW : Mineralocorticoid receptors in the central nervous system. J Steroid Biochem Mol Biol 56 (1-6 Spec No) : 179-183, 1996.
 
6) Birmingham MK, et al : Localization of aldosterone and corticosterone in the central nervous system, assessed by quantitative autoradiography. Neurochem Res 9 (3) : 333-350, 1984.
PubMed
7) Compagnone NA, et al : Expression of the steroidogenic enzyme P450scc in the central and peripheral nervous systems during rodent embryogenesis. Endocrinology 136 (6) : 2689-2696, 1995.
PubMed
8) Hu ZY, et al : Neurosteroids : oligodendrocyte mitochondria convert cholesterol to pregnenolone. Proc Natl Acad Sci USA 84 (23) : 8215-8219, 1987.
PubMed
9) Zhou MY, et al : Cloning of two alternatively spliced 21-hydroxylase CDNAs from rat adrenal. J Steroid Biochem Mol Biol 62 (4) : 277-286, 1997.
PubMed
10) Brown RC, et al : Pathways of neurosteroid biosynthesis in cell lines from human brain : regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid peptide. J Neurochem 74 (2) : 847-859, 2000.
PubMed
11) Mellon SH, Deschepper CF : Neurosteroid biosynthesis : genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res 629 (2) : 283-292, 1993.
PubMed
12) MacKenzie SM, et al : Expression of 11 beta-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol 24 (3) : 321-328, 2000.
 
13) YU L, et al : Steroidogenic enzyme gene expression in the human brain. Mol Cell Endocrinol 190 (1-2) : 9-17, 2002.
 
14) Gomez-Sanchez EP, et al : Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol 258 (3 Pt 1) : E482-484, 1990.
 
15) Gomez-Sanchez EP : Brain mineralocorticoid receptors : orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 13 (2) : 191-196, 2004.
PubMed
16) Gomez-Sanchez EP, et al : ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am J Physiol 258 (4 Pt 1) : E649-653, 1990.
 
17) Kageyama Y, Bravo EL : Hypertensive mechanisms associated with centrally administered aldosterone in dogs. Hypertension 11 (6 Pt 2) : 750-753, 1988.
 
18) Gomez-Sanchez EP, Gomez-Sanchez CE : Is aldosterone synthesized in the CNS regulated and functional? Trends Endocrinol Metab 14 (10) : 444-446, 2003.
PubMed
19) Ye P, et al : Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 144 (8) : 3321-3328, 2003.
PubMed
P.282 掲載の参考文献
1) Conn JW : Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45 : 3-17, 1955.
PubMed
2) Davis WW, et al : Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity. Am J Med 42 : 642-647, 1967.
PubMed
3) Sutherland DJA, et al : Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95 : 1109-1119, 1966.
 
4) Gordon RD, et al : High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 : 315-318, 1994.
PubMed
5) Kaplan NM : The current epidemic of primary aldosteronism causes and consequences. J Hypertens 22 : 863-869, 2004.
PubMed
6) Lifton RP, et al : Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 2 : 66-74, 1992.
PubMed
7) 柴田洋孝, 猿田享男 : 特発性アルドステロン症とデキサメサゾン反応性アルドステロン症. 内分泌・糖尿病科 12 : 234-242, 2001.
 
8) Delcayre C, et al : Cardiac aldosterone production and ventricular remodeling. Kidney Int 57 : 1346-1351, 2000.
PubMed
9) Rocha R, Stier CT Jr : Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12 : 308-314, 2001.
PubMed
10) Laragh JH, Sealy JE : The renin-angiotensin-aldosterone system in hypertensive disoders : a key to two forms of arteriolar constriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In : Hypertension : Pathophysiology, Diagnosis, and Management (ed by Laragh JH, Brenner BM), p 1329-1348, Raven Press, New York, 1990.
 
P.287 掲載の参考文献
1) Sasano H : New approaches in human adrenocortical pathology : assessment of adrenocortical function in surgical specimen of human adrenal glands. Endocr Pathol 3 : 4-13, 1992.
PubMed
2) Sasano H : Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocr J 41 : 471-482, 1994.
PubMed
3) Sasano H, et al : Adrenocortical cytopathology. Am J Clin Pathol 104 : 161-166, 1995.
PubMed
4) Hough AJ, et al : Prognostic factors in adrenal cortex tumors : A mathematical analysis of clinical and morphological data. Am J Clin Pathol 72 : 390-399, 1979.
PubMed
5) Weiss LM : Comparable histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8 : 163-169, 1984.
PubMed
6) Weiss LM, et al : Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13 : 202-206, 1989.
PubMed
P.291 掲載の参考文献
1) Kawamoto T, et al : Role of steroid 11 beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 89 : 1458-1462, 1992.
PubMed
2) 藤枝憲二 : 副腎皮質機能異常. 日内会誌 91 : 1172-1178, 2002.
 
3) Chua SC, et al : Cloning of cDNA encoding steroid 11 beta-hydroxylase (P450c11). Proc Natl Acad Sci USA 84 : 7193-7197, 1987.
PubMed
4) Merke DP, et al : Novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11 beta-hydroxylase deficiency. J Clin Endocrinol Metab 83 : 270-273, 1998.
PubMed
5) Kuribayashi I, et al : A novel nonsense mutation in the Cyp11B1 gene from a subject with the steroid 11 beta-hydroxylase form of congenital adrenal hyperplasia. Endocr Res 29 : 377-381, 2003.
PubMed
6) Zhu YS, et al : Mutations in CYP11B1 gene : phenotype-genotype correlations. Am J Med Genet 15 : 193-200, 2003.
 
7) Curnow KM, et al : Mutations in the CYP11B1 gene causing congenital adrenal hyperplasia and hypertension cluster in exons 6, 7, and 8. Proc Natl Acad Sci USA 90 : 4552-4556, 1993.
PubMed
8) New MI : Diagnosis and management of congenital adrenal hyperplasia. Annu Rev Med 49 : 311-328, 1998.
PubMed
9) Zachmann M, et al : Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients. J Clin Endocrinol Metab 56 : 222-229, 1983,
PubMed
10) Wang XL, et al : Transcriptional regulation of human 11 beta-hydroxylase (hCYP11B1). Endocrinology 141 : 3587-3594, 2002.
 
11) Condon JC, et al : Familial hyperaldosteronism. J Steroid Biochem Mol Biol 78 : 215-229, 2001.
 
12) White PC, et al : Congenital adrenal hyperplasia. N Engl J Med 316 : 1580-1586, 1987.
PubMed
13) New MI, et al : An update of congenital adrenal hyperplasia. Recent Prog Homl Res 37 : 105-181, 1981.
 
14) Lopez-Siguero JP, et al : Aldosterone synthase deficiency type I : hormonal and genetic analyses of two cases. Horm Res 52 : 298-300, 1999.
PubMed
P.294 掲載の参考文献
1) Biglieri EG, et al : 17-Hydroxylation deficiency in man. J Clin Invest 45 : 1946-1954, 1966.
 
2) Chung BC, et al : Cytochrome P450c17 (steroid 17α-hydroxylase/17, 20 lyase) : cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci USA 84 : 407-411, 1987.
 
3) Picado-Leonard J, Miller WL : Cloning and sequence of the human gene for P450c17 (steroid 17α-hydroxylase/17, 20 lyase) : similarity with the gene for P450c21. DNA 6 : 439-448, 1987.
 
4) Kagimoto M, et al : Structural characterization of normal and mutant human steroid 17α-hydroxylase genes : molecular basis of one example of combined 17α-hydroxylase/17, 20 lyase deficiency. Mol Endocrinol 2 : 564-570, 1988.
 
5) Van Den Akker EL, et al : Differential inhibition of 17-hydroxylase and 17, 20-lyase activities by three novel missense CYP17 mutations identhied in patients with P450c17 deficiency. J Clin Endocrinol Metab 87 : 5714-5721, 2002.
PubMed
6) Biglieri EG : 17α-Hydroxylase deficiency : 1963-1966. J Clin Endocrinol Metab 82 : 48-50, 1997.
 
7) Grumbach MM, et al : Disorders of sex differentiation. In : Williams Textbook of Endocrinology, 10th ed (ed by Larsen PR, et al), p 842-1002, WB Saunders, Philadelphia, 2003.
 
8) Santos MC, et al : Prevalence study of congenital adrenal hyperplasia in Brazilian medical centers. Arq Bras Endocrinol Metab 42 : 385-392, 1998.
 
9) Costa-Santos M, et al : Brazilian Congenital Adrenal Hyperplasia Multicenter Study Group : Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 89 : 49-60, 2004.
PubMed
10) Yanase T, et al : 17 alpha-hydroxylase/17, 20-lyase deficiency : from clinical investigation to molecular definition. Endocr Rev 12 : 91-108, 1991.
PubMed
P.301 掲載の参考文献
1) Lakshmi V, et al : Purhication and characterization of the corticosteroid l li9-dehydrogenase component of the rat liver 11β-hydroxysteroid dehydrogenase complex. Endocrinology 123 : 2390-2398, 1988.
 
2) Agarwal AK, et al : Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J Biol Chem 264 : 18939-18943, 1989.
PubMed
3) Tannin GM, et al : The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 266 : 16653-16658, 1991.
PubMed
4) Bujalska IJ, et al : A switch in dehydrogenase to reductase activity of 11β-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 87 : 1205-1210, 2002.
 
5) Walker EA, et al : Functional expression, characterization, and purification of the catalytic domain of human 11β-hydroxysteroid dehydrogenase type 1. J Biol Chem 276 : 21343-21350, 2001.
 
6) Odermatt A, et al : The N-terminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 274 : 28762-28770, 1999.
 
7) Taylor NF, et al : Cortisone reductase deficiency : evidence for a new inborn error in metabolism of adrenal steroids. J Endocrinol (Oxf) 102 (Suppl) : 90 (abstract), 1984.
 
8) Phillipou G, et al : A new defect in the peripheral conversion of cortisone to cortisol. J Steroid Biochem 22 : 435-436, 1985.
PubMed
9) Draper N, et al : Mutations in the genes encoding 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34 : 434-439, 2003.
 
10) Rodin A, et al : Hyperandrogenism in polycystic ovary syndrome : evidence of dysregulation of 11β-hydroxysteroid dehydrogenase. N Engl J Med 330 : 460-465, 1994.
 
11) Kotelevtsev Y, et al : 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94 : 14924-14929, 1997.
 
12) Yau JL, et al : Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA 98 : 4716-4721, 2001.
 
13) Sandeep TC, et al : 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101 : 6734-6739, 2004.
 
14) Masuzaki H, et al : Atransgenic model of visceral obesity and the metabolic syndrome. Science 294 : 2166-2170, 2001.
 
15) Paterson JM, et al : Metabolic syndrome without obesity : Hepatic overexpression of 11 beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 101 : 7088-7093, 2004.
PubMed
16) Tomlinson JW, et al : 11β-Hydroxysteroid dehydrogenase type 1 : Atissue-specific regtilator of glucocorticoid response. Endocr Rev 25 : 831-866, 2004.
 
P.307 掲載の参考文献
1) White PC, et al : 11 beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18 : 135-156, 1997.
PubMed
2) Funder JW, et al : Mineralocorticoid action ; target tissue specificity is enzyme, not receptor, mediated. Science 242 : 583-585, 1988.
PubMed
3) Mune T, et al : Human hypertension caused by mutations in the kidney isozyme of l lbeta-hydroxysteroid dehydrogenase. Nat Genet 10 : 394-399, 1995.
 
4) Quinkler M, et al : Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol 217 : 143-149, 2004.
PubMed
5) 宗友厚ほか : Apparent mineralocorticoid excess症候群. 循環器科 45 : 235-242, 1999.
 
6) Lavery GG, et al : Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 42 : 123-129, 2003.
PubMed
7) Wilson RC, et al : A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci USA 95 : 10200-10205, 1998.
PubMed
8) Tanahashi T, et al : Glycyrrhizic acid suppresses type 2 11 beta-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol 80 : 441-447, 2002.
PubMed
9) Edwards CR, et al : Dysfunction of placental glucocorticoid barrier : link between fetal environment and adult hypertension? Lancet 341 : 355-357, 1993.
PubMed
10) 安田圭吾ほか : 11βHSDタイプ2遺伝子のCAリピート多型と電解質・糖代謝との関連, 副腎ホルモン産生異常症調査研究班, 平成14年度研究報告書, p44-52, 2003.
 
11) Mune T, et al : Role of local llbeta-hydroxysteroid dehydrogenase type 2 expression in determining the phenotype of adrenal adenomas. J Clin Endocrinol Metab 88 : 864-870, 2003.
 
12) Parks LL, et al : Expression of 11 beta-hydroxysteroid dehydrogenase type 2 in ACTH producing small cell lung cancer. J Steroid Biochem Mol Biol 67 : 341-346, 1998.
 
13) Korbonits M, et al : Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary : induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. J Clin Endocrinol Metab 86 : 2728-2733, 2001.
PubMed
14) Rabbitt EH, et al : Prereceptor regulation of glucocorticoid action by llbeta-hydroxysteroid dehydrogenase : a novel determinant of cell proliferation. FASEB J 16 : 36-44, 2002.
 
15) Zbankova S, et al : Expression of 11 beta-hydroxysteroid dehydrogenase type 1 and 2 in colorectal cancer. Cancer Lett 210 : 95-100, 2004.
PubMed
16) Bland R, et al : Characterization of 11 beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J Endocrinol 161 : 455-464, 1999.
PubMed
17) Cooper MS, et al : Expression and functional consequences of 11 beta-hydroxysteroid dehydrogenase activity in human bone. Bone 27 : 375-381, 2000.
PubMed
18) Suzuki T, et al : Increased expression of 11 beta-hydroxysteroid dehydrogenase type 2 in the lungs of patients with acute respiratory distress syndrome. Pathol Int 53 : 751-756, 2003.
PubMed
P.312 掲載の参考文献
1) Wilson FH, et al : Human hypertension caused by mutations in WNK kinases. Science 293 : 1107-1112, 2001.
PubMed
2) Wilson FH, et al : Molecular pathogenesis of inherited hypertension with hyperkalemia : The Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci USA 100 : 680-684, 2003.
 
3) Yang C-L, et al : WNK kinases regulates thiazide-sensitive Na-Cl cotransporter. J Clin Invest 111 : 1039-1045, 2003.
PubMed
4) Kahle KT, et al : WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat Genet 35 : 372-376, 2003.
 
5) Yamauchi K, et al : Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci USA 101 : 4690-4694, 2004.
PubMed
6) Zambrowicz BP, et al : Wnk 1 kinase deficiency lowers blood pressure in mice : A gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100 : 14109-14114, 2003.
PubMed
7) Gitelman BH, et al : A new familial disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Physicians 79 : 221-235, 1966.
 
8) Bettinelli A, et al : Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis : Bartter and Gitelman syndromes. J Pediatr 120 : 38 -43, 1992.
 
9) Tsukamoto T, et al : Possible discrimination of Gitelman's syndrome from Bartter's syndrome by renal clearance study : report of two cases. Am J Kidney Dis 25 : 637-641, 1995.
PubMed
10) Simon DB, et al : Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 12 : 24-30, 1996.
 
11) Takeuchi K, et al : Association of a mutation in thiazide-sensitive Na-Cl cotransporter with familial Gitelman's syndrome. J Clin Endocrinol Metab 81 : 4496-4499, 1996.
PubMed
12) Monkawa T, et al : Novel mutations in thiazide-sensitive Na-Cl cotransporter gene of patients with Gitelman's syndrome. J Am Soc Nephrol 11 : 65-70, 2000.
PubMed
13) Lin S-H, et al : Intrafamilial phenotype variability in patients with Gitelman syndrome having the mutations in their thiazide-sensitive sodium/chloride cotransporter. Am J Kidney Dis 3 : 304-312, 2004.
PubMed
P.316 掲載の参考文献
1) Canessa CM, et al : Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 361 (6411) : 467-470, 1993.
PubMed
2) Lingueglia E, et al : Expression cloning of an epithelial amiloride-sensitive Na+ channel. A new Channel type with homologies to Caenorhabditis elegans degenerins. FEBS Lett 318 (1) : 95-99, 1993.
 
3) Firsov D, et al : The heterotetrameric architecture of the epithelial sodium channel (ENaC). EMBO J 17 (2) : 344-352, 1998.
PubMed
4) Kosari F, et al : Subunit stoichiometry of the epithelial sodium channel. J Biol Chem 273 (22) : 13469-13474, 1998.
PubMed
5) Staub O, et al : WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J 15 (10) : 2371-2380, 1996.
 
6) Schild L, et al : Identhication of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. EMBO J 15 (10) : 2381-2387, 1996.
PubMed
7) Chen SY, et al : Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci USA 96 (5) : 2514-2519, 1999.
PubMed
8) Shimkets RA, et al : Liddle's syndrome : heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79 (3) : 407-414, 1994.
PubMed
9) Schild L, et al : A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system. Proc Natl Acad Sci USA 92 (12) : 5699-5703, 1995.
 
10) Snyder PM, et al : Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel. Cell 83 (6) : 969-978, 1995.
 
11) Liddle GW, et al : A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 76 : 199-213, 1963.
 
12) Botero-Velez M, et al : Brief report : Liddle's syndrome revisited-a disorder of sodium reabsorption in the distal tubule. N Engl J Med 330 (3) : 178-181, 1994.
PubMed
13) Yamashita Y, et al : Two sporadic cases of Liddle's syndrome caused by De novo ENaC mutations. Am J Kidney Dis 37 (3) : 499-504, 2001.
PubMed
P.322 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
2) Pitt B, et al : Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (14) : 1309-1321, 2003.
 
3) Mizuno Y, et al : Aldosterone production is activated in the failing ventricles in humans. Circulation 103 (1) : 72-77, 2001.
PubMed
4) Nakamura S, et al : A possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation 110 : 1787-1793, 2004.
PubMed
P.329 掲載の参考文献
1) Pitt B, et al : For the Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on mortality and morbidity in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
2) Kayes-Wandover KM, et al : Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 85 : 2519-2525, 2000.
 
3) Yoshimura M, et al : Expression of aldosterone synthase gene in failing human heart : quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 87 : 3936-3940, 2002.
PubMed
4) 宮森勇 : アルドステロンの産生調節 : 心血管系. 血圧 9 : 23-26, 2002.
 
5) Tsutamoto T, et al : Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 36 : 838-844, 2000.
PubMed
6) Tsutamoto T, et al : Transcardiac gradient of aldosterone before and after spironolactone in patients with congestive heart failure. J Cardiovasc Pharmacol 41 (Suppl 1) : S19-S22, 2002.
 
7) Tsutamoto T, et al : Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients With congestive heart failure. J Am Coll Cardiol 37 : 1228-1233, 2001.
PubMed
8) Tsutamoto T, et al : Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure : prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 : 509-516, 1997.
PubMed
9) Hayashi M, et al : Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37 : 1820-1826, 2001.
PubMed
10) Hayashi M, et al : Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction : extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 38 : 1375-1382, 2001.
PubMed
11) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
12) Hayashi M, et al : Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107 : 2559-2565, 2003.
PubMed
P.334 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 : 709-717, 1999.
PubMed
2) Zannad F, et al : Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 102 : 2700-2706, 2000.
PubMed
3) Barr CS, et al : Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76 : 1259-1265, 1995.
 
4) MacFadyen RJ, et al : Aldosterone blockade reduces vascular collagen tumover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35 : 30-34, 1997.
 
5) Wang W : Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 24 : 571-575, 1994.
PubMed
6) Duprez DA, et al : Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 19 : 1371-1376, 1998.
 
7) Rocha R, et al : Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 : 451-458, 1998.
PubMed
8) The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES] ). Am J Cardiol 78 : 902-907, 1996.
 
9) Weber M, Brilla CG : Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 : 1849-1865, 1991.
 
10) Brilla CG, et al : Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67 : 1335-1364, 1990.
 
11) Jeunemaitre X, et al : Efficacy and tolerance of spironolactone in essenial hypertension. Am J Cardiol 60 : 820-825, 1987.
PubMed
12) de Gasparo M, et al : Three new epoxy-spironolactone derivatives : characterization in vivo and in vitro. J Pharmacol Exp Ther 240 : 650-656, 1987.
PubMed
P.340 掲載の参考文献
1) Pitt B, et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engle J Med 341 : 709-717, 1999.
 
2) Rocha R, et al : Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 : 4828-4836, 2002.
PubMed
3) MacFadyen RJ, et al : Aldosterone blockade reduces collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35 : 30-34, 1997.
PubMed
4) Suzuki G, et al : Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106 : 2967-2972, 2002.
PubMed
5) Hayashi M, et al : Immediate administration of mineralocorticoid recepter antagonist spironolactone prevents postinfarct left ventricular remodeling associated with suppression of a maker of myocardial collagen synthsis in patients with first anterior acute myocardial infarction. Circulation 107 : 2559-2565, 2003.
 
6) Pitt B, et al : Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 : 1309-1321, 2003.
PubMed
7) Rocha R, et al : Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 : H1802-1810, 2002.
PubMed
8) Virdis A, et al : Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 : 504-510, 2002.
PubMed
9) Brown NJ, et al : Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85 : 336-344, 2000.
PubMed
10) Struthers AD : Ndosterone-induced vasculopathy. Mol Cell Endocrinol 217 : 239-241, 2004.
PubMed
11) Zhang ZH, et al : The rennin-angiotensin-aldosterone system excites hypothalamic paraventricular nucleus neurous in heart failure. Am J Physiol Heart Circ Physiol 283 : 423-433, 2002.
 
12) Barr CS, et al : Effect of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76 : 1259-1265, 1995.
 
13) Korkmaz ME, et al : Effects of spironolantone on heart rate variability and left ventricular systolic function in severe ischemic failure. Am J Cardiol 86 : 649-653, 2000.
PubMed
14) Pitt B : Effect of aldosterone blockade in patients with systolic left ventricular dysfunction : implications of the RALES and EPHESUS studies. Mol Cell Endocrinol 217 : 53-58, 2004.
PubMed
P.346 掲載の参考文献
1) Omura M, et al : Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27 : 193 -202, 2004.
 
2) Sherwin RP, Conn JW : Present status of pathology of adrenal gland in hypertension. Am J Surg 107 : 136-143, 1964.
 
3) Fishman LM, et al : Incidence of primary aldosteronism uncomplicated "essential" hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA 205 : 497-502, 1968.
PubMed
4) Anderson GH, et al : The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 12 : 609-615, 1994.
PubMed
5) Gordon RD, et al : High incidence of primary hyperaldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 : 315-318, 1994.
PubMed
6) Abdelhamid S, et al : Prevalence of adrenal and extra-adrenal Conn syndrome in hypertensive patients. Arch Intern Med 156 : 1190-1195, 1996.
PubMed
7) Lim PO, et al : Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353 : 40, 1999.
 
8) Gordon R : Incidence and workup of primary aldosteronism-Greenslopes Hospital Series. Abstracts of primary aldosteronism and adrenal incidentaloma-into a new millennium, p13, Couran Cove, Resort, South Stradbroke Island Queensland, Australia, 1999.
 
9) Young WF Jr : Incidence and workup of primary aldosteronism-Mayo Clinic. Abstracts of primary aldosteronism and adrenal incidentaloma-into a new millennium, p 12, Couran Cove, Resort, South Stradbroke Island Queensland, Australia, 1999.
 
10) Nishikawa T, Omura M : Clinical characteristics of primary aldosteronism : its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 54 (Suppl 1) : 83-85, 2000.
 
11) Connell JM : Is there an epidemic of primary hyperaldosteronism? J Hum Hypertens 16 : 151-152, 2002.
PubMed
12) Lim PO, et al : High prevalence of primary hyperaldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14 : 311-315, 2000.
PubMed
13) Satornon MI, Tchertkoff V : Incidence and role of adrenocortical tumors in hypertension. Geriatrics 23 : 184, 1968.
 
14) Tucker RM, Labarthe DR : Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 though to 1975. Mayo Clin Proc 51 : 549-555, 1977.
 
15) Loh KC, et al : Prevalence of primary hyperaldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85 : 2854-2859, 2000.
PubMed
16) Rayner BL, et al : The aldosterone/renin ratio as a screening test for primary hyperaldosteronism. S Afr Med J 90 : 394-400, 2000.
PubMed
17) Plouin PF, et al on behalf of the COMETE-Conn Study Group : Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant 19 : 774-777, 2004.
 
18) Hiramatsu K, et al : A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity : results in hypertensive patients. Arch Intern Med 141 : 1589-1593, 1981.
PubMed
19) Fardella C, et al : Primary hyperaldosteronism in essential hypertensives : prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 : 1863-1867, 2000.
PubMed
20) Tanabe A, et al : Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 88 : 2489-2494, 2003.
PubMed
21) Omura M, et al : Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal sampling. Metabolism 51 : 350-355, 2002.
PubMed
22) Montori VM, Young WF Jr : Use of plasma aldosterone concentration-to plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 31 : 619-632, 2002.
PubMed

IX カリクレイン - キニン系

P.355 掲載の参考文献
1) Kraut H, et al : Der Nachweis eins Kreislaufhormons in der Parkreardruse. Hoppe Seylers Z Physiol Chem 189 : 97-106, 1930.
 
2) Elliott DF, et al : The structure of bradykinin a plasma kinin from ox blood. Biochem Biophys Res Commun 3 : 87-91, 1960.
 
3) Erdos EG, Skidgel RA : Structure and functions of human angiotensin I converting enzyme (kininase II). Biochem Soc Trans 13 : 42-44, 1985.
PubMed
4) Regoli D, et al : New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization. Trends Pharmacol Sci 11 : 156-161, 1990.
PubMed
5) Margolius HS, et al : Altered urinary kallikrein excretion in human hypertension. Lancet ii : 1063-1065, 1971.
 
6) Iimura O, et al : Study on the renal kalhkrein-kinin system in normal and low renin subgroups of essential hypertension. J Hypertens 2 (Suppl 3) : 297-299, 1984.
 
7) Shimamoto K, et al : The role of renal natriuretic depressor systems on hypertensive mechanisms in reduced renal mass hypertensive rats. Hypertens Res 18 (Suppl 1) : S53-S57, 1995.
 
8) Majima M, Katori M : Approaches to the development of novel antihypertensive drugs : crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci 16 : 239-246, 1995.
 
9) Uehara Y, et al : Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24 (6) : 770-778, 1994.
PubMed
10) Chao J, et al : Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 9 : 21-31, 1998.
PubMed
11) Powell JS, et al : Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 : 186-188, 1989.
PubMed
12) Murakami H, et al : Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34 : 164-170, 1999.
PubMed
13) Martorana PA, et al : Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182 : 395 -396, 1990.
 
14) Miki T, et al : Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation. J Am Coll Cardiol 28 : 1616-1622, 1996.
PubMed
15) Yoshida H, et al : Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35 (1 Pt 1) : 25-31, 2000.
 
P.361 掲載の参考文献
1) Kitamura N, et al : Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 260 : 8610-8617, 1985.
 
2) Ishimaru F, et al : Molecular characterization of total kininogen deficiency in Japanese patients. Int J Hematol 69 : 126-128, 1999.
PubMed
3) Weisel JW, et al : The shape of high molecular weight kininogen. J Biol Chem 269 : 10100-10106, 1994.
PubMed
4) Neth P, et al : The mRNAs of prekallikrein, factors XI and XII, and kininogen, components of the contact phase cascade are differentially expressed in multiple non-hepatic human tissues. Thromb Haemost 85 : 1043-1047, 2001.
PubMed
5) Zhao A, et al : Human kininogen gene is transactivated by the farnesoid X receptor. J Biol Chem 278 : 28765-28770, 2003.
PubMed
6) Colman RW, et al : High molecular weight kininogen, the extracellular inhibitor of thiol proteases, is deficient in hamsters with muscular dystrophy. Thromb Res 54 : 115-123, 1989.
PubMed
7) Wachtfogel YT, et al : High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem 269 : 19307-19312, 1994.
PubMed
8) Chavakis T, et al : Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin-and urokinase receptor-dependent interactions. Blood 96 : 514-522, 2000.
PubMed
9) Colman RW, et al : Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 100 : 1481-1487, 1997.
 
10) 朝倉伸司 : キニノゲンの新しい機能について. 血栓止血誌 6 : 155-166, 1995.
 
11) Kawasaki M, et al : Effect of His-Gly-Lys motif derived from domain 50f high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo. J Biol Chem 278 : 49301-49307, 2003.
 
12) Colman RW, et al : Kininogens are antithrombotic proteins in vivo. Arterioscler Thromb Vasc Biol 19 : 2245-2250, 1999.
 
13) Chavakis T, Preissner KT : Potential pharmacological applications of the antithrombotic molecule high molecular weight kininogen. Curr Vasc Pharmacol 1 : 59-64, 2003.
PubMed
14) Motta G, et al : High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells : a novel mechanism f6r contact activation. Blood 91 : 516-528, 1998.
 
15) Lin Y, et al : High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 90 : 690-697, 1997.
PubMed
16) Colman RW, et al : Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothehal cell proliferation and migration and inhibits angiogenesis. Blood 95 : 543-550, 2000.
 
17) Guo YL, et al : Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 21 : 1427-1433, 2001.
PubMed
18) Guo YL, et al : Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J Cell Biochem 89 : 622-632, 2003.
PubMed
19) Cao DJ, et al : Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res 94 : 1227-1234, 2004.
PubMed
20) 飯島憲司, 中村克己 : 高分子キニノゲン欠損症における接触相と凝固・線溶系. 臨床血液 30 : 1702-1707, 1989.
 
21) Gallimore MJ, et al : Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis. Thromb Res 114 : 91-96, 2004.
PubMed
22) Peerschke EI, et al : Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesions. Mol Immunol 41 : 759-766, 2004.
PubMed
P.367 掲載の参考文献
1) Song Q, et al : DNA polymorphisms in the 5'-flanking region of the human tissue kallikrein gene. Hum Genet 99 : 727-734, 1997.
PubMed
2) Slim R, et al : Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 13 : 968-976, 2002.
PubMed
3) Berge KE, et al : Analyses of mutations in the human renal kallikrein (hKLK1) gene and their possible relevance to blood pressure regulation and risk of myocardial infarction. Clin Genet 52 : 86-95, 1997.
PubMed
4) Yousef GM, et al : Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 276 : 125-133, 2000.
PubMed
5) Yousef GM, et al : Human kallikrein 5 : a potential novel serum biomarker for breast and ovarian cancer. Cancer Res 63 : 3958-3965, 2003.
PubMed
6) Yousef GM, et al : Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63 : 2223-2227, 2003.
PubMed
7) Anisowicz A, et al : A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2 : 624-636, 1996.
PubMed
8) Goyal J, et al : The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58 : 4782-4786, 1998.
PubMed
9) Yousef GM, et al : Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol 119 : 346-355, 2003.
PubMed
10) Yousef GM, et al : Cloning of a kallikrein pseudogene. Clin Biochem 37 : 961-967, 2004.
PubMed
11) Yousef GM, et al : Molecular cloning of a new gene which is differentially expressed in breast and prostate cancers. Tumour Biol 25 : 122-133, 2004.
PubMed
12) 平和伸仁, 梅村敏 : プロスタグランジン/ブラジキニン. 日本臨牀 62 (増刊号 6) : 183-188, 2004.
 
13) Hirawa N, et al : Mechanistic analysis of renal protection by angiotensin converting enzyme inhibitor in Dahl salt-sensitive rats. J Hypertens 12 : 909-918, 1994.
PubMed
14) Uehara Y, et al : Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats. Hypertension 24 : 770-778, 1994.
PubMed
15) Hirawa N, et al : Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is abradykinin B2-receptor-mediated event. Nephron 81 : 183-193, 1999.
PubMed
16) Meneton P, et al : Cardiovascular abnommalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98 : 2634-2639, 2001.
PubMed
17) Bergaya S, et al : Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 88 : 593-599, 2001.
PubMed
18) Phillips MI : Gene therapy for hypertension : the preclinical data. Hypertension 38 (3 Pt 2) : 543-548, 2001.
 
19) Chao J, et al : Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive rats. Kidney Int 54 : 1250-1260, 1998.
PubMed
20) Xiao X, et al : Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72 : 2224-2232, 1998.
PubMed
21) Wang T, et al : Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. Gene Ther 11 : 1342-1350, 2004.
PubMed
22) Berge KE, Berg K : No effect of TaqI polymorphism at the human renal kallikrein (KLK1) locus on normal blood pressure level or variability. Clin Genet 44 : 196-202, 1993.
PubMed
23) Friend LR, et al : Examination of the role of nitric oxide synthase and renal kallikrein as candidate genes for essential hypertension. Clin Exp Pharmacol Physiol 23 : 564-566, 1996.
PubMed
24) Yu H, et al : Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 61 : 1030-1039, 2002.
PubMed
P.374 掲載の参考文献
1) Farmer SG, Burch RM : The pharmacology of bradykinin receptors. In : Bradykinin Antagonists (ed by Burch RM), p1-31, Marcel Dekker, New York, 1991.
 
2) Marceau F, et al : The B1 receptors for kinins. Pharmacol Rev 50 : 357-386, 1998.
PubMed
3) Prado GN, et al : Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J Cell Physiol 193 : 275-286, 2002.
PubMed
4) Blaukat A : Structure and signaling pathways of kinin receptors. Andrologia 35 : 17-23, 2003.
PubMed
5) Pyne NJ, et al : Bradykinin stimulates cAMP synthesis Via mitogen-activated protein kinase-dependent regulation of cytosolic phospholipase A2 and prostaglandin E2 release in airway smooth muscle. Biochem J 328 : 689-694, 1997.
PubMed
6) Ricupero DA, et al : Des-Arg (10) -kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. J Biol Chem 275 : 12475-12480, 2000.
PubMed
7) Liebmann C : Bradykinin signaling to MAP kinase : Cell-specific connections versus principle mitogenic pathways. Biol Chem 382 : 49-55, 2001.
PubMed
8) Shi CS, Kehrl JH : PYK21inks Gqαand G13αsignaling to NF-κB activation. J Biol Chem 276 : 31845-31850, 2001.
 
9) Benzing T, et al : Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 99 : 2034-2040, 1999.
PubMed
10) Venema RC : Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int Immunol 2 : 1755-1762, 2002.
 
11) Abd Alla S, et al : AT1 receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 409 : 94-98, 1999.
 
12) Abd Alla S, et al : Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7 : 1003-1009, 2001.
PubMed
P.379 掲載の参考文献
1) Frey EK : Zusammenhange zwischen Herzarbeit und Nierentatigkeit. Langenbecks Arch Klin Chir 142 : 663-669, 1926.
 
2) Hagiwara M, et al : Renal protective role of bradykinin B1 receptor in stroke-prone spontaneously hypertensive rats. Hypertens Res 27 : 399-408, 2004.
PubMed
3) Figueroa CD, et al : Localisation of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 89 : 437-442, 1988.
PubMed
4) Katori M, Majima M : Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J pharmacol 70 : 95-128, 1996.
PubMed
5) Nolly H, et al : Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein. Circ Res 56 : 816-821, 1985.
PubMed
6) Oza NB, et al : Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykininase activity. J Clin Invest 85 : 597-600, 1990.
PubMed
7) Farhy RD, et al : Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72 : 1202-1210, 1993.
PubMed
8) Murakami H, et al : Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima fbrmation in the rat artery after balloon angioplasty. Hypertension 34 : 164-170, 1999.
PubMed
9) Agata J, et al : Bradyldnin B (1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 36 : 364-370, 2000.
PubMed
10) Nolly H, et al : Alocal kallikrein-kinin system is present in rat hearts. Hypertension 23 (6 Pt 2) : 919-923, 1994.
 
11) Linz W, et al : Role of kinins in the pathophysiology of myocardial ischemia. In Vitro and in Vivo studies. Diabetes 45 (Suppl 1) : S51-S58, 1996.
 
12) Dietze G, et al : Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during hypoxia. Hoppe Seylers Z Physiol Chem 358 : 633-638, 1977.
PubMed
13) Carvalho CR, et al : Etifect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46 : 1950-1957, 1997.
 
14) Kishi K, et al : Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 47 : 550-558, 1998.
PubMed
15) Raidoo DM, Bhoola KD : Kinin receptors on human neurones. J Neuroimmunol 77 : 39-44, 1997.
PubMed
P.384 掲載の参考文献
1) Wang J, et al : Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23 : 236-243, 1994.
PubMed
2) Wang D, et al : Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29 : 488-493, 1997.
PubMed
3) Alfie ME, et al : Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 29 : 483-487, 1997.
PubMed
4) Madeddu P, et al : Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96 : 3570-3578, 1997.
PubMed
5) Cervenka L, et al : Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension 37 : 967-973, 2001.
PubMed
6) Wang C, et al : Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95 : 1706-1710, 1995.
 
7) Jin L, et al : Gene therapy in hypertension : adenovirus-mediated kallikrein gene delivery in hypertensive rats. Hum Gene Ther 8 : 1753-1761, 1997.
PubMed
8) Chao J, et al : Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 9 : 21-31, 1998.
PubMed
9) Yayama K, et al : Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31 : 1104-1110, 1998.
PubMed
10) Dobrzynski E, et al : Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects renal injury in deoxycorticosterone-salt rats. Immunopharmacology 44 : 57-65, 1999.
PubMed
11) Wang D, et al : Enhanced renal function in bradykinin B (2) receptor transgenic mice. Am J Physiol 278 : F484-F491, 2000.
 
12) Imig JD, et al : The bradykinin B2 receptor is required for full expression of renal COX-2 and renin. Peptides 24 : 1141-1147, 2003.
PubMed
13) Alfie ME, et al : An enhanced effect of arginine vasopressin in bradykinin B2 receptor null mutant mice. Hypertension 33 : 1436-1440, 1999.
PubMed
14) Siragy HM, Carey RM : The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100 : 264-269, 1997.
PubMed
15) Siragy HM, et al : Sustained hypertensivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 96 : 6506-6510, 1999.
 
16) Abadir PM, et al : Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 42 : 600-604, 2003.
PubMed
17) El-Dahr SS, et al : Bradykinin B2 null mice are prone to renal dysplasia : gene-enviroment interactions in kidney development. Physiol Genomics 3 : 121-131, 2000.
 
18) Harrison-Bernard LM, et al : Renal and blood pressure phenotype in 18-mo-old bradykinin B2R (-/-) CRD mice. Am J Physiol 285 : R782-R790, 2003.
 
19) Schanstra Jp, et al : In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110 : 371-379, 2002.
PubMed
20) Kakoki M, et al : Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 101 : 13302-13305, 2004.
PubMed
21) Wolf WC, et al : Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58 : 730-739, 2000.
PubMed
22) Emanueli C, et al : Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 100 : 2359-2365, 1999.
PubMed
23) Yang XP, et al : Role of kinins in the cardioprotective effect of preconditioning : study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30 : 735-740, 1997.
PubMed
24) Yoshida H, et al : Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35 : 25-31, 2000.
PubMed
25) Yang XP, et al : Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B (2) kinin receptor gene knockout mice. Circ Res 88 : 1072-1079, 2001.
 
26) Tschope C, et al : Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18 : 828-835, 2004.
PubMed
27) Murakami H, et al : Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34 : 164-170, 1999.
PubMed
28) Emanueli C, et al : Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103 : 125-132, 2001.
PubMed
29) Emanueli C, et al : Targeting kinin B (1) receptor for therapeutic neovascularization. Circulation 105 : 360-366, 2002.
PubMed
30) Xia CF, et al : Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43 : 452-459, 2004.
PubMed
31) Emanueli C, et al : Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. Circulation 106 : 993-999, 2002.
PubMed
32) Duka I, et al : Role of the B (2) receptor of bradykinin in insulin sensitivity. Hypertension 38 : 1355-1360, 2001.
 
P.391 掲載の参考文献
1) Sharma JN : Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol 43 : 1187-1195, 2003.
PubMed
2) Campbell DJ : The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 28 : 1060-1065, 2001.
PubMed
3) Campbell DJ : Vasopeptidase inhibition : a double-edged sword? Hypertension 41 : 383-389, 2003.
PubMed
4) Carretero OA, Scicli AG : Kinins paracrine hormone. Kidney Int Suppl 26 : S52-59, 1998.
 
5) 尾股健, 阿部圭志 : キニン・カリクレイン. ホルモンと臨床 46 (増刊) : 414-420, 1998.
 
6) 笠井豊, 阿部圭志 : キニン・カリクレイン. 臨床検査 34 (増刊) : 1495-1502, 1990.
 
7) Porcu P, et al : Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia. Circulation 105 : 67-72, 2002.
PubMed
8) Schmaier AH : The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 285 : R1-13, 2003.
PubMed
9) 平山良孝, 茅切浩 : ブラジキニン受容体拮抗薬の開発現況と今後の展開. 日薬理誌 119 : 45-53, 2002.
Medical*Online
10) McLean PG, et al : Kinin B (1) receptors and the cardiovascular system : regulation of expression and function. Cardiovasc Res 48 : 194-210, 2000.
PubMed
11) Ura N, et al : Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32 : 507-513, 1987.
PubMed
12) Corti R, et al : Vasopeptidase inhibitors : a new therapeutic concept in cardiovascular disease? Circulation 104 : 1856-1862, 2001.
PubMed
13) Tomiyama H, et al : Insulin sensitivity and endothelial function in hypertension : A comparison of temocapril and candesartan. Am J Hypertens, 2004. (in press)
 
14) Carbini LA, et al : The molecular biology of the kallikrein-kinin system : III. The human kallikrein gene family and kallikrein substrate. J Hypertens 11 : 893-898, 1993.
PubMed
15) Emanueli C, Madeddu P : Role of the kallikrein-kinin system in the maturation of cardiovascular phenotype. Am J Hypertens 12 (10 Pt 1) : 988-999, 1999.
 
P.397 掲載の参考文献
1) Ura N, et al : Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32 : 507, 1987.
PubMed
2) Ura N, et al : Renal kininase I, kininase II and neutral endopeptidase 24.11 activities in patients with essential hypertension, primary aldosteronism and Cushing's syndrome. Hypertens Res 16 : 253, 1993.
 
3) Hagiwara M, et al : Renal protective role of bradykinin B1 receptor in stroke-prone spontaneously hypertensive rats. Hypertens Res 27 : 399, 2004.
PubMed
4) Shimamoto K, et al : Role of the renal kallikrein-kinin system in sodium metabolism in normotensives and essential hypertensives. N Z Med J 96 : 905, 1983.
 
5) Tomiyama H, et al : Changes in renal function induced by intrarenal kinin blockade. Hypertension 14 : 338, 1989.
 
6) Mukai H, et al : Bradykinin B2 receptor antagonist increases chloride and water absorption in rat modularly collecting duct. Am J Physiol 271 : R352, 1996.
 
7) Ura N, et al : The mechanisms of the renal effects of neutral endopeptidase inhibitor in rats. Clin Exp Hypertens 17 : 1183, 1995.
PubMed
8) Stoos BA, et al : Endothelium-derived relaxing factor inhibits transport and increases cGMP content in cultured mouse cortical collecting duct cells. J Clin Invest 89 : 761, 1992.
 
9) Garcia NH, et al : Nitric oxide inhibits ADH-stimulated osmotic water permeability in cortical collecting ducts. Am J Physiol 270 : F206, 1996.
PubMed
10) Shimamoto K, et al : Mechanisms of suppression of renal kallikrein activity in low renin essential hypertension and renoparenchymal hypertension. Hypertension 14 : 375, 1989.
PubMed
11) Lu B, et al : The control of microvascular permeability and blood pressure by neutral endopeptidase. Nat Med 3 : 904, 1997.
PubMed
12) Marcos EA, et al : Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224 : 625, 1996.
 
13) Madeddu P, et al : Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96 : 3570, 1997.
PubMed
14) Shimamoto K, et al : Renal kallikrein-kinin, prostaglandin E2, and dopamine systems in young normotensive subjects with a family history of essential hypertension. Am J Med Sci 307 : S70, 1994.
PubMed
15) Wang DZ, et al : Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29 : 488, 1997.
PubMed
P.402 掲載の参考文献
1) Kon V, Hunley TE : Kinin and endothelin. In : The Kidney, 3rd ed (ed by Giebisch G, Seldin DW), p889-903, Lipincott Williams & Wilkins, Philadelphia, 2000.
 
2) Candido R, et al : Vasoactive peptides and the kidney. In : Brenner & Rector'sThe Kidney, 7th ed (ed by Brenner BM), p661-726, WB Saunders, Philadelphia, 2004.
 
3) Muto S : Potassium transport in the mammalian collecting duct. Physiol Rev 81 : 85-116, 2001.
PubMed
4) Lewis SA, Alles WP : Urinary kallikrein : a physiological regulator of epithelial Na+absorption. Proc Natl Acad Sci USA 83 : 5345-5348, 1986.
PubMed
5) Vallet V, et al : An epithelial serine protease activates the amiloride-sensitive sodium channel. Nature 389 : 607-610, 1997.
PubMed
6) YU JX, et al : Prostasin is a novel human serine proteinase from seminal fluid. Purification, tissue distribution, and localization in prostate gland. J Biol Chem 269 : 18843-18848, 1994.
PubMed
7) Siragy HM, et al : Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide. Hypertension 29 : 757-762, 1997.
PubMed
8) Tomita K, et al : Control of Na+ and K+ transport in the cortical collecting duct of the rat. Effects of bradykinin, vasopressin, and deoxycorticosterone. J Clin Invest 76 : 132-136, 1985.
 
9) Tomita K, et al l Effects of vasopressin and bradykinin on anion transport by the rat cortical collecting duct. Evidence for an electroneutral sodium chloride transport pathway. J Clin Invest 77 : 136-141, 1986.
 
10) Schuster VL : Mechanism of bradykinin, ADH, and cAMP interaction in rabbit cortical collecting duct. Am J Physiol 249 : F645-F653, 1985.
PubMed
11) Rouch AJ, et al : Na+ transport in isolated rat CCD : effects of bradykinin, ANP, clonidine, and hydrochlorothiazide. Am J Physiol 260 : F86-F95, 1991.
PubMed
12) Zeidel ML, et al : Kinins inhibit conductive Na+uptake by rabbit inner medullary collecting duct cells. Am J Physiol 258 : F1584-F1591, 1990.
PubMed
13) Kose H, et al : Bradykinin regulation of salt transport across mouse inner medullary collecting duct epithelium involves activation of a Ca2+ -dependent Cl-conductance. Br J Pharmacol 131 : 1689-1699, 2000.
PubMed
14) Mukai H, et al : Bradykinin B2 receptor antagonist increases chloride and water absorption in rat medullary collecting duct. Am J Physiol 271 : R352-R360, 1996.
PubMed
15) Schuster VL, et al : Interactions of lysyl-bradykinin and antidiuretic hormone in the rabbit cortical collecting tubule. J Clin Invest 73 : 1659-1667, 1984.
PubMed
16) Alfie ME, et al : An enhanced effect of arginine vasopressin in bradykinin B2 receptor null mutant mice. Hypertension 33 : 1436-1440, 1999.
PubMed
17) Hays S, et al : Hormonal regulation of proton secretion in rabbit medullary collecting duct. J Clin Invest 78 : 1279-1286, 1986.
PubMed
18) Marin-Grez M, et al : Involvement of renal kallikrein in the regulation of bicarbonate excretion in rats. J Physiol 488 : 163-170, 1995.
PubMed
19) Marin-Grez M, Valles P : Evidence for an inhibitory effect of kallikrein on collecting duct bicarbonate secretion in rats and rabbits. Ren Physiol Biochem 17 : 301-306, 1994.
PubMed
P.408 掲載の参考文献
1) Damas J, et al : The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 20 : 288-297, 2004.
PubMed
2) Wicklmayr M, et al : The kallikrein/kinin system in the pathogenesis of hypertension in diabetes mellitus. Diabete Metab 15 (5 Pt 2) : 306-310, 1989.
 
3) Pahor M, et al : Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 23 : 888-892, 2000.
PubMed
4) Bosch J, et al : HOPE Investigators : Heart outcomes prevention evaluation. Use of ramipril in preventing stroke : double blind randomised trial. BMJ 324 : 699-702, 2002.
PubMed
5) Ogihara T, et al : Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 40 : 872-879, 2002.
PubMed
6) Ogihara T, et al : Contribution of salt intake to insulin resistance associated with hypertension. Life Sci 73 : 509-523, 2003.
PubMed
7) Nakagawa H, et al : Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J Cardiovasc Pharmacol 34 : 28-33, 1999.
PubMed
8) Ura N, et al : The mechanisms of insulin sensitivity improving effects of angiotensin converting enzyme inhibitor. Immunopharmacology 44 : 153-159, 1999.
PubMed
9) Shiuchi T, et al : ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40 : 329-334, 2002.
PubMed
10) Shiuchi T, et al : Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43 : 1003-1010, 2004.
PubMed
11) Couture R, Girolami JP : Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 500 : 467-485, 2004.
PubMed
12) Christopher J, et al : Regulation of B2-kinin receptors by glucose in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 280 : H1537-1546, 2001.
PubMed
P.414 掲載の参考文献
1) Elliot A, Nuzum FR : Urinary excretion of a depressor substance (kallikrein of Ferey and Kraut) in arterial hypertension. Endocrinology 18 : 462-474, 1934.
 
2) Matsuda H, et al : Role of endothelium-derived hyperpolarizing factor in ACE inhibitor induced renal vasodilation in vivo. Hypertension 43 : 603-609, 2004.
PubMed
3) Sharma JN, Zeitlin IJ : Altered plasma kininogen in clinical hypertension. Lancet i (8232) : 1259-1260, 1981.
PubMed
4) Overlack A, et al : Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 3 : 118-121, 1981.
 
5) Ogawa K, et al : Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension. Klin Wochenschr 63 : 332-336, 1985.
PubMed
6) Duka I, et al : Mechanisms mediating the vasoactive effects of the B1 receptors of bradykinin. Hypertension 42 : 1021-1025, 2003.
PubMed
7) Wang C, et al : Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95 : 1710-1716, 1995.
PubMed
8) Keller C, et al : LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors. Lancet 341 : 60-61, 1993.
PubMed
P.421 掲載の参考文献
1) Omata K, et al : Localization of active and inactive kallikrein (kininogenase activity) in the microdissected rabbit nephron. Kidney Int 22 : 602, 1982.
PubMed
2) Margolius HR : Kallikreins and kinins. Hypertension 26 : 221, 1995.
 
3) Monbouli JV, Vanhoutte PM : Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 35 : 679, 1995.
 
4) 平山良孝, 茅切浩 : ブラジキニン受容体拮抗薬の開発現況と今後の展開. 日薬理誌 (Folia Pharmacol Jpn) 119 : 45, 2002.
 
5) Majima M, Katori M : Approaches to the development of novel antihypertensive drugs : crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci 16 : 239, 1995.
 
6) Madeddu P, et al : Kallikrein-kinin system and blood pressure sensitivity to salt. Hypertension 29 (Part 2) : 471, 1997.
 
7) Alfie ME, et al : Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 29 (Part 2) : 483, 1997.
 
8) Wang D, et al : Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29 (Part 2) : 488, 1977.
 
9) Schmaier AH : The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 285 : R1, 2003.
PubMed
10) Elliot AH, Nuzum FR : Urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18 : 462, 1934.
 
11) 阿部圭志, 尾股健 : カリクレインーキニン系. 臨床生理学シリーズ 4 腎臓 (黒川清, 今井正編), p278, 南江堂, 1989.
 
P.424 掲載の参考文献
1) Dhamrait SS, et al : Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J 24 : 1672-1680, 2003.
PubMed
2) Aoki S, et al : The genetic factor in acute myocardial infarction with hypertension. Jpn Circ J 65 : 621-626, 2001.
PubMed
3) Matsumoto T, et al : Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol 44 : 451-457, 2004.
PubMed
4) Prasad A, et al : Contribution of bradykinin receptor dysfunction to abnormal coronary vasomotion in humans. J Am Coll Cardiol 36 : 1467-1473, 2000.
PubMed
5) Kitakaze M, et al : Beneficial effects of inhibition of angiotensin-converting enzyme on ischemic myocardium during coronary hypoperfusion in dogs. Circulation 92 : 950-961, 1995.
PubMed
6) Jalowy A, et al : AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 93 (Suppl 2) : S85-S91, 1998.
 
7) Miki T, et al : Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning via bradykinin B2 receptor activation. J Am Coll Cardiol 28 : 1616-1622, 1996.
 
8) Nakano A, et al : Effects of neutral endopeptidase 24.11 inhibition on myocardial infarct size and ischemic preconditioning in rabbits. Naunyn Schmiedebergs Arch Pharmacol 366 : 335-342, 2002.
PubMed
9) 三浦哲嗣 : 虚血プレコンディショニングの分子機構. 医学のあゆみ 210 : 558-562, 2004.
 
10) O'Rourke B : Myocardial KATP channel in preconditioning. Circ Res 87 : 845-855, 2000.
PubMed
11) Yang XP, et al : Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 88 : 1072-1079, 2001.
PubMed
12) Maestri R, et al : Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 41 : 1151-1155, 2003.
PubMed
13) Emanueli C, et al : Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 100 : 2359-2365, 1999.
PubMed
14) Meneton P, et al : Cardiovascular abnormalities With normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98 : 2634-2639, 2001.
PubMed
15) Walther T, et al : AT1 receptor blockade increases cardiac bradykinin Via neutral endopeptidase after induction of myocardial infarction in rats. FASEB J 16 : 1237-1241, 2002.
PubMed
P.430 掲載の参考文献
1) Kon V, et al : Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 44 : 545-550, 1993.
PubMed
2) Hirawa N, et al : Regression of glomerular injury by kallikrein infusion in Dahl salt-sensitive rats is abradykinin B2-receptor-mediated event. Nephron 81 : 183-193, 1999.
PubMed
3) Wolf WC, et al : Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure. Kidney Int 58 : 730-739, 2000.
PubMed
4) Zhang JJ, et al : Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66 : 722-732, 2004.
PubMed
5) Siragy HM, Carey RM : The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100 : 264-269, 1997.
PubMed
6) Nolly H, et al : Alocal kallikrein-kinin system is present in rat hearts. Hypertension 23 : 919-923, 1994.
 
7) Martorana PA, et al : Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182 : 395-396, 1990.
PubMed
8) Yang XP, et al : Role of kinins in the cardioprotective effect of preconditioning : study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30 (3 Pt 2) : 735-740, 1997.
 
9) Yoshida H, et al : Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. Hypertension 35 (1 Pt 1) : 25-31, 2000.
 
10) Agata J, et al : Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 40 : 653-659, 2002.
PubMed
11) Dixon BS, Dennis MJ : Regulation of mitogenesis by kinins in arterial smooth muscle cells. Am J Physiol 273 (1 Pt 1) : C7-20, 1997.
 
12) Farhy RD, et al : Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72 : 1202-1210, 1993.
PubMed
13) Murakami H, et al : Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension 34 : 164-170, 1999.
PubMed
14) Agata J, et al : Bradykinin B (1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 36 : 364-370, 2000.
PubMed
15) Emanueli C, et al : Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol 20 : 2379-2385, 2000.
PubMed
P.435 掲載の参考文献
1) Monbouli JV, Vanhoutte PM : Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 35 : 679, 1995.
 
2) 尾股健, 阿部圭志 : キニン・カリクレイン. ホルモンと臨床 46 (増刊号) : 414, 1998.
 
3) Blaukat A : Structure and signalling pathways of kinin receptors. Andrologia 35 : 17, 2003.
PubMed
4) Marceau F, et al : The B1 receptor for kinins. Pharmacol Rev 50 : 357, 1998.
PubMed
5) 平山良孝, 茅切浩 : ブラジキニン受容体拮抗薬の開発現況と今後の展開. 日薬理誌 (Folia Pharmacol Jpn) 119 : 45, 2002.
 
6) Hatta E, et al : Bradykinin promotes ischemic norepinephrine release in guinea pig and human hearts. J Pharmacol Exp Ther 288 : 919, 1999.
PubMed
7) Majima M, Katori M : Approaches to the development of novel antihypertensive drugs : crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci 16 : 239, 1995.
 
8) Wang D, et al : Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29 (Part 2) : 488, 1977.
 
9) Fein AM, et al : Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127) : Results of a randomized, double-blind, placebo controlled trial. J Am Med Assoc 277 : 482, 1997.
 
10) Lung CC, et al : Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol 99 : 134, 1997.
PubMed
11) Campbell CA, et al : SB-238592 (CP-0127) does not reduce indices of ischemic damage following permanent or transient focal cerebral ischemia in normotensive rats. Br J Pharmacol 122 : 324P, 1997.
 
12) Calixto JB, et al : Kinins in pain and inflammation. Pain 87 : 1-5, 2000.
PubMed
13) Relton JK, et al : Blockade of the bradykinin B1 receptor reverses the neuroprotective effect of B2 receptor antagonism after focal cerebral ischaemia in the rat. Br J pharmacol 120 : 76P, 1997.
 
14) Fenoy FJ, Roman RJ : Effect of kinin receptor antagonists on renal hemodynamic and natriuretic responses to volume expansion. Am J Physiol 263 : R1136, 1992.
PubMed
15) Bachvarov DR, et al : Characterization of two polymorphic sites in the human kinin Bl receptor gene : Altered frequency of an allele in patients with a history of end stage renal failure. J Am Soc Nephrol 9 : 958, 1998.
 
P.440 掲載の参考文献
1) Gohlke P, et al : Angiotensin-convening enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 23 (4) : 411-418, 1994.
 
2) Hecker M, et al : Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation : interaction at the receptor level. Br J Pharmacol 111 (1) : 238-244, 1994.
PubMed
3) Hecker M, et al : ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br J Pharmacol 121 (7) : 1475-1481, 1997.
PubMed
4) Marcic BM, Erdos EG : Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther 294 (2) : 605-612, 2000.
PubMed
5) Minshall RD, et al : Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res 81 (5) : 848-856, 1997.
 
6) Ignjatovic T, et al : Novel mode of action of angiotensin I converting enzyme inhibitors : direct activation of bradykinin B1 receptor. J Biol Chem 277 (19) : 16847-16852, 2002.
 
7) Marin-Castano ME, et al : Induction of functional bradykinin b (1) -receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation 105 (5) : 627-632, 2002.
PubMed
8) Ferrario CM, et al : Counterregulatory actions of angiotensin- (1-7). Hypertension 30 (3 Pt 2) : 535-541, 1997.
 
9) Souza Dos Santos RA, et al : Interactions between angiotensin- (1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 38 (3 Pt 2) : 660-664, 2001.
 
10) Donoghue M, et al : A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (5) : E1-9, 2000.
 
11) Hiyoshi H, et al : Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressureoverloaded aorta after banding. Hypertension 43 : 1258-1263, 2004.
PubMed
12) AbdAlla S, et al : AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407 (6800) : 94-98, 2000.
PubMed
13) AbdAlla S, et al : Increased AT (1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7 (9) : 1003-1009, 2001.
PubMed

X バソプレシン

P.449 掲載の参考文献
1) Oliver G, Schafer EA : On the physiological actions of extract of pituitary body and certain other gland organs. J physiol 18 : 277-279, 1895.
 
2) von den Velden R : Nierenwirkung von Hypophysenextrakten beim Menschen. Berlin Klin Wochsch 50 : 2083-2086, 1919.
 
3) du Vigneaud V : Hormones of the posterior pituitary gland : oxytocin and vasopressin. Harvey Lect 50 : 1-26, 1956.
 
4) Verney EB : The antidiuretic hormone and the factors which determine its release. Proc R Soc Med B135 : 25-106, 1947.
 
5) Share L : Vasopressin, its bioassay and the physiological control of its release. Am J Med 42 : 701-712, 1967.
PubMed
6) Robertson GL, Athar S : The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab 42 : 613-620, 1976.
 
7) Fink E : Ueber Beziehungen der Hypophyse zum Diabetes insipidus. Berlin Klin Wochsch 49 : 393-397, 1912.
 
8) Carter AC, Robbins J : The use of hypertonic saline infusions in the differential diagnosis and psychogenic polydipsia. J Clin Endocrinol 7 : 753, 1947.
 
9) Saito T, et al : Chronic hypernatremia associated with inflammation of the neurohypophysis. J Clin Endocrinol Metab 31 : 391-396, 1970.
PubMed
10) Imura H, et al : Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 329 : 683-689, 1993.
PubMed
11) Sachs H : Biosynthesis and release of vasopressin. Am J Med 42 : 687-700, 1967.
PubMed
12) Schmale H, et al : Vasopressin biosynthesis : from gene to peptide hormone. Kidney Int 32 : S8-S13, 1987.
 
13) Schwartz WB, et al : A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 23 : 529-542, 1957.
PubMed
14) Schrier RW, Berl T : Disorders of water metabolism. In : Renal and Electrolyte Disorders, 3rd ed (ed by Schrier RW), p1-77, Little, Brown and Company, Boston, 1986.
 
15) Mohring J, et al : Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension. Am Jphysiol 232 : F260-F269, 1977.
 
16) Saito T, Yajima Y : Development of DOCA-salt hypertension in the Brattleboro rat. Ann NY Acad Sci 394 : 309-318, 1982.
PubMed
17) Naitoh M, et al : Modulation of genetic hypertension by short-term AVP V1a or V2 receptor antagonism in young SHR. Am J Physiol 272 : F229-F234, 1997.
PubMed
18) Tachikawa K, et al : Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat. Am J Physiol 285 : E1161-E1166, 2003.
 
19) Lee CR, et al : Vasopressin : a new target for the treatment of heart failure. Am Heart J 146 : 9-18, 2003.
PubMed
20) Lolait SJ, et al : Cloning and charactedzation of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357 : 336-339, 1992.
PubMed
21) Thibonnier M : Genetics of vasopressin receptors. Curr Hypertens Rep 6 : 21-26, 2004.
PubMed
22) Fushimi K, et al : Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 361 : 549-552, 1993.
 
23) Manning M, SaWer WH : Synthesis and receptor specificities of vasopressin antagonists. J Cardiovasc Pharmacol 8 (Suppl 7) : S29-S35, 1986.
 
24) Yamamura Y, et al : Characterization of a novel aquaretic agent, OPC-31260, an orally effective, nonpeptide vasopressin V2-receptor antagonist. Br J Pharmacol 105 : 787-791, 1992.
PubMed
25) Saito T, et al : Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82 : 1054-1057, 1997.
PubMed
26) Gheorghiade M, et al : Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure : a randomized controlled trial. JAMA 291 : 1963-1971, 2004.
PubMed
27) De Wied D, et al : Memory deficit in rats with hereditary diabetes insipidus. Brain Res 85 : 152-156, 1975.
 
28) Bielsky IF, et al : Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29 : 483-493, 2004.
PubMed
29) Lim MM, et al : The role of vasopressin in the genetic and neural regulation of monogamy. J Neuroendocrinol 16 : 325-332, 2004.
PubMed
P.456 掲載の参考文献
1) Land H, et al : Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature 295 : 299-303, 1982.
PubMed
2) Mohr E, Richer D : Sequence analysis of the promoter region of the rat vasopressin gene. FEBS Lett 260 : 305-308, 1990.
 
3) Lightman SL, Young WS 3rd : Vasopressin, oxytocin, dynorphin, enkephalin and corticotropin-releasing factor mRNA stimulation in the rat. J Physiol 394 : 23-29, 1987.
 
4) Harmar AJ, et al : The VPAC (2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109 : 497-508, 2002.
PubMed
5) Ishikawa S, et al : Vasopressin secretion in health and disease. In : The Pituitary Gland, 2nd ed (ed by Imura H), p 331-350, Raven Press, New York, 1994.
 
6) Rabadab-Diehl C, et al : Regulation of pituitary V1b vasopressin receptor messenger ribonucleic acid by adrenalectomy and glucocorticoid administration. Endocrinology 138 : 5189-5194, 1997.
 
7) Sladek CD, Joynt RJ : Cholinergic involvement in osmotic control of vasopressin release by the organ cultured rat hypothalamo-neurohypophysial system. Endocrinology 105 : 367-371, 1979.
PubMed
8) Sved AF, et al : Vasopressin contributes to hypertension caused by nucleus tractus solitarius lesions. Hypertension 7 : 262-267, 1985.
PubMed
9) Blessing W, Willoughby JO : Inhibiting the rabbit caudal ventrolateral medulla prevents the baroreceptor-initiated secretion of vasopressin. J physiol 367 : 253 -265, 1985.
 
10) Kannan H, Yagi K : Supraoptic neurosecretory neurons : evidence for the existence of converging inputs both from carotid baroreceptors and osmoreceptors. Brain Res 145 : 385-390, 1978.
 
11) Morel A, et al : Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356 : 523-526, 1992.
PubMed
12) Dunser MW, et al : Arginine vasopressin in advanced vasodilatory shock : aprospective, randomized, controlled study. Circulation 107 : 2313-2319, 2003.
 
13) O'Brien A, et al : Terlipressin for norepinephrine-resistant septic shock. Lancet 359 : 1209-1210, 2002.
PubMed
14) Fushimi K, et al : Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 361 : 549-552, 1993.
 
15) Griebel G, et al : Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99 : 6370-6375, 2002.
PubMed
P.458 掲載の参考文献
1) Thibonnier M, et al : Structure, sequence, expression, and chromosomal localization of the human V1a vasopressin receptor gene. Genomics 31 : 327-334, 1996.
PubMed
2) Phillips PA, et al : Localization of vasopressin binding sites in rat tissues using specific V1 and V2 selective ligands. Endocrinology 126 : 1478-1484, 1990.
PubMed
3) Egashira N, et al : V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze. Neurosci Lett 356 : 195-198, 2004.
 
4) Bielsky IF, et al : Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29 : 483-493, 2004.
PubMed
5) Young IJ, et al : Increased affiliative response to vasopressin in mice expressing the V1a receptor from a monogamous vole. Nature 400 : 766-768, 1999.
 
6) Rousseau-Merck MF, et al : Chromosomal localization of the human V3 pituitary vasopressin receptor gene (AVPR3) to 1q32. Genomics 30 : 405-406, 1995.
PubMed
7) Wersinger SR, et al : Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry 7 : 975-984, 2002.
PubMed
8) Birnbaumer M, et al : Molecular cloning of the receptor for human antidiuretic hormone. Nature 357 : 333-335, 1992.
PubMed
9) Lolait SJ, et al : Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 357 : 336-339, 1992.
PubMed
10) Kambouris M, et al : Localization of the gene for X-linked nephrogenic diabetes insipidus to Xq28. Am J Med Genet 29 : 239-246, 1988.
PubMed
11) Ludwig M, Pittman QJ : Talking back : dendritic neurotransmitter release. Trends Neurosci 26 : 255-261, 2003.
PubMed
12) Sabatier N, et al : Intracellular calcium increase and somatodendritic vasopressin release by vasopressin receptor agonists in the rat supraoptic nucleus : involvement of multiple intracellular transduction signals. J Neuroendocrinol 16 : 221-236, 2004.
PubMed
P.464 掲載の参考文献
1) Sausville E, et al : The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. J Biol Chem 260 : 10236-10241, 1985.
 
2) Schmale H, Richter D : Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature 308 : 705-709, 1984.
PubMed
3) Grant FD : Genetic models of vasopressin deficiency. Exp Physiol 85 : 203S-209S, 2000.
PubMed
4) Ito M, et al : A single base substitution in the coding region for neurophysin II associated with familial central diabetes insipidus. J Clin Invest 87 : 725-728, 1991.
 
5) Grant FD, et al : Two novel mutations of the vasopressin gene associated with familial diabetes insipidus and identification of an asymptomatic carrier infant. J Clin Endocrinol Metab 83 : 3958-3964, 1998.
PubMed
6) Burbach JP, et al : Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 81 : 1197-1267, 2001.
PubMed
7) Shoji M, et al : Effects of acute salt loading on vasopressin mRNA level in the rat brain. Am J Physiol 266 : R1591-1595, 1994.
 
8) Shoji M, et al : Effects of acute hypotensive hemorrhage on arginine vasopressin gene transcription in the rat brain. Neuroendocrinology 58 : 630-636, 1993.
PubMed
9) Shoji M, et al : Glucocorticoidal regulation of pituitary vasopressin content in rats. Hypertens Res 22 : 39-42, 1999.
PubMed
10) Iwasaki Y, et al : Positive and negative regulation of the rat vasopressin gene promoter. Endocrinology 138 : 5266-5274, 1997.
PubMed
11) Arima H, et al : Neuronal activity is required for the circadian rhythm of vasopressin gene transcription in the suprachiasmatic nucleus in vitro. Endocrinology 143 : 4165-4171, 2002.
PubMed
12) Yoshida M, et al : Gene therapy for central diabetes insipidus : effective antidiuresis by muscle-targeted gene transfer. Endocrinology 145 : 261-268, 2004.
PubMed
13) Skutella T, et al : Vasopressin antisense oligonucleotide induces temporary diabetes insipidus in rats. J Neuroendocrinol 6 : 121-125, 1994.
PubMed
14) Budisavljevic MN, et al : Hyponatremia associated with 3, 4-methylenedioxymethylamphetamine ("Ecstasy") abuse. Am J Med Sci 326 : 89-93, 2003.
PubMed
15) Korbonits M, et al : Hexarelin as a test of pituitary reserve in patients with pituitary disease. Clin Endocrinol (Oxf) 51 : 369-375, 1999.
PubMed
P.470 掲載の参考文献
1) Valtin H, et al : Familial hypothalamic diabetes insipidus in rats. Nature 196 : 1109-1110, 1962.
PubMed
2) Schmale H, Richter D : Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature 308 (5961) : 705-709, 1984.
PubMed
3) Guldenaar SE, Pickering BT : Mutant vasopressin precursor in the endoplasmic reticulum of the Brattleboro rat. Ultrastructural evidence from individual "vasopressin" cells localized with the light microscope by use of a new gold/silver method for immunostain enhancement. Cell Tissue Res 253 (3) : 671-676, 1988.
PubMed
4) Krisch B, et al : Immunocytochemical staining of supraoptic neurons from homozygous Brattleboro rats by use of antibodies against two domains of the mutated vasopressin precursor. Cell Tissue Res 244 (2) : 351-358, 1986.
PubMed
5) Williams AR, et al : Altered emotionality of the vasopressin-deficient Brattleboro rat. Peptides 6 (Suppl 1) : 69-76, 1985.
 
6) Uhl GR, et al : Vasopressin mRNA in situ hybridization : localization and regulation studied with oligonucleotide cDNA probes in normal and Brattleboro rat hypothalamus. Proc Natl Acad Sci USA 82 (16) : 5555-5559, 1985.
PubMed
7) Richards SJ, et al : Solitary magnocellular neurons in the homozygous Brattleboro rat have vasopressin and glycopeptide immunoreactivity. Neuroscience 16 : 617-623, 1985.
PubMed
8) Bankir L, et al : Selective V2 antagonism with SR121463A aggravates diabetes insipidus in Brattleboro rats, revealing significant endogenous V2 agonism in these rats. Possible role of oxytocin. Program and Abstracts, World Congress on Neurohypophyseal. Hormones : Abstract 159, 1997.
 
9) Bonner TI, Brownsterin MJ : Vasopressin, tissue-specific defects and the Brattleboro rat. Nature 310 (5972) : 17, 1984.
 
10) Grant FD, et al : Vasopressin-null mutation (knock-out) mice demonstrate role of vasopressin in regulatory of the hypothalamic-pituitary adrenal axis. OR48-5, The Endocrine Society, San Diego, 1999.
 
11) Habener JF, et al : Metallothionein-vasopressin fusion gene expression in transgenic mice. Nephrogenic diabetes insipidus and brain transcripts localized to magnocellular neurons. J Biol Chem 264 (31) : 18844-18852, 1989.
PubMed
12) Miller M, et al : Altered alertness of vasopressin-secreting transgenic mice. Peptides 16 (8) : 1329-1333, 1995.
PubMed
13) Nagasaki H, et al : Overexpression of vasopressin in the rat transgenic for the metallothionein-vasopressin fusion gene. J Endocrinol 173 (1) : 35-44, 2002.
PubMed
14) Yokoi H, et al : Adaptation to sustained high plasma vasopressin in water and electrolyte homeostasis in the rat transgenic for the metallothionein-vasopressin fusion gene. J Endocrinol 173 (1) : 23-33, 2002.
PubMed
15) Tachikawa K, et al : Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat. Am J Physiol Endocrinol Metab 285 (6) : E1161-1166, 2003.
PubMed
16) Grant FD, et al : Expression of the rat arginine vasopressin gene in transgenic mice. Mol Endocrinol 7 (5) : 659-667, 1993.
PubMed
17) Waller S, et al : Neurohypophyseal and fluid homeostasis in transgenic rats expressing a tagged rat vasopressin prepropeptide in hypothalamic neurons. Endocrinology 137 (11) : 5068-5077, 1996.
PubMed
18) Si-Hoe SL, et al : Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophyseal diabetes insipidus mutant vasopressin transgene. FASEB J 14 (12) : 1680-1684, 2000.
PubMed
19) Russell TA, et al : A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest 112 (11) : 1697-1706, 2003.
PubMed
P.476 掲載の参考文献
1) 木村時久ほか : 水電解質代謝の基礎. Mebio 5 (4) : 36-41, 1988,
 
2) Robertson GL, et al : Vasopressin. In : Methods in Radioimmunoassay of Peptide Hormones (ed by Yalow RS), p140-151, North-Holland Publishing Company, London, 1976.
 
3) Husain MK, et al : Radioimmunoassay of arginine vasopressin in human plasma. J Clin Endocrinol 37 : 616-625, 1973.
 
4) Skowsky WR, et al : Radioimmunoassay measurement of arginine vasopressin in serum : Development and apprecation. J Clin Endocrinol 38 : 278-287, 1974.
 
5) Morton JJ, et al : A radioimmunoassay for plasma arginine vasopressin in man and dog : application to physiological and pathological states. J Endocrinol 65 : 411-424, 1975.
 
6) Kimura T, et al : Radioimmunoassay of arginine vasopressin in human plasma and urine, a resin microcolumn method. Tohoku J Exp Med 131 : 37-46, 1980.
PubMed
7) 吉田尚ほか : AVP-RIAキットによる血漿アルギニンバゾプレッシンの測定法. ホルモンと臨床 35 : 127-131, 1987.
 
8) Chard T : An introduction to radioimmunoassay and related techniques. In : Laboratory Techniques in Biochemistly and Molecular Biology (ed by Work TS, Work E), p 301-328, North-Holland Publishing Company, Amsterdam, New York, Oxford, 1978.
 
9) 木村時久 : 輸液療法の実際. 図説病態内科講座 内分泌・代謝2 (高久史麿編), p30-41, メジカルビュー社, 1995.
 
10) 木村時久 : 下垂体後葉ホルモン. 実践臨床検査医学 (大久保昭行ほか編), p309-311, 文光堂, 1998.
 
11) 木村時久 : 尿崩症. 内科学 (上田英雄ほか編), p1358-1363, 朝倉書房, 1991.
 
P.483 掲載の参考文献
1) Nomura M, et al : Estrogen receptor-beta regulates transcript levels for oxytocin and arginine vasopressin in the hypothalamic paraventricular nucleus of male mice. Brain Res Mol Brain Res 109 : 84-94, 2002.
PubMed
2) Gionis D, et al : Hypothalamic-pituitary adrenal axis and interleukin-6 activity in children with head trauma and syndrome of inappropriate secretion of antidiuretic hormone. J pediatr Endocrinol Metab 16 : 49-54, 2003.
PubMed
3) Dhillo WS, et al : The hypothalamic melanocortin system stimulates the hypothalamo-pituitary-adrenal axis in vitro and in vivo in male rats. Neuroendocrinology 75 : 209-216, 2002.
PubMed
4) Wren AM, et al : Hypothalamic actions of neuromedin U. Endocrinology 143 : 4227-4234, 2002.
PubMed
5) Dhillo WS, et al : Paraventricular nucleus administration of calcitonin generelated peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology 144 : 1420-1425, 2003.
PubMed
6) Sugimura Y, et al : Centrally administered tuberoinfundibular peptide of 39 residues inhibits arginine vasopressin release in conscious rats. Endocrinology 144 : 2791-2796, 2003.
PubMed
7) Saito T, et al : Alteration in water channel AQP-2 by removal of AVP stimulation in collecting duct cells of dehydrated rats. Am J Physiol 272 : F183-191, 1997.
PubMed
8) Rai T, et al : Cloning of rat and mouse aquaporin-2 gene promoters and identification of a negative cis-regulatory element. Am J Physiol 273 : F264-273, 1997.
PubMed
9) Kanno K, et al : Urinary excretion of aqaporin-2 in patients with diabetes insipidus. N Engl J Med 332 : 1540-1545, 1995.
PubMed
10) Petersen RS, et al : Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. Kidney Int 63 : 1417-1425, 2003.
 
11) Funayama H, et al : Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 66 : 1387-1392, 2004.
PubMed
12) Nakamura T, et al : Decrease in urinary excretion of aquaporin-2 associated with impaired urinary concentrating ability in diabetic nephropathy. Nephron 92 : 445-448, 2002.
PubMed
13) Preston GM, et al : Appearance of water channels in Xenopus oocytes expressing red cell CHIP28 protein. Science 256 : 385-387, 1992.
PubMed
14) Fushimi K, et al : Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 361 : 549-552, 1993.
 
15) 桑原道雄 : 腎性尿崩症 (AQP2). 腎と透析 45 (臨時増刊号) : 409-413, 1998.
 
P.488 掲載の参考文献
1) Morel A, et al : Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 356 : 523-526, 1992.
PubMed
2) Okada K, et al : Mechanisms of vasopressin-induced increase in intracellular Na+ in vascular smooth muscle cells. Am J Physiol 261 : F1007-F1012, 1991.
 
3) Granot Y, et al : Direct evidence for tyrosine and threonine phosphorylation and activation of mitogen activated protein kinase by vasopressin in cultured rat vascular smooth muscle cells. J Biol Chem 268 : 9564-9569, 1993.
 
4) Ghosh PM, et al : Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol 280 : F972-F979, 2001.
 
5) Kusaka I, et al : The activation of phospholipase D participates in the mitogenic action of arginine vasopressin in cultured rat glomerular mesangial cells. Endocrinology 137 : 5421-5428, 1996.
PubMed
6) Fujita N, et al : Failure of cdc2 promoter activation and G2/M transition by ANG II and AVP in vascular smooth muscle cells. Am J Physiol 277 : H515-H523, 1999.
PubMed
7) Fujita N, et al : Differences in E2F subunit expression in quiescent and proliferating vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 283 : H204-212, 2002.
PubMed
8) Ishikawa S, et al : Low density lipoprotein enhances the cellular action of arginine vasopressin in rat glomerular mesangial cells in culture. J Clin Invest 93 : 2710-2717, 1994.
PubMed
9) Okada K, et al : Effect of inhibition of Na+, K+ -adenosine triphosphatase on vascular action of vasopressin. J Clin Invest 86 : 1241-1248, 1990.
 
10) Ishikawa S, et al : Simvastatin inhibits the cellular signalling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells. Endocrinology 136 : 1954-1961, 1995.
 
11) Higashiyama M, et al : Arginine vasopressin inhibits apoptosis of rat glomerular mesangial cells via V1a receptors. Life Sci 68 : 1485-1493, 2001.
PubMed
12) Wenzel V, et al : A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 350 : 105-113, 2004.
PubMed
13) Gheorghiade M, et al : Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291 : 1963-1971, 2004.
PubMed
14) Udelson JE, et al : Acute hemodynamic effects of conivaptan, a dual V1a and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 : 2417-2423, 2001.
PubMed
P.495 掲載の参考文献
1) Jurzak M, et al : Vasopressin and sensory circumventricular organs. "Advances in Brain Vasopressin". Prog Brain Res 119 : 221-245, 1998.
 
2) Ferguson AV, et al : Angiotensin II. A peptidergic neurotransmitter in central autonomic pathways. Prog Neurobiol 54 : 169-192, 1998.
PubMed
3) Latchford Kl, et al : ANG II-induced excitation of paraventricular nucleus magnocellular neurons : a role for glutamate interneurons. Am J Physiol Regul Integr Comp Physiol 286 : R894-R902, 2004.
 
4) Anthes N, et al : Heterogeneous actions of vasopressin on ANG II-sensitive neurons in the subfomical organ of rats. Am J physiol 273 : R2105-R2111, 1997.
 
5) Washburn DL, et al : Inhibition of subfornical organ neuronal potassium channels by vasopressin. Neuroscience 93 : 349-359, 1999.
PubMed
6) Yang Z, et al : Neuropeptides, amines and amino acids as mediators of the sympathetic effects of paraventricular nucleus activation in the rat. Exp Physiol 87 (6) : 663-674, 2002.
PubMed
7) Malpas SC, et al : Role of vasopressin in sympathetic response to paraventricular nucleus stimulation in anesthetized rats. Am J physiol 266 : R228-R236, 1994.
PubMed
8) Hermes MLHJ, et al : Vasopressin increases GABAergic inhibition of rat hypothalamic paraventricular nucleus neurons in vitro. J Neurophysiol 83 : 705-711, 2000.
 
9) Kolaj M, et al : Vasopressin-induced currents in rat neonatal spinal lateral horn neurons are G-protein mediated and involve two conductances. J Neurophysiol 80 : 1900-1910, 1998.
 
10) Kumagai H, et al : Involvement of renal sympathetic nerve in pathogenesis of hypertension. Kidney and Blood Pressure Regulation. Contrib Nephrol 143 : 32-45, 2004.
 
11) Yang Z, et al : The influence of vasopressin on tonic activity of cardiovascular neurons in the ventrolateral medulla of the hypertensive rat. Auton Neurosci 104 : 83-87, 2003.
PubMed
12) Lowes VL, et al : Vasopressin actions on area postrema neurons in vitro. Am J physiol 269 : R463-R468, 1995.
PubMed
13) Kumagai H, et al : Baroreflex control of renal sympathetic nerve activity is potentiated in early phase of two-kidney, one clip Goldblatt hypertension in conscious rabbits. Circ Res 67 : 1309-1322, 1990.
PubMed
14) Kumagai H, et al : Central and peripheral vasopressin interact differently with sympathetic nervous system and renin-angiotensin system in renal hypertensive rabbits. Circ Res 72 : 1255-1265, 1993.
PubMed
15) Brooks VL, et al : Hormonal-sympathetic interactions in long-term regulation of arterial pressure : a hypothesis. Am J Physiol 268 : R1343-R1358, 1995.
PubMed
P.501 掲載の参考文献
1) Kumada M, et al : Arterial baroreceptor reflex : its central and peripheral neural mechanisms. Prog Neurobiol 35 : 331-361, 1990.
PubMed
2) 桑木共之 : 圧受容器反射機構と血管運動中枢. 日本臨牀 58 (増刊 : 高血圧 (上)) : 25-29, 2000.
 
3) Sved AF, Gordon FJ : Amino acids as central neurotransmitters in the baroreceptor reflex pathway. News Physiol Sci 9 : 243-246, 1994.
 
4) Sato T, et al : New analytic framework for understanding sympathetic baroreflex control of arterial pressure. Am J Physiol 276 : H2251-H2261, 1999.
PubMed
5) Nosaka S : Modhications of arterial baroreflexes : obligatory roles in cardiovascular regulation in stress and poststress recovery. Jpn J physiol 46 : 271-288, 1996.
PubMed
6) Cowley AW Jr, et al : Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 34 : 505-514, 1974.
PubMed
7) Bishop VS, et al : Hormonal modulation of baroreceptor reflexes. In : Baroreceptor Reflexes (ed by Persson PB, Kirchheim HR), p 226-236, Springer-Verlag, Berlin, 1991.
 
8) Unger T, et al : Differential modulation of the baroreceptor reflex by brain and plasma vasopressin. Hypertension 8 : II157-II162, 1986.
PubMed
9) Luk J, et al : Role of V1 receptors in the action of vasopressin on the baroreflex control of the heart. Am J Physiol 265 : R524-R529, 1993.
PubMed
10) Scheuer DA, Bishop VS : Effect of vasopressin on baroreflex control of lumbar sympathetic nerve activity and hindquarter resistance. Am J Physiol 270 : H1963-H1971, 1996.
PubMed
11) Hasser EM, et al : Area postrema and sympathetic nervous system effects of vasopressin and angiotensin II. Clin Exp Pharmacol Physiol 27 : 432-436, 2000.
PubMed
12) Xue B, et al : Role of the area postrema in angiotensin II modulation of baroreflex control of heart rate in conscious mice. Am J Physiol 284 : H1003-H1007, 2003.
 
13) Joy MD, Lowe RD : Evidence that the area postrema mediates the central cardiovascular response to angiotensin II. Nature 228 : 1303-1304, 1970.
PubMed
14) Guo GB, Abboud FM : Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol 246 : H80-H89, 1984.
PubMed
15) Nasa Y, et al : Abnormal baroreceptor reflex in vasopressin V1a-receptor-deficient mice. J Pharmacol Sci 94 : 222, 2004.
 
P.505 掲載の参考文献
1) Baylis PH, Cheetham T : Diabetes insipidus. Arch Dis Child 79 : 84-89, 1998.
PubMed
2) Irwin S, et al : The management of diabetes insipidus in adults. Arch InternMed 157 : 1293-1301, 1997.
 
3) Bichet DG : Nephrogenic and central diabetes insipidus. In : Diseases of the Kidney and Urinary Tract (ed by Schrier RW), p 2549-2576, Lippincott Williams & Wilkins, Philadelphia, 2001.
 
4) 石川三衛 : バソプレシン受容体不活性型変異による腎性尿崩症. 日本臨牀 60 : 350-355, 2002.
Medical*Online
5) 石川三衛 : Fishberg試験, 抗利尿ホルモン負荷試験. 日本臨牀 45 (増刊 : 体液) : 1115-1121, 1987.
 
6) Fujisawa I : Magnetic resonance imaging of the hypothalamic-neurohypophyseal system. J Neuroendocrinol 16 : 297-302, 2004.
PubMed
P.509 掲載の参考文献
1) Dreyfus D, et al : Acute infectious pneumonia is accompanied by a latent vasopressin-dependent impairment of renal water excretion. Am Rev Respir Dis 138 : 583-589, 1988.
 
2) 大野良之 : 厚生科学研究費補助金特定疾患対策事業 特定疾患治療対策研究事業未対策疾患の疫学像を把握するための調査研究班, 平成11年度研究事業業績集, p3-15, 2000.
 
3) Miller M, et al : Hyponatremia in a nursing home population. J Am Geriat Soc 43 : 1410-1413, 1995.
 
4) 加藤譲 : 厚生省特定疾患間脳下垂体機能障害調査研究班, 平成10年度総括研究事業報告書, p41-42, 1996.
 
P.513 掲載の参考文献
1) Hall JE, et al : Renal escape from vasopressin : role of pressure diuresis. Am J physiol 250 (5 Pt 2) : F907-916, 1986.
 
2) Cowley AW Jr, et al : Long-term influence of vasopressin on the control of arterial blood pressure independent of volume changes. J Hypertens Suppl 2 (3) : S337-339, 1984.
PubMed
3) Szentivanyi M Jr, et al : Nitric oxide in the renal medulla protects from vasopressin-induced hypertension. Hypertension 35 (3) : 740-745, 2000.
PubMed
4) Park F, et al : Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla. Hypertension 32 (5) : 896-901, 1998.
PubMed
5) Wu F, et al : Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney. Am J physiol 276 (6 Pt 2) : F874-881, 1999.
 
6) Mori T, et al : Vasopressin increases intracellular NO concentration via Ca2+ signaling in inner medullary collecting duct. Hypertension 39 (2 Pt 2) : 465-469, 2002.
 
7) Yuan B, Cowley AW Jr : Evidence that reduced renal medullary nitric oxide synthase activity of dahl srats enables small elevations of arginine vasopressin to produce sustained hypertension. Hypertension 37 (2 Part 2) : 524-528, 2001.
 
8) Vagnes O, et al : Upregulation of V1 receptors in renal resistance vessels of rats developing genetic hypertension. Am J Physiol Renal Physiol 278 (6) : F940-948, 2000.
PubMed
9) 森建文 : フリーラジカルによる腎髄質血流調節と高血圧-腎髄質尿細管血管クロストークを中心に-. 血管 26 (3) : 115-121, 2003.
 
10) Del Bo A : Vasopressin and human hypertension. Cell Mol Neurobiol 23 : 617-624, 2003.
PubMed
11) Bussien JP, et al : Blockade of the vascular effect of vasopressin in patients With mild essential hypertension. Arch Int Pharmacodyn 282 : 130-139, 1986.
PubMed
12) Kawano Y, et al : The role of vasopressin in essential hypertension : plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes. Am J Hypertens 10 : 1240-1244, 1997.
PubMed
13) 木村時久 : Vasopressin antagonistの臨床応用. Annual Review 内分泌・代謝 (岡博ほか編), p45-50, 中外医学社, 1996.
 
P.519 掲載の参考文献
1) Schrier RW, Abraham WT : Hormones and hemodynamics in heart failure. N Engl J Med 341 : 577-585, 1999.
PubMed
2) Xu YJ, Gopalakrishnan V : Vasopressin increases cytosolic free [Ca2+] in the neonatal rat cardiomyocyte. Evidence for Vl subtype receptors. Circ Res 69 : 239-245, 1991.
 
3) Yamane Y : Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 32 : 745-759, 1968.
PubMed
4) Francis GS, et al : Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82 : 1724-1729, 1990.
PubMed
5) Price JF, et al : Arginine vasopressin levels are elevated and correlate with functional status in infants and children with congestive heart failure. Circulation 109 : 2550-2553, 2004.
PubMed
6) Goldsmith SR, et al : Increased plasma arginine vasopressin in patients with congestive heart failure. J Am Coll Cardiol 1 : 1385-1390, 1983.
PubMed
7) Creager MA, et al : Contribution of vasopressin to vasoconstriction in patients with congestive heart failure : comparison with the renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 7 : 758-765, 1986.
PubMed
8) Udelson JE, et al : Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 : 2417-2423, 2001.
PubMed
9) Gheorghiade M, et al : Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. JAMA 291 : 1963-1971, 2004.
PubMed
P.524 掲載の参考文献
1) Burbach JP, et al : Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 81 : 1197-1267, 2001.
PubMed
2) Christensen JH, et al : Six novel mutations in the arginine vasopressin gene in 15 kindreds with autosomal dominant familial neurohypophyseal diabetes insipidus give further insight into the pathogenesis. Eur J Hum Genet 12 : 44-51, 2004.
PubMed
3) Willcutts MD, et al : Autosomal recessive familial neurohypophyseal diabetes insipidus with continued secretion of mutant weakly active vasopressin. Hum Mol Genet 8 : 1303-1307, 1999.
PubMed
4) Rittig S, et al : Autosomal dominant neurohypophyseal diabetes insipidus due to substitution of histidine for tyrosine (2) in the vasopressin moiety of the hormone precursor. J Clin Endocrinol Metab 87 : 3351-3355, 2002.
PubMed
5) Zheng C, et al : The behavior of the active site salt bridge of bovine neurophysins as monitored by 15N NMR spectroscopy and chemical substitution. Relationship to biochemical properties. Biochemistry 35 : 11763-11772, 1996.
PubMed
6) Nijenhuis M, et al : Mutations in the vasopressin prohormone involved in diabetes insipidus impair endoplasmic reticulum export but not sorting. J Biol Chem 274 : 21200-21208, 1999.
 
7) Russell TA, et al : A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons. J Clin Invest 112 : 1697-1706, 2003.
PubMed
8) Evans DA, et al : Frameshift mutations at two hotspots in vasopressin transcripts in post-mitotic neurons. Proc Natl Acad Sci USA 91 : 6059-6063, 1994.
PubMed
9) Ideno J, et al : Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in Brattleboro rats. Mol Ther 8 : 895-902, 2003.
PubMed
10) Yoshida M, et al : Gene therapy for central diabetes insipidus : effective antidiuresis by muscle-targeted gene transfer. Endocrinology 145 : 261-268, 2004.
PubMed
11) Knoers NV, Deen PM : Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr Nephrol 16 : 1146-1152, 2001.
PubMed
12) Kinoshita K, et al : A novel deletion mutation in the arginine vasopressin receptor 2 gene and skewed X chromosome inactivation in a female patient with congenital nephrogenic diabetes insipidus. J Endocrinol Invest 27 : 167-170, 2004.
 
13) Bernier V, et al : Functional rescue of the constitutively internalized V2 Vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 18 : 2074-2084, 2004.
PubMed
14) Preston GM, et al : Mutations in aquaporin-1 in phenotypically normal humans without functional CHIP water channels. Science 265 : 1585-1587, 1994.
PubMed
15) Roudier N, et al : AQP3 deficiency in humans and the molecular basis of a novel blood group system, GIL. J Biol Chem 277 : 45854-45859, 2002.
 
P.528 掲載の参考文献
1) Lee CR, et al : Vasopressin : a new target for the treatment of heart failure. Am Heart J 146 (1) : 9-18, 2003.
PubMed
2) Sawyer WH, Manning M : The use of antagonists of vasopressin in studies of its physiological functions. Fed Proc 44 (1 Pt 1) : 78-80, 1985.
 
3) Yamamura Y, et al : OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 252 (5005) : 572-574, 1991.
PubMed
4) Yamamura Y, et al : Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105 (4) : 787-791, 1992.
PubMed
5) Naitoh M, et al : Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol 267 (6 Pt 2) : H2245-2254, 1994.
 
6) Yatsu T, et al : Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 376 (3) : 239-246, 1999.
PubMed
7) Udelson JE, et al : Acute hemodynamic effects of conivaptan, a dual V (1A) and V (2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 104 (20) : 2417-2423, 2001.
PubMed
8) Bardoux P, et al : Diabetes-induced albuminuria : role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 18 (9) : 1755-1763, 2003.
PubMed
9) Kurihara I, et al : Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Nephron 73 (4) : 629-636, 1996.
PubMed
10) Fujisawa G, et al : Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 44 (1) : 19-23, 1993.
 
11) Saito T, et al : Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82 (4) : 1054-1057, 1997.
PubMed
12) Decaux G : Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 110 (7) : 582-584, 2001.
PubMed
13) Wong F, et al : A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia : a multicenter, randomized, placebo-controlled trial. Hepatology 37 (1) : 182-191, 2003.
 
14) Gattone VH 2nd, et al : Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9 (10) : 1323-1326, 2003.
PubMed
15) Griebel G, et al : Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99 (9) : 6370-6375, 2002.
PubMed

XI 特論 - カテコールアミン -

P.536 掲載の参考文献
1) 荻原俊男 (日本語版監), Nicolas Postel-Vinay (ed) : 高血圧の世紀, 先端医学社, 1997.
 
2) von Euler US : Historical perspective : growth and impact of the concept of chemical neurotransmission. In : Chemical Neurotransmission-75 Years (ed by Stjarne L, et al), p 3-12, Academic Press Ltd, London, 1981.
 
3) 増山善明 (班長) : 厚生省循環器病研究委託費による「高血圧における神経機構に関する研究」報告書, 1984.
 
4) Hjemdahl P : Catecholamine measurements by high-performance liquid chromatography. Am J Physiol 247 (1 Pt 1) : E13-20, 1984.
 
5) Yoshizumi M, et al : Physiological significance of plasma sulfoconjugated dopamine : experimental and clinical studies. Hypertens Res 18 (Suppl 1) : s101-106, 1995.
 
6) Ueyama T, et al : Release of nerve growth factor from cultured aortic smooth-muscle cells. Blood Vessels 28 : 532-536, 1991.
PubMed
7) Ueyama T, et al : New role of nerve growth factor-an inhibitory neuromodulator of adrenergic transmission. Brain Res 559 : 293-296, 1991.
PubMed
8) Ueyama T, et al : Increased level of nerve growth factor in spontaneously hypertensive rats. J Hypertens 10 : 215-219, 1992.
PubMed
9) Ueyama T, et al : Reduction of inhibitory effect of adrenergic transmission by nerve growth factor in the mesenteric vasculatures of spontaneously hypertensive rats. Genetic Hypertension 218 : 89-91, 1992.
 
10) Goldstein DA, et al : Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest 81 (1) : 213-220, 1988.
 
11) Mizukoshi M, et al : Plasma norepinephrine and its deaminated metabolites in essential hypertension and pheochromocytoma. Jpn Circ J 49 : 1035, 1985.
PubMed
P.541 掲載の参考文献
1) 名和田新ほか : 厚生省特定疾患, 内分泌系疾患, 調査研究班「副腎ホルモン産生異常症」調査分科会平成10年度研究報告書.
 
2) 宮地幸隆ほか : 厚生省特定疾患内分泌系疾患調査研究班「副腎ホルモン産生異常症」調査分科会平成12年度研究報告書.
 
3) 高橋伯夫 : 偶発腫瘍として発見される褐色細胞腫. ホルモンと臨床 52 : 451-459, 2004.
 
4) Isobe K, et al : Pathogenesis of pheochromocytoma. In : Frontiers in Hormone Research, Pheochromocytoma. Pathophysiology and Clinical Management (ed by Lehnert H), p26, Karger, Basel, 2004.
 
5) Neumann HP, et al : Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346 : 1459-1466, 2002.
PubMed
6) Kaelin WG Jr : Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 : 673-682, 2002.
PubMed
7) Takaya K, et al : Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J Mol Med 74 : 617-621, 1996.
PubMed
8) Isobe K, et al : Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas. Eur J Endocrinol 138 : 383-387, 1998.
PubMed
9) Isobe K, et al : Enhanced expression of mRNA coding for the adrenaline-secreting pheochromocytomas. J Urol 163 : 357 -362, 2000.
 
10) Isobe K, et al : Expression of mRNA for PACAP and its receptors in intra-and extra-adrenal human pheochromocytomas and their relationship to catecholamine synthesis. Regul Pep 110 : 213-217, 2003.
 
11) Yasunari K, et al : A dopamine-secreting pheochromocytoma. J Cardiovasc Pharmacol 36 (Suppl 2) : S75-77, 2000.
 
12) Wiesner TD, et al : Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. J Clin Endocrinol Metab 88 : 3632-3636, 2003.
PubMed
13) Fasshauer M, et al : Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 507 : 142-146, 2001.
PubMed
14) Isobe K, et al : Expression of the human telomerase reverse transcriptase in pheochromocytoma and neuroblastoma tissues. Endocr J 51 : 47-50, 2004.
PubMed
P.546 掲載の参考文献
1) Hano T, Rho J : Norepinephrine overflow in perfused mesenteric arteries of spontaneously hypertensive rats. Hypertension 14 : 44, 1989.
PubMed
2) Hano T, et al : Norepinephrine overflow and re-uptake in perfused mesenteric arteries of Dahl salt-sensitive and salt-resistant rats. J Hypertens 7 : 43, 1989.
PubMed
3) Nishio I, et al : Relationship between the sympathetic nervous system and sodium potassium adenosine triphosphatase inhibitor in salt-sensitive patients with essential hypertension. J Hypertens Suppl 6 (4) : s216-218, 1988.
PubMed
4) Goldstein DS : Plasma catecholamines in essential hypertension. An analytical review. Hypertension 5 : 86, 1983.
PubMed
5) Masuyama Y : The neuronal and vascular factors in the pathogenesis of hypertension. 高血圧 11 : 133, 1989.
 
6) Mizukoshi M, et al : Plasma norepinephrine and its deaminated metabolites in essential hypertension and pheochromocytoma. Jpn Circ J 49 : 1035, 1985.
PubMed
7) Esler M, et al : Norepinephrine kinetics in essential hypertension. Defective neuronalπ of norepinephrine in some patients. Hypertension 3 : 149, 1981.
 
8) Goldstein D, et al : Plasma L- [3H] norepinephrine, D- [14H] norepinephrine and D, L- [3H] isoproterenol kinetics in essential hypertension. J Clin Invest 72 : 1748, 1983.
 
9) Shima H, et al : Relation of sodium-potassium adenosine triphosphatase inhibitor to sympathetic nervous system during salt-loading in essential hypertension. Jpn J Med 28 : 165, 1989.
PubMed
10) 羽野卓三 : 高血圧における神経終末でのNE再摂取に関する研究-体液性因子による影響および神経興奮時の変化について-, 文部省科学研究費補助金研究成果報告書, 1992.
 
11) Takatsu H, et al : Cardiac sympathetic denervation from the early stage of Parkinson'sdisease : clinical and experimental studies with radiolabeled MIBG. J Nucl Med 41 (1) : 71-77, 2000.
 
12) Boh-Oka S, et al : Neurally mediated syncope and cardiac beta-adrenergic receptor function. J Cardiovasc Pharmacol 38 (Suppl 1) : S75-79, 2001.
 
P.551 掲載の参考文献
1) Sibley DR, Monsma FJ Jr : Molecular biology of dopamine receptors. Trends Pharmacol Sci 13 : 61-69, 1992.
PubMed
2) Jose PA, et al : Role of dopamine receptors in the kidney in the regulation of blood pressure. Current Opin Nephrol Hypertens 11 : 87-92, 2002.
 
3) Sanada H, et al : Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension. Hypertension 33 : 1036-1042, 1999.
PubMed
4) Felder RA, et al : Gprotein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA 99 : 3872-3877, 2002.
 
5) Kirstein SL, et al : Autonomic nervous system pharmacogenomics : a progress report. Pharmacol Rev 56 : 31-52, 2004.
PubMed
6) Milano CA, et al : Myocardial expression of a constitutively active alpha IB-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91 : 10109-10113, 1994.
 
7) MacMillan LB, et al : Central hypotensive effects of the alpha2a-Adrenergic receptor subtype. Science 273 : 801-803, 1996.
PubMed
8) Link RE, et al : Cardiovascular regulation in mice lacking alpha2-Adrenergic receptor subtypes b and c. Science 273 : 803-805, 1996.
 
9) Ehmke H, et al : Neurogenic control of pressure natriuresis in conscious dogs. Am J Physiol 259 : F466-473, 1990.
PubMed
10) Sanchez A, et al : Dietary sodium regulation of blood pressure and renal alpha 1-and alpha 2-receptors in WKY and SH rats. Life Sci 29 : 2795-2802, 1981.
PubMed
11) Lockette W, et al : Alpha 2-adrenergic receptor gene polymorphism and hypertension in blacks. Am J Hypertens 8 : 390-394, 1995.
PubMed
12) Kotanko P, et al : Essential hypertension in African Caribbeans associates with a variant of the beta2-adrenoceptor. Hypertension 30 : 773-776, 1997.
PubMed
13) Lau J, et al : Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327 : 248-254, 1992.
PubMed
14) Packer M, et al : The U. S. Carvedilol Heart Failure Study Group : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 : 1349-1355, 1996.
 
15) Murphy MB, et al : Drug Therapy : Fenoldopam-a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345 : 1548-1557, 2001.
PubMed
P.558 掲載の参考文献
1) Cohn JN : Current therapy of the failing heart. Circulation 78 : 1099-1107, 1988.
PubMed
2) Cohn JN, et al : Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 : 819-823, 1984.
PubMed
3) Inglese J, et al : Structure and mechanism of the G-protein-coupled receptor kinases. J Biol Chem 268 : 23738-23753, 1993.
 
4) Minamisawa S, et al : Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is critical calcium cycling defect in dilated cardiomyopathy. Cell 99 : 313-322, 1999.
PubMed
5) Marx SO, et al : PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor) : defective regulation in failing hearts. Cell 101 : 365-376, 2000.
PubMed
6) Reiken S, et al : β-Adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104 : 2843-2848, 2001.
 
7) Doi M, et al : Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 105 : 1374-1379, 2002.
PubMed
8) Waagstein F, et al : Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37 : 1022-1036, 1975.
PubMed
9) Waagstein F, et al : for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group : Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342 : 1441-1446, 1993.
 
10) CIBIS-II Investigators and Committee : The cardiac insufficiency bisoprolol study II (CIBIS-II) : A randomized trial. Lancet 353 : 9-13, 1999.
 
11) MERIT-HF Study Group : Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomized Investigation Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 : 2001-2007, 1999.
 
12) Packer M, et al : Effect of carvedilol on surVival in severe chronic heart failure. N Engl J Med 344 : 1651-1658, 2001.
PubMed
13) Ishise H, et al : Time course of sympatho-vagal balance and left ventricular dysfunction in conscious dogs with heart failure. J Appl Physiol 84 : 1234-1241, 1998.
 
14) Malliani A, Montano N : Emerging excitatory role of cardiovascular sympathetic afferents in pathophysiological conditions. Hypertension 39 : 63-68, 2002.
PubMed
15) The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure : Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 : 1429-1435, 1987.
 
P.564 掲載の参考文献
1) Simpson P, et al : Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 51 (6) : 787-801, 1982.
PubMed
2) Dahlof B : Effect of angiotensin II blockade on cardiac hypertrophy and remodelling : a review. J Hum Hypertens 9 (Suppl 5) : S37-44, 1995.
 
3) Ito H, et al : Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92 (1) : 398-403, 1993.
PubMed
4) Clerk A, et al : Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J Biol Chem 269 (52) : 32848-32857, 1994.
PubMed
5) Glennon PE, et al : Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res 78 (6) : 954-961, 1996.
PubMed
6) Nemoto S, et al : Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy. Mol Cell Biol 18 (6) : 3518-3526, 1998.
PubMed
7) Wang Y, et al : Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273 (4) : 2161-2168, 1998.
PubMed
8) Ueyama T, et al : Activated RhoA stimulates c-fos gene expression in myocardial cells. Circ Res 81 (5) : 672-678, 1997.
PubMed
9) Parker TG, et al : Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 85 (2) : 507-514, 1990.
PubMed
10) Ito H, et al : Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87 (5) : 1715-1721, 1993.
PubMed
11) Pennica D, et al : Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA 92 (4) : 1142-1146, 1995.
PubMed
12) Hirota H, et al : Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92 (11) : 4862-4866, 1995.
PubMed
13) Hirota H, et al : Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97 (2) : 189-198, 1999.
PubMed
14) Molkentin JD, et al : A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (2) : 215-228, 1998.
PubMed
15) Rockman HA, et al : Seven-transmembrane-spanning receptors and heart function. Nature 415 : 206-212, 2002.
PubMed
16) Ishikawa Y, Homcy CJ : The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res 80 : 297-304, 1997.
PubMed
17) Ishikawa Y : Regulation of cAMP signaling by phosphorylation. Adv Second Messenger Phosphoprotein Res 32 : 99-120, 1998.
PubMed
18) Zou Y, et al : Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J Biol Chem 274 : 9760-9770, 1999.
PubMed
19) Daaka Y : Switching of the coupling of the β-adrenergic receptor to different G proteins by protein kinase A. Nature 390 : 88-91, 1997.
 
20) Razani B, et al : Regulation of cAMP-mediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J Biol Chem 274 : 26353-26360, 1999.
PubMed
P.571 掲載の参考文献
1) 廣岡良隆 : 動脈圧受容体反射機能検査法. 臨床医のための循環器自律神経機能検査法 (今泉勉編), p13-26, メディカルレビュー社, 1997.
 
2) 後藤英司, 住田晋一 : 概論 : 神経系による血圧調節. 日本臨牀 58 (増刊 : 高血圧 (上)) : 19-24, 2000.
 
3) Gavras I, et al : The 2-adrenergic receptors in hypertension and heart failure : experimental and clinical studies. J Hypertens 19 : 2115-2124, 2001.
 
4) Hashimoto J, et al : Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension : evaluation using home-based pressure measurements. J Hypertens 21 : 805-811, 2003.
PubMed
5) Bousquet P, et al : Does it make sense to develop new centrally acting cardiovascular drugs? Clin Exp Pharmacol Physiol 28 : 976-978, 2001.
PubMed
6) Head GA, Burke SL : Sympathetic responses to stress and rilmenidine in 2K1C rabbits : evidence of enhanced nonvascular effector mechanism. Hypertension 43 : 636-642, 2004.
PubMed
7) Cohn JN, et al : Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 : 659-667, 2003.
PubMed
8) Swedberg K, et al : Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepnephrine in patients with chronic heart failure. Circulation 105 : 1797-1803, 2002.
 
9) Floras JS : The "unsympathetic" nervous system of heart failure. Circulation 105 : 1753-1755, 2002.
PubMed
10) Hayar A, Guyenet PG : Prototypical imidazoline-1 receptor ligand moxonidine activates alpha2-adrenoceptors in bulbospinal neurons of the RVL. J Neurophysiol 83 : 766-776, 2000.
PubMed
11) Brede M, et al : Feedback inhibition of catecholamine release by two different α2-adrenoceptor subtypes prevents progression of heart failure. Circulation 106 : 2491-2496, 2002.
 
12) Cohn JN : Sympathetic nervous system in heart failure. Circulation 106 : 2417-2418, 2002.
PubMed
13) Dobrucki LW, et al : Central hypotensive action of clonidine requires nitric oxide. Circulation 104 : 884-1886, 2001.
 
14) Sy GY, et al : Nitric oxide discriminates the sites and mechanisms of action of centrally acting antihypertensive drugs in rabbits. Neuropharmacology 43 : 1330-1338, 2002.
PubMed
15) Hirooka Y, et al : Effect of overproduction of nitric oxide in the brain stem on the cardiovascular responses in conscious rats. J Cardiovasc Pharmacol 41 : S119-S126, 2003.
PubMed
16) Li G, et al : Agmatine : an endogenous clonidine-displacing substance in the brain. Science 263 : 966-969, 1994.
PubMed
17) Waagstein F, et al : Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342 : 1441-1446, 1993.
PubMed
18) Packer M, et al : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 : 1349-1355, 1996.
PubMed
19) Esler M, et al : Sympathetic nerve activity and neurotransmitter release in humans : transduction from pathophysiology into clinical practice. Acta Physiol Scand 177 : 275-284, 2003.
 
20) Bristow MR, et al : Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-blocker evaluation of survival trial. Circulation 110 : 1437-1442, 2004.
 
21) 小澤利男, 西永正典 : 交感神経抑制薬. 日本臨牀 58 (増刊 : 高血圧 (下)) : 118-122, 2000.
 
22) ALLHAT Collaborative Research Group : Major cardiovascular events in hypertensive patients randomized to doxazosin vs chrorthalizone : the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283 : 1967-1975, 2000.
 
23) Igawa A, et al : Long-term treatment with low-dose, but not high-dose, guanethidine improves ventricular function and survival of rats with heart failure after myocardial infarction. J Am Coll Cardiol 42 : 541-548, 2003.
 
24) Aggarwal A, et al : Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension 41 : 553-557, 2003.
PubMed

XII 特論 - エストロゲン -

P.582 掲載の参考文献
1) Kannel WB, et al : Menopause and risk of cardiovascular disease : the Framingham Study. Ann Intern Med 85 : 447-452, 1976.
PubMed
2) Kodama K, et al : Trend of coronary heart disease and its relationship to risk factors in a Japanese population : a 26-year follow-up, Hiroshima/Nagasaki study. Jpn Circ J 54 : 414-421, 1990.
 
3) Akishita M, et al : Effects of estrogen on atherosclerosis formation and serum nitrite/nitrate concentrations in cholesterol-fed ovariectomized rabbits. J Atheroscler Thromb 3 : 114-119, 1996.
PubMed
4) Akishita M, et al : Estrogen inhibits cuff-induced intimal thickening of rat femoral artery : Effects on migration and proliferation of vascular smooth muscle cells. Atherosclerosis 130 : 1-10, 1997.
PubMed
5) Han S-Z, et al : 17β-estradiol inhibits Ca2+ influx and Ca2+ release induced by thromboxane A2 in porcine coronary artery. Circulation 91 : 2619-2626, 1995.
 
6) Akishita M, et al : Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Atherosclerosis 125 : 27-38, 1996.
 
7) Hashimoto M, et al : Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92 : 3431-3435, 1995.
PubMed
8) Kawano H, et al : Menstrual cycle variation of endothelium-dependent vasodilation of the brachial artery. Proc Assoc Am Physicians 108 : 473-480, 1996.
PubMed
9) Hashimoto M, et al : Effects of long-term and reduced dose homlone replacement therapy on endothelial function and intima-media thickness in postmenopausal women. Menopause 9 : 58-64, 2002.
PubMed
10) Chambliss KL, Shaul PW : Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 23 : 665-686, 2002.
PubMed
11) Simoncini T, et al : Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 : 538-541, 2000.
PubMed
12) Simoncini T, et al : Molecular basis of cell membrane estrogen receptor interaction With phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 23 : 198-203, 2003.
PubMed
13) Goetz RM, et al : Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 96 : 2788-2793, 1999.
PubMed
14) Sudoh N, et al : Estrogen prevents oxidative stress-induced endothelial cell apoptosis in rats. Circulation 103 : 724-729, 2001.
PubMed
15) Strehlow K, et al : Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 : 3059-3065, 2003.
PubMed
16) Karas RH, et al : Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res 89 : 534-539, 2001.
PubMed
17) Pare G, et al : Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90 : 1087-1092, 2002.
PubMed
18) Makela S, et al : Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors alpha and beta. Proc Natl Acad Sci USA 96 : 7077-7082, 1999.
PubMed
19) Watanabe T, et al : Estrogen receptor beta mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation. Cardiovasc Res 59 : 734-744, 2003.
PubMed
20) Mercuro G, et al : Estradiol-17β reduces blood pressure and restores the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 11 : 909-913, 1998.
 
21) Brussaard HE, et al : Short-term oestrogen replacement therapy improves insuhn resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 40 : 843-849, 1997.
PubMed
22) Tchernof A, et al : Menopause, central body fatness, and insulin resistance : effects of hormone-replacement therapy. Coron Artery Dis 9 : 503-511, 1998.
PubMed
23) Koh KK, et al : Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 99 : 354-360, 1999.
PubMed
24) Hulley S, et al : Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 : 605-613, 1998.
PubMed
25) Writing Group for the Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288 : 321-333, 2002.
 
26) Cushman M, et al : Effect of postmenopausal hormones on inflammation-sensitive proteins : the Postmenopausal Estrogen Progestin Interventions (PEPI) study. Circulation 100 : 717-722, 1999.
PubMed
27) Cummings SR, et al : The effect of raloxifene on risk of breast cancer in postmenopausal women : results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281 : 2189-2197, 1999.
PubMed
28) Fisher B, et al : Tamoxifen for prevention of breast cancer : report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 : 1371-1388, 1998.
PubMed
29) Brzozowski AM, et al : Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 : 753-758, 1997.
PubMed
30) Pike AC, et al : Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18 : 4608-4618, 1999.
 
31) Zhang X, et al : A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 12 : 513-524, 1998.
 
32) Shang Y, Brown M : Molecular determinants for the tissue specificity of SERMs. Science 295 : 2465-2468, 2002.
PubMed
33) Simoncini T, et al : Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105 : 1368-1373, 2002.
PubMed
34) Mori-Abe A, et al : Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 178 : 417-426, 2003.
 
35) Takahashi K, et al : Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 178 : 19-29, 2003.
 
P.589 掲載の参考文献
1) Marin P, et al : Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension : a 3-year follow-up study. J Hum Hypertens 18 (1) : 25-31, 2004.
PubMed
2) Stella P, et al : Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 43 (2) : 265-270, 2004.
PubMed
3) Ruppert V, Maisch B : Genetics of human hypertension (Review). Herz 28 (8) : 655-662, 2003,
PubMed
4) Schuit SC, et al : Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 291 (24) : 2969-2977, 2004.
PubMed
5) Gardner CD, et al : Population frequency distributions of HDL, HDL (2), and HDL (3) cholesterol and apolipoproteins A-I and B in healthy men and women and associations with age, gender, hormonal status, and sex hormone use. the Stanford Five City Project. Prev Med 31 : 335-345, 2000.
 
6) Urabe M, et al : Effect of estrogen replacement therapy on hepatic triglyceride lipase, lipoprotein lipase and lipids including apolipoprotein E in climacteric and elderly women. Endocr J 43 : 737-742, 1996.
PubMed
7) Gallagher PE, et al : Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33 : 323-328, 1999.
PubMed
8) Proudler AJ, et al : Hormone replacement therapy and serum angiotensin-convening-enzyme activity in postmenopausal women. Lancet 346 : 89-90, 1995.
 
9) Nickenig G, et al : Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97 : 2197-2201, 1998.
PubMed
10) 山内康弘 : エストロゲンのACE活性調節に関する機序. 埼玉医科大学雑誌 29 (2) : 149-159, 2002.
 
11) Wenger NK, et al : Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) tria1. Am J Cardiol 90 (11) : 1204-1210, 2002.
 
12) Kincaid-Smith P : Hypothesis : obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis'. J Hypertens 22 (6) : 1051-1055, 2004.
 
13) Hollenberg NK : Aldosterone in the development and progression of renal injury. Kidney Int 66 (1) : 1-9, 2004.
PubMed
14) Safar ME, Smulyan H : Hypertension in women (Review). Am J Hypertens 17 (1) : 82-87, 2004.
PubMed
P.596 掲載の参考文献
1) Yasue H, Kugiyama K : Coronary spasm : clinical features and pathogenesis. Intern Med 36 : 760-765, 1997.
PubMed
2) 泰江弘文 : 急性冠症候群 (Acute Coronary Syndrome) の病因と対策. 日内会誌 87 : 296-301, 1998.
 
3) Glagov S, et al : Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 : 1371-1375, 1987.
PubMed
4) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326 : 242-250, 1992.
PubMed
5) Milner KA, et al : Gender differences in symptom presentation association With coronary heart disease. Am J Cardiol 84 : 396-399, 1999.
PubMed
6) Tunstall-Pedoe H, et al : Sex differences in myocardial infarction and coronary deaths in the Scottish MONICA population of Glasgow 1985 to 1991. Circulation 93 : 1981-1992, 1996.
PubMed
7) 豊福守ほか : 日本人若年女性における急性心筋梗塞の臨床的特徴. J Cardiol 28 : 313-319, 1996.
 
8) Yasue H, et al : Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment possible role of early coronary atherosclerosis. Circulation 81 : 482-493, 1990.
PubMed
9) Celermajer DS, et al : Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24 : 471-476, 1994.
PubMed
10) Belchetz PE : Hormone treatment of postmenopausal women. N Engl J Med 330 : 1062-1071, 1994.
PubMed
11) Losordo DW, et al : Variable expression of the estrogen receptor in normal and atherosclerostic coronary arteries of premenopausal women. Circulation 89 : 1501-1510, 1994.
 
12) Mendelsohn ME, Karas RH : The protective effects of estrogen on the cardiovascular system. N Engl J Med 340 : 1801-1811, 1999.
PubMed
13) Yasue H, et al : Coronary artery spasm in ischemic heart disease and its pathogenesis Circ Res 52 : 147-152, 1983.
 
14) Yasue H, et al : Circadian variation of exercise capacity in patients with Prinzmetar s variant angina : role of exercise-induced coronary arterial spasm. Circulation 59 : 938-948, 1979.
PubMed
15) Yasue H, et al : Induction of coronary artery spasm by acetylcholine in patients with variant angina : possible role of the parasympathetic nervous system. Circulation 74 : 955-963, 1986.
PubMed
16) Eeckhout E, Kern MJ : The coronary no-reflow phenomenon : a review of mechanisms and therapies. Eur Heart J 22 : 729-739, 2001.
PubMed
17) Belchetz PE : Hormone treatment of postmenopausal women. N Engl J Med 330 : 1062-1071, 1994.
PubMed
18) O'Keefe JH Jr, et al : Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 29 : 1-5, 1997.
PubMed
19) Grodstein F, et al : Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335 : 453-461, 1996.
PubMed
20) Grady D, et al : Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117 : 1016-1037, 1992.
PubMed
21) Hulley S, et al : Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA 280 : 605-613, 1998.
 
22) Herrington DM, et al : Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 : 522-529, 2000.
PubMed
23) Rossouw JE, et al ; Writing Group for the Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 : 321-333, 2002.
 
24) Mosca L, et al : Hormone replacement therapy and cardiovascular disease. Circulation 104 : 499-503, 2001.
PubMed
P.601 掲載の参考文献
1) Women's Health Initiative Investigators, Rossouw JE, et al : Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Wbmen's Health Initiative randomized controlled trial. JAMA 288 : 321-333, 2002.
PubMed
2) 大内やす義 : エストロゲンの脈管系に対する作用. 産科と婦人科 8 : 1027-1034, 2003.
 
3) 秋下雅弘 : HRTの効果と限界 心血管障害・脳血管障害. 産婦人科の実際 52 : 2209-2215, 2003.
 
4) 低用量ピル (OC) 医師向け情報提供資料, 服用者向け情報提供資料, p68-71, 薬事日報社, 1999.
 
5) 宮田敏行, 内山真一郎 : 血栓性素因. 脳卒中学 (山口武典ほか編), p199-214, 医学書院, 1998.
 
6) 茂田博行 : ピルと血液凝固, その対策. 日産婦誌 52 : N142-145, 2000,
 
7) 内山真一郎 : 血液凝固異常症による脳梗塞の診断と手引き. 若年性脳卒中治療の手引き ; 循環器病研究委託費12指-2若年世代の脳卒中の診断, 治療, 予防戦略に関する全国多施設共同研究 (峰松一夫編), p31-37, 大阪国立循環器病センター内科脳血管部門, 2003.
 
8) WHO Scientific Group : Cardiovascular disease and steroid hormone contraception. WHO Technical Report Series 877 : 1-87, 1998.
 
9) 水口弘司 : 低用量経口避妊薬の使用に関するガイドライン. からだの科学増刊 : 342-350, 2003.
 
10) 安達知子 : ホルモン補充療法と血栓塞栓症. 産婦人科治療 86 : 618-624, 2003.
 
11) Simon JA, et al : Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 103 : 638-642, 2001.
PubMed
12) Viscoli CM, et al : A clinical trial of estrogen-replacement therapy and risk of stroke. N Engl J Med 345 : 1243-1249, 2001.
PubMed
13) Wassertheil-Smoller S, et al : Effect of estrogen plus progestin on stroke in postmenopausal women. The Wbmen's Health Initiative : a randomized trial. JAMA 289 : 2673-2684, 2003.
 
14) 森田順子, 村上節 : 血栓症, ホルモン補充療法にともなうリスクの対策. 産婦人科の実際 53 : 553-559, 2004.
 
P.606 掲載の参考文献
1) Simoncini T, et al : Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 : 538-541, 2000.
PubMed
2) Song RX, et al : Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16 : 116-127, 2002.
PubMed
3) Orimo A, et al : Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun 195 : 730-736, 1993.
PubMed
4) Andersson C, et al : Immunocytochemical demonstration of oestrogen receptor beta in blood vessels of the female rat. J Endocrinol 169 : 241-247, 2001.
 
5) Lobo RA : Benefits and risks of estrogen replacement therapy. Am J Obstet Gynecol 173 (3 Pt 2). 982-989, 1995.
 
6) Simoncini T, et al : Selective estrogen receptor modulators : different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Clin Endocrinol Metab 84 : 815-818, 1999.
PubMed
7) Scheidegger KJ, et al : Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective effects. J Biol Chem 275 : 38921-38928, 2000.
PubMed
8) Yoon BK, et al : 17Beta-estradiol inhibits proliferation of cultured vascular smooth muscle cells induced by lysophosphatidylcholine via a nongenomic antioxidant mechanism. Menopause 8 : 58-64, 2001.
 
9) Ospina JA, et al : 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 33 : 600-605, 2002.
PubMed
10) Krasinski K, et al : Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 95 : 1768-1772, 1997.
PubMed
11) Spyridopoulos I, et al : Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation 95 : 1505-1514, 1997.
PubMed
12) Sudhir K, et al : Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349 : 1146-1147, 1997.
 
13) Pare G, et al : Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90 : 1087-1092, 2002.
PubMed
14) Zhu Y, et al : Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 295 : 505-508, 2002.
PubMed
P.611 掲載の参考文献
1) Grady D, et al : Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117 : 1016-1037, 1992.
PubMed
2) Colditz GA, et al : A prospective study of parenta1 history of myocardial lnfarction and coronary heart disease in women. Am J Epidemiol 123 : 48-58, 1986.
 
3) Stampfer MJ, et al : Postmenopausal estrogen therapy and cardiovascular disease : Ten-year follow-up from the Nurse's Health Study. N Engl J Med 325 : 756-762, 1991.
 
4) Willett WC, et al : Reproducibility and validity of a semiquantitative food frequency questionnair. Am J Epidemiol 122 : 51-65, 1985.
PubMed
5) Grodstein F, et al : Postmenopausal hormone therapy and mortality. N Engl J Med 336 : 1769-1775, 1997.
PubMed
6) Hu FB, et al : Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 343 : 530-537, 2000.
PubMed
7) Rossouw JE, et al : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 : 321-333, 2002.
PubMed
8) Hulley S, et al : Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 : 605-613, 1998.
PubMed
9) Grady D, et al : Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 288 : 49-57, 2002.
PubMed
10) Manson JE, et al : Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 : 523-534, 2003.
PubMed
11) 佐久間一郎 : 心血管疾患 (CVD) に対するホルモン補充療法をめぐるコントロバーシー : 是の立場から. 医学のあゆみ 207 : 144-146, 2003.
Medical*Online
12) Hodis HN, et al : Estrogen in the prevention of atherosclerosis : a randomized, double-blind, placebo-controlled trial. Ann Intern Med 135 : 939-953, 2001.
PubMed
13) Byington RP, et al : Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease : HERS B-mode substudy. Arterioscler Thromb Vasc Biol 22 : 1692-1697, 2002.
PubMed
14) Anderson GL, et al : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled trial. JAMA 291 : 1701-1712, 2004.
PubMed
15) Koh KK, Sakuma I : Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler Thromb Vasc Biol 24 : 1171-1179, 2004.
PubMed
16) 佐久間一郎, 北畠顕 : 女性の閉経と心血管疾患. 日内会誌 92 : 1690-1694, 2003.
 
17) Koh KK, et al : Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 24 : 1516-1521, 2004.
 
P.617 掲載の参考文献
1) Cosman F, Lindsay R : Selective estrogen receptor modulators : clinical spectrum. Endocr Rev 20 (3) : 418-434, 1999.
PubMed
2) Rossouw JE, et al : Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3) : 321-333, 2002.
PubMed
3) Anderson GL, et al : Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women's Health Initiative randomized controlled tria1. JAMA 291 (14) : 1701-1712, 2004.
 
4) Barrett-Connor E, et al : Raloxifene and cardiovascular events in osteoporotic postmenopausal women : four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287 (7) : 847-857, 2002.
PubMed
5) Barrett-Connor E : Clinical review 162 : cardiovascular endocrinology 3 : an epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 88 (9) : 4031-4042, 2003.
PubMed
6) McKenna NJ, O'Malley BW : An issue of tissues : divining the split personalities of selective estrogen receptor modulators. Nat Med 6 (9) : 960 -962, 2000.
 
7) Katzenellenbogen JA, et al : Tripartite steroid hormone receptor pharmacology : interaction with multiple effector sites as a basis for the cell-and promoter-spechic action of these hormones. Mol Endocrinol 10 (2) : 119-131, 1996.
PubMed
8) Paech KP, et al : Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites [see comments]. Science 277 (5331) : 1508-1510, 1997.
 
9) Doherty TM, et al : Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev 25 (4) : 629-672, 2004.
PubMed
10) Ettinger B, et al : Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (7) : 637-645, 1999.
PubMed
11) Delmas PD, et al : Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis : four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87 (8) : 3609-3617, 2002.
PubMed
12) Blumenthal RS, et al : Cardiovascular effects of raloxifene : the arterial and venous systems. Am Heart J 147 (5) : 783-789, 2004.
PubMed
13) Walsh BW, et al : Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol 88 (7) : 825-828, 2001.
 
14) Figtree GA, et al : Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100 (10) : 1095-1101, 1999.
PubMed
15) Saitta A, et al : Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-11evels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 21 (9) : 1512-1519, 2001.
 
16) Simoncini T, et al : Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69 (8-9) : 537-542, 2004.
 
17) Kung AW, et al : Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab 88 (7) : 3130-3136, 2003.
 
18) Barrett-Connor E, et al : Risk-benefit profile for raloxifene : 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 19 (8) : 1270-1275, 2004.
 
P.623 掲載の参考文献
1) Suzuki J, et al : Roles of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 106 : 847-853, 2002.
PubMed
2) Akishita M, et al : Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 102 : 1684-1689, 2000.
PubMed
3) Wu L, et al : Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104 : 2716-2721, 2001.
 
4) Adams MR, et al : Inhibition of coronary artery atherosclerosis by 17beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10 : 1051-1057, 1990.
PubMed
5) Nickenig G, et al : Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97 : 2197-2201, 1998.
PubMed
6) Wu Z, et al : Estrogen regulates adrenal angiotensin AT (1) receptors by modulating AT (1) receptor translation. Endocrinology 144 : 3251-3261, 2003.
PubMed
7) Suarez C, et al : Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia. Am J Physiol Endocrinol Metab 286 : 786-794, 2004.
 
8) Matsubara Y, et al : Estrogen activates phosphatases and antagonizes growth-promoting effect of angiotensin II. Hypertension 39 : 41-45, 2002.
 
9) Liu H-W, et al : Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension 40 : 451-457, 2002.
PubMed
10) Dantas AP, et al : Gender differences in superoxide generation in microvessels of hypertensive rats : role of NAD (P) H-oxidase. Cardiovasc Res 61 : 22-29, 2004.
PubMed

書評

最近チェックした商品履歴

Loading...